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 i 
Abstract 
Hepatitis C virus (HCV) is a major cause of global morbidity, causing long-term 
pathologies, including cirrhosis and hepatocellular carcinoma.  While hepatocytes are 
the major site of viral replication, the liver contains multiple non-parenchymal cells 
that regulate the hepatic microenvironment and may affect HCV infection in vivo.  
Current understanding of the role of non-parenchymal cells in HCV infection is limited. 
Therefore, this project aimed to establish co-culture systems that allowed 
investigations into interactions between hepatocytes and non-parenchymal cells, and 
how these interactions affected HCV infection.  
 
The results showed that in co-culture, activated liver myofibroblasts (aLMFs) 
negatively regulate HCV entry, replication and spread of infection in a cell contact 
dependent manner.  Soluble factors, including extracellular matrix proteins, and 
common antiviral pathways did not induce this effect.  Instead, we found that aLMF-
modulated cell-contact affected hepatocyte membrane receptor dynamics, reducing 
the mobility of the HCV receptor, CD81, impairing viral entry and replication. In 
addition, we found that aLMF surface expressed VAP-1 also significantly reduced 
virus infection independently of receptor modulation. These findings greatly improved 
our understanding of how the interactions between hepatic cells affect HCV, 
highlighting the importance of non-parenchymal cells in mediating infection in the 
liver microenvironment. 
 
 ii 
 
 
 
 
 
 
 
 
 
 
“Curiouser and Curiouser!” 
-Alice in Wonderland 
 
 
 iii 
Dedication 
 
This thesis is dedicated to my family, friends and Nikki, for all the support, advice and 
for always believing in me – you are all truly amazing. 
 
I would also like to dedicate this thesis in loving memory of my grandmother, Swarn 
Kaur Galsinh, your kind words of encouragement still give me strength today. 
 
 iv 
Acknowledgements  
I would like to thank my supervisors Professor Jane McKeating and Professor Chris 
Buckley for their support and guidance throughout this PhD project, and Dr Peter 
Balfe for his advice during the writing up phase.  I would like to thank past and 
present members of the Birmingham HCV group; Luke Meredith, Elizabeth Benedikz, 
Sam Lissauer, Ke Hu, Reina Lim, Alan Zhuang, Nick Frampton, Isla Sheree 
Humphreys, Donall Forde, Amarkumar Rajgoor, Mandy Diskar, Amy Barnes, Zania 
Stamataki, Tessa Lawrence, Michelle Farquhar, Nicola Fletcher, Ian Rowe, Helen 
Harris, Garrick Wilson, Ditte Hedegaard.   
 
I would like to extend a special thank you to; Luke Meredith for guidance during my 
project and writing up, Tessa Lawrence for guidance with writing up, Zania Stamataki 
for support and advice throughout, Elizabeth Benedikz for constant support and proof 
reading, Amy Barnes for training in FRAP and Ke Hu for support and training in 
tissue culture.  
 
Thank you to Gill Muirhead, Janine Youster, Chris Weston, Elizabeth Humphreys and 
Trish Lalor (Centre of Liver Research) for the kind gift of primary cells, reagents and 
advice throughout my project.  Thank you to The Centre for Translational 
Inflammation Group, University of Birmingham for supplying primary fibroblasts from 
different sites.  I would like to thank Professor Sven van Ijzendoorn and the 
Department of Cell Biology for hosting my research visit to UMCG, The Netherlands, 
funded by the SGM President’s Fund for Research Visits and the College of Medical 
and Dental Science Overseas Work Experience Scholarship.  This project was 
funded by the Medical Research Council for which I am very grateful.  
 
I would like to say a massive thank you to my parents Manjeet and Jaswinder, and 
siblings Mandeep, Hardeep and Charandeep, for supporting me through the difficult 
times, listening to me when I just needed to talk and all the encouragement.  To my 
lovely Siberian Husky Nikki, thank you for keeping me sane, happy and company 
when working throughout the nights.  I would also like to say a big thank you my 
close friends; Rakesh Chumber, Ravinder Barham and Parminder Virdi, for all your 
kind encouragement, laughter and support. 
 
 v 
Frequently used abbreviations 
 
aLMF  Activated liver myofibroblasts 
FBS   Foetal bovine serum 
CHO  Chinese hamster ovary cells 
HCVcc Cell culture hepatitis C virus 
HCVpp Hepatitis C virus pseudoparticles  
HCV  Hepatitis C virus 
HSC  Hepatic stellate cell 
IFN  Interferon  
ISG56  Interferon stimulated gene-56 
LMF  Liver myofibroblast 
LX-2  Lieming Xu-2 stellate cell line 
PHH  Primary Human Hepatocytes 
SR-B1 Scavenger Receptor Class B member I 
TGFβ  Transforming Growth Factor-beta 
 
 vi 
Table of contents 
Chapter 1 Introduction 1 
1.0 General introduction 1 
1.1 The liver function and microenvironment 3 
1.2 Fibrosis and aLMF 11 
1.3 Hepatitis C virus 18 
1.4 Model systems to study HCV 38 
1.5 HCV lifecycle 46 
1.5.1 HCV attachment factors 47 
1.5.2 HCV entry factors 50 
1.5.3 HCV replication, assembly and release 53 
1.6 Role of aLMF in HCV pathogenesis 56 
1.7 Project Aims 60 
Chapter 2 Materials and methods 61 
2.0 Tissue culture, Cell lines and primary cells 61 
2.0.1 Tissue culture 61 
2.0.2 Liver tissue samples 63 
2.0.3 Isolation of primary aLMF 63 
2.0.4 Isolation and cryopreservation of primary human hepatocytes 64 
2.0.5 Isolation of primary fibroblasts from different sites 65 
2.1 Routine techniques 67 
2.1.1 Antibodies and application 67 
2.1.2 List of plasmids 70 
2.1.3 HCV cell culture (HCVcc) generation and infection 71 
 vii 
2.1.4 Pseudoparticle virus generation and infection 74 
2.1.5 HCVcc-gLuc generation 75 
2.1.6 Indirect immunofluorescence 77 
2.1.7 Western blotting 78 
2.1.8 Real time quantification PCR (qRT-PCR) 79 
2.2 Specific techniques 82 
2.2.1 Co-culture of stromal cells with hepatoma cells 82 
2.2.2 Transwell assay 85 
2.2.3 Conditioned media 85 
2.2.4 ISG56 detection 86 
2.2.5 Human anti-viral Response PCR array 88 
2.2.6 Inhibition of nitric oxide (NO) pathway and detection of NO in extracellular 
media 89 
2.2.7 Matrigel 3D cultures 90 
2.2.8 Cell IQ live cell imaging 91 
2.2.9 Virus binding to cell membrane and ECM assay 92 
2.2.10 Generation of TRIP virus 93 
2.2.11 Fluorescence recovery after photobleaching (FRAP) 94 
2.3 Statistical analysis 96 
Chapter 3 aLMF are non-permissive to HCV but have the ability to inhibit HCV 
infection in co-culture 97 
3.0 Introduction 97 
3.1 Isolation and phenotyping of primary activated liver myofibroblasts 99 
3.2 aLMF do not support HCV infection 102 
 viii 
3.3 Key receptors mediating HCV entry are not present on aLMF 105 
3.4 The role of aLMF on HCV infection in a co-culture system 108 
3.4.1 Establishing a co-culture system to investigate the effects of aLMF on 
hepatocellular HCV infection 108 
3.4.2 aLMF can limit HCV entry in co-culture 114 
3.4.3 aLMF can reduce HCV replication over time in co-culture 120 
3.4.4 Co-culture of aLMF with Huh7.5 cells inhibits HCVcc spread at 48 hours 123 
3.8 Discussion 128 
Chapter 4 Pathways and mechanisms not contributing to the anti-viral activity 
of aLMF in co-culture 136 
4.0 Introduction 136 
4.1 Stromal cell anti-viral activity is mediated primarily via a cell contact dependant 
mechanism 138 
4.2 Stromal cell anti-viral activity is also mediated via a cell contact dependant 
mechanism in cytokine sensitive hepatomas 143 
4.3 Stromal cell anti-viral activity is not mediated through an interferon dependent 
pathway 146 
4.4 Anti-viral response PCR array shows no significant contribution to stromal cell 
anti-viral activity 151 
4.5 Blocking the VEGF pathway does not suppress stromal cell anti-viral activity 157 
4.6 Stromal cell anti-viral activity is independent of the nitric oxide pathway 160 
4.7 aLMF limit HCVcc infection in PHH 164 
4.8 The differentiation status of hepatoma cells in co-culture with aLMF remain 
unchanged 168 
 ix 
4.9 HepG2 polarity is altered when in co-culture with aLMF 171 
4.10 aLMF may reduce HCVcc infection at physiologically relevant oxygen levels 174 
4.11 Discussion 177 
Chapter 5 aLMF inhibit HCV infection via two independent mechanisms: 
limiting CD81 lateral diffusion and VAP-1 expression 183 
5.0 Introduction 183 
5.1 aLMF in 3D co-culture have the ability to limit HCVpp entry 185 
5.2 aLMF are more mobile than hepatoma cells 189 
5.3 Binding of HCVcc by aLMF cells or ECM is minimal 194 
5.4 aLMF in co-culture limit the lateral diffusion speed of CD81 but not EGFR on 
membrane of hepatoma cells 197 
5.5 Exploring the role of VAP-1 in HCV infection 201 
5.5.1 VAP-1 expression on various liver cell types 201 
5.5.2 Inhibiting VAP-1 restores HCV infection in co-culture 204 
5.5.3 Anti-viral activity of rVAP-1 is dose dependant 206 
5.5.4 rVAP-1 does not affect the speed CD81 diffuses 209 
5.6 The ability of aLMF to reduce HCV infection is not specific to liver myofibroblasts
 211 
5.7 Discussion 215 
Chapter 6 General Discussion 221 
Chapter 7 Bibliography 233 
 
 x 
List of figures 
Figure 1-1 Anatomy of the liver       5 
Figure 1-2 The liver architecture       10 
Figure 1-3 Origins of liver myofibroblasts     12 
Figure 1-4 Stromal cells create the microenvironment    15  
Figure 1-5 Cellular mechanisms of liver fibrosis     16 
Figure 1-6 HCV genotypes        20 
Figure 1-7 HCV genome        25 
Figure 1-8 HCV disease progression      30 
Figure 1-9 HCV replicon system         40 
Figure 1-10 HCV pseudotype virus particle (HCVpp) system   42 
Figure 1-11 Key HCV receptors         48  
Figure 1-12 HCV lifecycle        55   
Figure 2-1 Electroporated Huh7.5 cells stained for HCV NS5A  73  
Figure 2-2 Schematic diagram illustrating co-culture set up     84  
Figure 3-1 Phenotype of primary isolated aLMF     101  
Figure 3-2 aLMF do not support HCVcc infection              104 
Figure 3-3 aLMF lack expression of key HCV receptors             107 
Figure 3-4 The effects of aLMF on hepatocellular HCV infection   
in co-culture                          112 
Figure 3-5 aLMF can limit HCVpp entry in co-culture             117  
Figure 3-6 aLMF can reduce HCV replication over time in co-culture          122  
Figure 3-7 Co-culture of aLMF with Huh7.5 cells inhibits  
HCVcc spread at 48 hours                         126 
 xi 
Figure 4-1 Stromal cells mediate their anti-viral effect primarily via  
cell contact                 141 
Figure 4-2 Testing conditioned media using cytokine sensitive  
hepatoma cells                145 
Figure 4-3 Measuring ISG56 activation in co-culture                       149 
Figure 4-4 Human anti-viral response PCR array             154  
Figure 4-5 Blocking the VEGF pathway does not restore HCV  
infection in co-culture               159 
Figure 4-6 Blocking the NO pathway does not restore HCV  
infection in co-culture                 163 
Figure 4-7 aLMF limit HCVcc infection in PHH                       167 
Figure 4-8 The differentiation status of hepatoma cells when in  
co-culture with aLMF remains unchanged            169 
Figure 4-9 HepG2 polarity is altered when in co-culture with aLMF              173 
Figure 4-10 aLMF can still reduce HCVcc infection at  
physiologically relevant oxygen levels                       176 
Figure 5-1 aLMF cultured in 3D limit HCVpp entry             188 
Figure 5-2 aLMF are more mobile than hepatoma cells            192 
Figure 5-3 aLMF do not bind virus whereas aLMF ECM depletes  
virus minimally                196 
Figure 5-4 aLMF limit CD81 lateral diffusion on the hepatoma cell 
membrane but have no effect on EGFR             200 
Figure 5-5 VAP expression on various liver cell types                       203 
Figure 5-6 Inhibiting VAP-1 restores HCV infection in co-culture                 205 
 xii 
Figure 5.7 Anti-viral activity of rVAP-1 is dose dependant            208 
Figure 5-8 rVAP-1 does not affect CD81 mobile fraction or  
diffusion coefficient                          210 
Figure 5-9 The ability of aLMF to reduce HCV infection is not  
specific to liver myofibroblasts              213 
 xiii 
List of tables 
 
Table 1-1 Cellular composition of the liver      8 
Table 1-2 Mechanisms by which HCV evades the host  
immune response       34 
Table 1-3 Summary table of animal models used in HCV research  45 
Table 1-4 HCV mediated liver fibrosis      59  
Table 2-1 Cell lines and primary cells with details of  
cell growth medium       62 
Table 2-2 Primary Antibodies       68 
Table 2-3 Secondary Antibodies       69 
Table 2-4 List of plasmids        70 
Table 3-1 Disease aetiologies of patient derived aLMF   100 
Table 3-2 Hepatitis C viral inhibition by aLMF in co-culture   
with Huh7.5 cells                113 
Table 3-3 Pseudoparticle entry inhibition by aLMF in  
co-culture with Huh7.5 cells               119 
Table 4-1 Table summarising anti-viral array data             156
  
1 
Chapter 1 Introduction 
 
1.0 General introduction 
 
The liver is a large, complex organ responsible for a number of important functions 
and contains of a variety of different cell types.  It is involved in many functions such 
as: processing digested foods, controlling metabolic homeostasis, synthesising 
plasma proteins for example, albumin or clotting factors, detoxifying harmful products, 
drug metabolism, synthesising, and excreting bile, which is involved in lipid fat 
digestion, and removing other metabolised compounds from the body (Taub, 2004b).   
 
The liver is a unique organ because it has the ability to regenerate, which is clinically 
very important as this allows the liver to repair itself especially following acute liver 
failure caused by factors such as drugs or toxins.  This also has great implications for 
treating patients suffering from chronic liver failure.  Patients can either undergo a 
liver transplant; where  the donor liver is divided and used to treat several patients as 
it is able to regenerate over time, or they can undergo a partial hepatectomy to 
remove a section of their own liver, which may be damaged or contain a tumour, and 
the remaining liver is left to regenerate (Bismuth, 1982, Couinaud, 1957, Lefkowitch, 
2011).  Chronic liver failure is often caused by repetitive liver injury, which causes 
chronic inflammation.  Factors such as high alcohol intake, having a fatty liver or viral 
infection can cause chronic liver disease.  Prolonged inflammation of the liver initiates 
fibrosis, the liver wound healing response, which, although reversible, causes 
scarring of the liver and can lead to severe scarring of the liver, known as cirrhosis.  
Liver cirrhosis is often irreversible, causing liver failure and increasing the risk of 
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hepatocellular carcinoma or liver cancer.  At this stage of liver disease, although 
patients can undergo a liver transplant or partial hepatectomy this may not always be 
possible due to the limited availability of donor organs.  As a result, liver disease is a 
major cause of death. Furthermore, viral infection, a large proportion of which is due 
to Hepatitis C virus (HCV), causes a great burden on liver transplantation in the UK 
and western world (Brown, 2005, Gitto et al., 2009). 
 
The infection caused by HCV can be acute and asymptomatic but approximately 
80% of infected individuals develop persistent and chronic infection, which can 
progress to hepatocellular carcinoma when the patient will require a liver transplant.  
Treatments for patients with chronic HCV infection have recently advanced with 
newly licensed antivirals, which specifically target HCV.  Before these new treatments, 
the standard treatment for HCV infected patients was a combination therapy of 
interferon-α and pegylated ribavirin, which had many adverse effects.  The new 
antivirals are also being offered in combination therapy with the standard treatment of 
interferon-α and pegylated ribavirin, which not only increases the adverse effects but 
also increases the cost of treatment.  There is still a need for better therapies that 
have fewer side effects and are more cost effective to ensure wider use.  In order to 
develop these new therapies, new targets need to be identified, preferably at earlier 
stages of HCV disease (Blight et al., 2003b, Lindenbach et al., 2005a, Evans et al., 
2007, Lemon et al., 2010, Sharma and Feld, 2014, Meredith et al., 2012a). 
 
The key liver cell type involved in fibrosis is the hepatic stellate cell (HSC), which in 
response to liver injury such as viral disease, is activated to become a liver 
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myofibroblast (aLMF) to help repair the damage.  This process of liver repair involves 
aLMFs secreting various extracellular matrix components, which would normally be 
degraded once the liver has repaired.  However, when there is an accumulation of 
extracellular matrix (ECM) in the liver it leads to fibrosis and eventually cirrhosis.  
Thus, this project aimed to understand the role of aLMF in hepatocellular HCV 
infection, the impact these cells have on the hepatitis C viral lifecycle and their 
mechanism of action, potentially identifying new pathways that could be targets for 
novel therapies (Wynn, 2008, Kisseleva and Brenner, 2008, Kisseleva et al., 2012, 
Seldon et al., 1999). 
 
1.1 The liver function and microenvironment  
 
The liver anatomy  
The liver is a large organ weighing between 1.2-1.5 kilograms and is located in the 
upper right area of the abdomen cavity below the diaphragm and next to the stomach.  
The liver is protected by the rib cage as it is a key organ responsible for a number of 
vital functions such as the synthesis, storage, and secretion of factors involved in 
metabolic homeostasis (Taub, 2004b).  Anatomically, the liver can be separated into 
two distinct lobes visible from the anterior.  The right lobe is the larger of the two 
lobes, which are separated by the falciform ligament anteriorly and the ligamentum 
teres inferiorly.  These ligaments provide a structural support to the liver and assist in 
holding the liver in position together with the abdomen walls (Bismuth, 1982, Diehl-
Jones and Fraser Askin, 2002, van Leeuwen et al., 1994). 
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The location of the liver within the body assists with its function, as does its rich dual 
blood supply.  The liver is supplied with blood directly from the gut via the hepatic 
vein accounting for 80% of the blood supply.  The remaining 20% of the blood flow is 
supplied from the heart via the hepatic artery.  The blood supplied from the 
gastrointestinal tract is deoxygenated blood rich in nutrients and the blood supplied 
from the heart is oxygenated blood.  Upon entering the liver, they become mixed as 
the blood travels along a vast network of branched sinusoidal blood vessels.  The 
mixed blood supply is collected in the central vein where it then travels to the inferior 
vena cava via the hepatic vein and here the blood is re-oxygenated (Lalor et al., 
2002a).  The liver can be further separated into 8 distinct functional segments based 
on the network of blood supply, identified by Couinaud and illustrated in Figure 1-1 
(Couinaud, 1957; Bismuth, 1982; Bismuth, 2014; Yoshida et al., 2012).   Each 
segment has its own major vascular supply (a separate arterial blood supply and bile 
drainage system), which allows them to be surgically separated from the remaining 
liver during liver resection surgery (Bismuth, 1982).   
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Figure 1-1 Anatomy of the liver  
Cartoon illustrating the functional anatomy of the liver, with each of the 8 distinct 
functional segments identified by Couinaud labelled (I-VIII).  The light blue vessels 
illustrate the blood supply from the portal vein and the dark blue illustrate drainage 
into the hepatic veins (Lefkowitch, 2011) 
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The liver microenvironment 
The liver is a complex organ and contains of a variety of cells, but the main cell type, 
responsible for most of it functions, is the hepatocyte.  Hepatocytes account for 
approximately 80% of the liver mass and are also referred to as liver parenchymal 
cells.  These epithelial cells are large (20-30 µm across) and polygonal in shape, 
which allows hepatocytes to form multiple contacts with neighbouring hepatocytes 
and non-parenchymal cells  (Pertoft and Smedsrod, 1987). 
 
These multiple contacts are achieved as a result of the complex polarity hepatocytes 
have, where the membranes are linked by tight junction proteins.  The basolateral 
surface of hepatocytes allows the cells to secrete various serum factors into the 
venous blood, conditioning the blood as it passes through the liver.  Whereas the 
apical surface forms the canalicular structures and allow the hepatocytes to secrete 
bile into canaliculi, which then merge with bile ducts (Decaens et al., 2008; Musch, 
2014; Perrault and Pecheaur, 2009; Selden et al., 1999).  The correct physiological 
functioning of the liver is a result of complex polarity and the tight junction proteins 
which help maintain it, and separate the blood flow from the secreted bile (Decaens 
et al., 2008, Perrault and Pecheur, 2009, Adams and Eksteen, 2006, Selden et al., 
1999, Cereijido et al., 1998).   
 
The remaining 20% of the liver mass consists of non-parenchymal cells, also referred 
to as the stroma, which include: liver sinusoidal endothelial cells (LSEC), hepatic 
stellate cells (HSC), biliary epithelial cells (BEC) (also referred to as cholangiocytes), 
Kupffer cells, activated liver myofibroblasts (aLMF), Pit cells (NK cells), hepatic 
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dendritic cells, and NK T cells.  Details of the proportions for each different cell type 
are listed in Table 1-1 (Millward-Sadler et al., 1992, Lavon and Benvenisty, 2005b, 
Meredith et al., 2012a).  These non-parenchymal cells have complex and multiple 
interactions with the hepatocytes.  The hepatocytes form plates, which are one cell 
thick, and in between two plates is the sinusoid, a vascular channel supplying the 
hepatocytes with blood.  The walls of sinusoids are lined by LSEC, a specialised type 
of endothelial cell with fenestrations that act as a sieve, allowing various nutrients to 
pass through into the Space of Disse (Braet et al., 2009, Lai et al., 2006, Lozach et 
al., 2004, Pohlmann et al., 2003). 
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Table 1-1 Cellular composition of the livera 
Cell Type Number % Volume % Cell diameter (μm) 
Parenchymal 65 92.5 10-34 
Non-parenchymal 35 7.5 6-15 
Sinusoidal endothelial 21 3.3 6-11 
Kupffer 8.5 2.5 7-15 
Stellate 5.5 1.7 10-13 
aTable adapted from (Pertoft 1987) detailing the cellular composition of a 
rat liver and the proportions of different cell types.  The proportion of cells 
is similar to that found in the human liver. 
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Within the Space of Disse there are various extracellular matrix components such as 
collagen, fibronectin and HSCs.  The location of HSCs in relation to hepatocytes is 
illustrated in Figure 1-2 (Millward-Sadler, 1992, Lavon and Benvenisty, 2005a, 
Meredith et al., 2012b).  HSCs store vitamin A and become activated in response to 
liver injury into aLMF cells.  These aLMF synthesize collagen and various other 
factors which ultimately lead to liver fibrosis (Taub, 2004a). Kupffer cells and pit cells 
are liver specific macrophages, which are responsible for phagocytising various 
pathogens and foreign particles that enter the liver and are found in the peripheral 
region of the liver (Millward-Sadler, 1992, Lavon and Benvenisty, 2005a).  The liver 
also contains BEC that are located in the biliary tracts.  As a result these cells often 
become the first cells a pathogen will encounter when it enters the liver via the bile 
duct, so they produce a range of cytokines in response to various pathogens 
(Millward-Sadler, 1992, Lavon and Benvenisty, 2005a, Kanno et al., 2000).  
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Figure 1-2 The liver architecture  
An illustration showing the organisation of different cell types in the liver.  Within the 
Space of Disse there are various extracellular matrix components such as collagen 
and fibronectin, and stromal cells such as hepatic stellate cells which are in direct 
contact with hepatocytes.  Upon activation in response to liver injury such as viral 
infection, the stromal hepatic stellate cells become activated liver myofibroblasts 
(aLMF). 
 
  
11 
1.2 Fibrosis and aLMF  
 
Fibrosis is a dynamic process between the deposition of extracellular matrix 
components (ECM) and the degradation of ECM.  It is defined as the excessive 
healing response with scarring of the various tissues and excess ECM, particularly 
collagen, in response to continuous liver injury.  Liver fibrosis is a result of chronic 
inflammation of the liver, which can be caused by a number of stimuli including: 
autoimmune diseases, metabolic diseases, alcohol abuse, viral hepatitis, cholestatic 
liver disease or toxins (Wynn 2008; Kisseleva et al., 2011; Kisseleva et al., 2008; 
Selden, Khalil et al., 1999).  Myofibroblast cells are the key player in liver fibrosis as 
determined both clinically and experimentally.  The origin of myofibroblasts is still in 
debate and it has been suggested that fibrosis induced by different types of injury 
may give rise to different fibrogenenic cells as illustrated in Figure 1-3 (Kisseleva et 
al 2008; (Iredale, 2007).  Several potential sources giving rise to myofibroblasts have 
been identified and it is thought that HSCs are the primary source as demonstrated 
by Mederacke and colleagues (Mederacke et al., 2013). They identified that HSCs 
can give rise to 82-96% of myofibroblasts using a novel Cre-transgenic mouse and 
fate tracing (Su et al 2014; Mederacke et al., 2013). 
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Figure 1-3 Origins of liver myofibroblasts  
Diagram illustrating the possible sources of liver myofibroblasts.  Current evidence 
suggests quiescent hepatic stellate cells (HSC) are the major source of 
myofibroblasts.  The contribution of hepatocytes and biliary epithelial cells to 
myofibroblasts, via epithelial-mesenchymal transition (EMT) and endothelial to 
mesenchymal transition, was considered controversial but studies have shown these 
cells types are minor contributors of fibrogenic cells (Iredale, 2007).
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Under normal conditions, aLMF are not found in the liver but HSC can be found in the 
space of Disse in a quiescent phenotype.  HSC store vitamin A in lipid droplets which 
when activated in response to liver injury, lose the stored vitamin A and acquire 
contractility (Taub, 2004a).  HSC express neural markers including synaptophysin, 
glial fibrilar acidic protein (GFAP) and synemin but once activated, these neural 
markers are down regulated and mesenchymal markers are up regulated such as α-
SMA and fibronectin (Iredale, 2007; Geerts, 2001; Iredale et al., 2010).  
Myofibroblasts can also be derived from portal fibroblasts and bone marrow (BM)-
derived mesenchymal cells.  Portal fibroblasts do not store vitamin A and do not 
express α-SMA, unlike HSC and BM stroma do not express hematopoitic markers 
(Kisseleva et al., 2008).  Hepatic epithelial cells can undergo epithelial-to-
mesenchymal transition (EMT) into liver myofibroblasts.  This process of 
differentiation is reversible and studies have shown transforming growth factor (TGF)-
β is a key cytokine closely linked to driving EMT (Taura et al., 2010; Kisseleva et al., 
2008).  Interestingly, there have also been suggestions of endothelial cells 
differentiating into aLMF in a similar process called endothelial-mesenchymal 
transition (EndMT) (Kalluri et al., 2003; Wynn, 2008).  Stromal cells create the 
microenvironment in the liver, supporting hepatocyte function via various cytokines, 
extracellular matrix (ECM) and cell contacts as shown in Figure 1-4.  The 
myofibroblast synthesises various ECM components particularly collagen (types I, III, 
IV and V), elastin, laminin, fibronectin and proteoglycans, which can lead to scar 
tissue when excess is produced and not degraded.  ECM tends to accumulate during 
fibrosis when ECM-removing matrix metalloproteinases (MMPs) are down-regulated, 
whilst tissue inhibitors of MMPs (TIMPs) are up-regulated, particularly TIMP-1 
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(Schulze-Krebs et al., 2005; Gomez et al., 2009).  Although myofibroblasts create the 
microenvironment and are the key player in liver fibrosis, the cellular mechanisms of 
fibrogenesis actually involve a number of different liver cell types in a complex 
interplay illustrated in Figure 1-5.  Fibrogenesis can be resolved if the underlying 
cause of liver injury is treated and cured, leading to fibrosis resolution which involves 
aLMF cells undergoing apoptosis and the regeneration of hepatocytes (Bataller and 
Brenner 2005). 
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Figure  1-4  Stromal cells create the microenvironment  
Mechanisms by which non-parenchymal stromal cells create a microenvironment for 
the hepatocytes to function, via the release of various cytokines, extracellular matrix 
and cell contacts.  The cytokines secreted also mediate hepatocyte proliferation, 
differentiation, maturation and enhance hematopoiesis (Gomez-Aristizabel et 
al.,2009). 
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Figure 1-5 Cellular mechanisms of liver fibrosis  
Schematic diagram of the complex interplay between different liver cell types during 
hepatic fibrogenesis.  Following liver injury, damaged hepatocytes and biliary 
epithelial cells release inflammatory cytokines and various other soluble factors which 
activate and recruit T cells as well as activate Kupffer cells.  This inflammation state 
leads to the activation of quiescent HSC to release various cytokines and extra 
cellular matrix components (ECM).  There is an accumulation of aLMF, cytokines and 
ECM following repeated liver injury during fibrogenesis, which can be resolved once 
the underlying cause of liver injury has been removed.  During fibrosis resolution, 
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activated HSC undergo apoptosis and there is a regeneration of hepatocytes 
(Bataller and Brenner 2005). 
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1.3 Hepatitis C virus 
 
Discovery of HCV 
Hepatitis C virus (HCV) is one of five hepatitis viruses (named hepatitis virus A, B, C, 
D and E) that all cause acute or chronic hepatitis in humans.  HCV is a blood borne 
virus that was first discovered during the 1970s, when it was noticed that post-blood 
transfusion, a viral agent that was a non-A and non-B , was causing hepatitis disease 
progression in patients.  When the virus successfully crossed from humans to 
chimpanzees in the late 1970’s Choo and colleagues worked on isolating and 
sequencing clones from chimpanzees which lead to the identification of a clone that 
was a single–stranded, positive sense RNA genome and was named hepatitis C 
virus (Choo et al., 1989, Lindenbach et al., 2005b, Wakita et al., 2005b, Zhong et al., 
2005b).   
 
HCV genotypes and epidemiology 
HCV is an enveloped virus belonging to the genus, Hepacivirus, of the Flaviviridae 
family.  Other hepaciviruses include novel viruses identified across a range of 
animals including rodents, bats, dogs, horses, and primates (Kapoor et al., 2013, 
Drexler et al., 2013, Lauck et al., 2013).  It can be divided into six major genotypes, 
which genetically vary in complete viral genome by approximately 30-35% 
(Simmonds, 1993; Simmonds, 2004). Currently, HCV infects approximately 170 
million individuals worldwide and the distribution for each genotype varies 
geographically.  Patients in Europe and North Americas are more commonly infected 
with genotypes 1a, 1b and 3a. However patients in Asia, the Middle East and North 
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Africa are more commonly infected with genotypes 2, 4, 5 and 6 (Simmonds, 1993 et 
al; Simmonds 1995; Simmonds, 2004;Ishrad et al 2010; Bruggmann 2014; 
Simmonds, 2005).  There are reports of a seventh HCV genotype, genotype 7a, 
which has recently been found in blood samples from Belgium, Central Africa and 
Canada.  The sequence diversity is illustrated by phylogenetic analysis in Figure 1-6 
(Simmonds et al., 1993, Gottwein et al., 2009).  Within the genotype subtypes there 
appears to be further sequence differences which give rise to more than 70 subtypes 
(labelled a, b, c and so forth) (Simmonds et al., 1993, Shi et al., 2012).  To add 
further to the genetic variation, HCV infected individuals are not positive for a single 
sequence of HCV but instead positive for a population of sequences which, although 
they vary with one another, are evolutionary closely related.  This population of 
variants are known as quasispecies, which arise from the high mutation and 
replication rate of the HCV RNA polymerase.  The rate of fixation of mutations in the 
HCV genome per year has been estimated as 1.44 – 1.92 x 10-3 substitutions per 
genomic site.  As a result, within the pool of variants there are mutants that are better 
adapted to escaping the immune response and antiviral therapies, for examples 
some mutations can alter the conformation of site where DAA compounds bind, 
leading to variants which are resistant to various antiviral therapies (Sarrazin et al., 
2007, Simmonds et al., 2005, Gomez et al., 1999). 
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Figure 1-6 HCV genotypes  
A phylogenetic analysis of HCV RNA polymerase (non-structural protein 5B) which 
illustrates the areas with high sequence diversity (Simmonds et al., 2005).   
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Hepatitis C viral particles have a diameter of approximately 50-60nm.  The viral 
envelope is formed of a lipid bilayer containing E1 and E2 glycoproteins, which 
interact with the host cell.  This envelope surrounds a capsid made up of core 
proteins, which contains the positive sense, single-stranded RNA genome.  Despite 
variation between genotypes, subtypes and quasispecies, all HCV genomes are 
have a length of approximately 9.6 kilo bases, containing one open reading frame 
(ORF) with non-translated regions (NTR) at both the 5’ and 3’ terminus.  This 
genomic material acts as messenger RNA (mRNA) from which the viral proteins can 
be translated.  The ORF encodes for a polyprotein, which is cleaved by both viral and 
cellular proteinases, in a co- and post- translational manner, into several non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B) and structural proteins 
(core, envelope 1 (E1), envelope 2 (E2), p7).   An additional protein of unknown 
function has also been identified and is a result of a ribosomal frameshift occurring 
during translation, and so it has been termed the F (frameshift) or ARF (alternative 
reading frame) protein (Lemon et al., 2010, Lemon, 2001, Brass et al., 2006, Appel et 
al., 2006, Blight et al., 2003a, Rehermann, 2009).    
 
The structural genes are located at the 5’ terminal and the non-structural genes are 
located at the 3’ terminal, and the locations of various cleavage sites, cleaved by 
either host or viral enzymes, are demonstrated in Figure 1-7A-C (Lemon et al., 2010, 
Rehermann, 2009).  As mentioned, the structural proteins core, E1 and E2 are 
essential components of the HCV virion as they form the viral capsid and envelope.  
The core protein has a molecular weight of 21kDa and mature core molecules are 
thought to form homo-dimers in vivo, at the endoplasmic reticulum (ER) membrane.  
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Not only does the core protein form the viral capsid, but it also regulates viral particle 
assembly, viral RNA binding and RNA translation.  More recently, it has been 
suggested that the core protein may also play a role in various cell signalling 
pathways such as apoptosis, carcinogenesis and lipid metabolism (Matsumoto et al., 
1996, Ait-Goughoulte et al., 2006, Santolini et al., 1994, Tellinghuisen et al., 2005).  
There are two envelope structural proteins, E1 and E2, which are both type I 
transmembrane proteins that have short transmembrane domains (TMD) and large 
hydrophilic ectodomains.  The TMD is involved in anchoring E1 and E2 in the ER 
membrane and is involved in forming E1-E2 heterodimer complexes.  These E1-E2 
complexes are key in HCV adsorption and entry steps as they interact with CD81 and 
low density lipoprotein receptor (LDLR) leading to the viral envelope fusing with the 
host cell membrane, however other factors are also involved in the complicated entry 
mechanism and are discussed further in section 1.5.  The E2 protein contains two 
hypervariable regions (HVR1 and HVR2) which can vary in amino acid sequence by 
80% as a result of the immune response and exposure to HCV specific antibodies, 
therefore it is a key region for neutralising antibodies to target (Cocquerel et al., 1999, 
Duvet et al., 1998, Flint et al., 1999, Farci et al., 1996, Op De Beeck et al., 2000, 
Brass et al., 2006). 
 
Between the E2 and N2 regions, there is a small protein called the p7 protein which 
forms an ion channel in the ER and it is thought to play a role in the assembly and 
formation of infectious virus particles but has been shown to be non-essential for the 
replication stage (Blight et al., 2000, Lohmann et al., 1999, Haqshenas et al., 2007, 
Griffin et al., Pavlović et al., 2003).  It is the non-structural (NS) proteins which are 
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associated with HCV replication.  NS2 forms the NS2/NS3 cysteine protease with the 
NS3 protein (N-terminal portion), which can cleave the polyprotein precursor by 
autocatalysis between the NS2 and NS3 region.  The NS2 protein is thought to play a 
role in the virus assembly stage, possibly by interacting with E1-E2 complexes and 
the NS3/NS4A complexes.  However, it has also been shown to interact with a 
number of cellular pathways including pro-apoptotic pathways, cell growth inhibition, 
arresting cell growth in the S phase and inhibiting IFNβ production (Grakoui et al., 
1993, Santolini et al., 1995, Jones et al., 2007, Erdtmann et al., 2003, Kaukinen et al., 
2013).  The NS3 protein has fewer functions and is thought to interact with other viral 
proteins to assist its various functions however further work is required to fully 
understand these interactions and their role in HCV replication.  Nevertheless, the C 
terminal of NS3 has been shown to have ATPase/helicase activity and the N terminal 
has been shown to utilise a portion of NS54 in order to have serine protease activity 
(Jennings et al., 2008, Failla et al., 1994, Bartenschlager et al., 1995, Lin et al., 1995, 
Tanji et al., 1995).  The NS4A protein is actually a small polyprotein which acts as a 
cofactor for the NS3 serine protease and it also targets NS3 to the ER where it acts 
to stabilise NS3 further (Failla et al., 1994, Bartenschlager et al., 1995, Lin et al., 
1995, Tanji et al., 1995, Wölk et al., 2000).  The N terminal of the NS4B protein 
targets it the ER where it forms oligomers as an integral membrane protein.  The 
localisation of NS4B at the ER is key for its functions as NS4B is essential in HCV 
replication because it can bind RNA, induces an ER derived membranous web 
structure and is thought to be responsible for forming the HCV RNA replication 
complex at the ER (Yu et al., 2006, Elazar et al., 2004, Gretton et al., 2005, Einav et 
al., 2004, Blight, 2011). 
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The membrane associated phophoprotein NS5A is involved in virus assembly, 
replication and virus release.  The role of NS5A in HCV RNA replication is not fully 
understood however it is thought to have an essential but complicated role as it has 
been shown to interact with numerous cellular proteins, making it difficult to 
determine its main functions.  Studies have shown NS5A to have an IFNα sensitivity-
determining role (ISDR), interact with cytosolic cyclophilin A (CypA) (essential for 
HCV replication), and prevent oxidative stress mediated apoptosis to ensure the virus 
can continue to produce viral particles within a live host cell (Enomoto et al., 1995, 
Enomoto et al., 1996, Chatterji et al., 2009, Amako et al., 2013, Appel et al., 2008).  
The NS5B protein is the HCV RNA polymerase which is essential to the HCV 
replication complex located at the NS4B induced membranous web structure at the 
ER.  NS5B has a high replication error rate as it lacks a proof-reading mechanism 
and as a result, this gives rise to high genetic variability between patients and within 
a patients own liver also (Behrens et al., 1996, Schmidt-Mende et al., 2001).  
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Figure 1-7 HCV genome  
(A) The single-stranded HCV RNA genome encoded along one ORF, flanked by two 
untranslated regions (UTR).  Translation is initiated at the 5’ UTR, which contains the 
internal ribosomal entry site (IRES).  (B) Following translation, the polyprotein is 
processed by host and viral proteases.  The cleavage sites are labelled with the 
amino acid number below the polyprotein.  (C) There are a total of 10 structural and 
non-structural proteins, each labelled the diagram.  There is also a short protein of 
unknown function as a result a frameshift (F) leading to the translation of an 
alternative reading frame (ARF) which is labelled F/ARF (Rehermann, 2009) 
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HCV disease progression 
HCV is transmitted through the sharing of contaminated needles among injection-
drug users.  It can also be transmitted via blood transfusions or organ transplants 
from infected donors, however this route of transmission has become less common 
since more robust screening tests were introduced.  Other routes of transmission 
include sexual and perinatal transmission (Busch, 2001). Once HCV particles enter 
the blood stream, the virus reaches the liver via the sinusoidal vascular channels 
running between plates of hepatocytes.   The sinusoidal endothelial fenestrations act 
like a sieve allowing the virus to pass through into the Space of Disse, although it is 
thought that they may also help the virus infect hepatocytes by binding infectious 
virus particles (Braet et al., 2009, Lai et al., 2006, Lozach et al., 2004, Pohlmann et 
al., 2003).   
 
Hepatocytes are the primary target cells for HCV, as they support entry and full HCV 
replication, however recent studies suggest there may be extrahepatic sites of 
replication with the detection of HCV RNA in the brain, CNS tissue and in peripheral 
blood mononuclear cells (Murray et al., 2008, Fishman et al., 2008, Weissenborn et 
al., 2009, Weissenborn et al., 2004).  In order to accurately determine HCV 
replication, both negative- and positive-stranded RNA must be detected and other 
studies have shown primary lymphocytes cannot support the entry and replication of 
HCV but associate with the virus and this association allows the lymphocytes to 
transfer infectious virus to hepatocytes in vitro (Marukian et al., 2008, Meredith et al., 
2012b).  A number of studies have also detected HCV RNA in the CSF and CNS 
tissue, with some identifying genetic variations between the sequences isolated from 
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the liver and brain from the same patient, but proof of HCV replication within these 
tissues is required before it can be stated that they support the full HCV lifecycle 
(Murray et al., 2008, Fishman et al., 2008, Forton et al., 2004, Wilkinson et al., 2010, 
Meredith et al., 2012b).  A recent study by Fletcher and colleagues (2010) has shown 
several neuroepithelioma cell lines can support high levels of HCV entry and low 
levels of replication, indicating hepatocytes are not the only cells that can support 
HCV infection (Fletcher et al., 2010, Fletcher et al., 2012b, Fletcher et al., 2012a). 
 
The infection caused by HCV is often asymptomatic but once established in the liver, 
chronic infection can progress to scarring of the liver (fibrosis) and advanced scarring 
(cirrhosis), which in some cases can go on to develop into liver cancer 
(hepatocellular carcinoma) represented by the cartoon in Figure 1-8A.  Of the 
approximately 170 million HCV infected people worldwide, about 70% of those 
acutely infected individuals go on to develop persistent and chronic infection with 
about 20-30% progressing to chronic active hepatitis with cirrhosis and about 7% 
developing hepatocellular carcinoma (HCC) which is fatal end stage liver disease 
(Fig.1-8B) (Lindenbach et al., 2005b, Blight et al., 2003a, Farquhar and McKeating, 
2008, Lemon et al., 2010, Meredith et al., 2012b).   Chronic HCV infection is defined 
as chronic if the infection has persisted for more than six months, however, it remains 
unclear why in many cases HCV develops into a chronic infection.  Chronic HCV 
disease progression also varies in individuals and certain cohorts of patients.  
Although a number of factors which may contribute towards the variation in disease 
progression have been identified, we still do not fully understand why disease 
progression varies so much in individual patients (Vogel et al., 2009).  Age and 
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gender appear to impact HCV disease progression as there are reports of faster 
disease progression in patients who became initially infected with HCV aged 
between 40 to 55 years compared to younger patients or children and faster disease 
progression has been observed in male patients (Svirtlih et al., 2007).  Ethnic 
background also appears to impact disease progression with African-Americans 
showing slower disease progression and less severe changes in their liver histology 
(Sterling et al., 2004).  Alcohol consumption has been linked with increased HCV 
replication, faster disease progression and liver injury, with even moderate amounts 
of alcohol having been shown to increase fibrosis, patients suffering from chronic 
HCV should avoid alcohol consumption (Gitto et al., 2009).  In patients coinfected 
with other viruses such as HIV or acute HBV, there is generally an acceleration in 
HCV disease progression except for those patients infected with chronic HBV which 
may lead to lower levels of HCV replication compared to HCV mono-infected patients 
but even in this situation, HCV infection will predominate (Danta et al., 2008, Darby et 
al., 1997, Giordano et al., 2004, Chu and Lee, 2008, Jardi et al., 2001, Zarski et al., 
1998).  Other factors which may increase or accelerate HCV disease progression 
include the use of steroids, daily use of marijuana and host factors such as the HCV-
specific immune response and the genetic polymorphisms of genes which may 
influence the progression rate of fibrosis for example adiponutrin (PNPLA3) or 
transforming growth factor B1 (TGF B1) (Jonsson et al., 2008, Zimmer and Lammert, 
2011, Hraber et al., 2007)   
 
Interestingly, 15-20% of infected individuals can spontaneously clear the acute 
infection following a strong immune response, the mechanism of which is not fully 
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understood (Rehermann, 2009).  Although it is rare for patients with acute HCV 
infection to suffer from fulminant hepatic failure as a result of the infection, there is an 
increased risk of this occurring in patients who are coinfected with chronic HBV.  In 
cohorts with HIV and HCV coinfection, the weakened immune response to HCV 
caused by the underlying HIV infection reduces the chances of spontaneously 
clearing the HCV infection even further (Chu et al., 1998, Vogel and Rockstroh, 2010, 
Thomson et al., 2011). 
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Figure 1-8 HCV disease progression  
(A) Cartoon diagram of the liver illustrating liver disease progression from chronic 
hepatitis with scarring of the liver (fibrosis), to cirrhosis (advanced scarring) and then 
hepatocellular carcinoma (HCC) (Racino, 2013).  (B) HCV disease progression 
detailing the percentages of patients who advance from acute infection to disease 
resolution or chronic infection advancing to cirrhosis and HCC. 
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HCV infection and immunity 
Most patients become aware that they are infected with HCV when the disease has 
progressed to end stage liver failure, typically over the course of 20-30 years, and 
symptoms of liver damage appear (Sharma and Feld, 2014; Ferenci et al, 2007).  
Patients suffering with either cirrhosis or hepatocellular carcinomas (HCC) are likely 
to undergo liver transplantation.  Liver transplants in HCV infected people are fairly 
successful, however the new liver graft becomes reinfected in 100% of cases with 
circulating HCV particles.  There is a possibility that some patients may require 
additional liver transplants over time, therefore HCV infection is the greatest burden 
on liver transplants (Brown, 2005). 
 
Following initial HCV exposure there is often a variable incubation period when the 
viral RNA may be undetectable but 1-8 weeks after infection; HCV RNA can be 
detected in the blood plasma or the liver by PCR, reaching around 106 genome 
copies per mL.  The level of HCV RNA then increases to peak viral loads, often 
maintaining constant levels for 4-8 weeks before beginning to decrease as the 
adaptive immune system responds to the virus.  HCV antibodies are produced 
typically 8 weeks following infection; however the antibodies are usually not 
detectable by ELISA until several months time (Vogel 2009; Neumann et al 1998; 
(Thimme et al., 2001, Major et al., 2004).  Despite HCV antibodies being produced 
during the acute phase, the number of patients who can spontaneously clear the 
virus remains very low and infection persists into chronic stages for approximately 
70% of those acutely infected patients.  It is thought that 1012 viral particles are 
produced daily, and given the high mutation rate and genetic diversity, this may 
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assist HCV to escape immune recognition (Neumann et al 1998; Logvinoff et al 2004; 
Meunier et al 2005).  High titres of neutralising HCV antibodies can be detected 
during chronic HCV infection which targets the HCV E1 and E2 proteins.  However, 
exposure of the hypervariable regions (HVRs) within E1 and E2 to HCV specific 
antibodies leads to high variability with these regions.  This selective pressure from 
the adaptive immune response, combined with the high viral mutation rate leads to 
the virus evolving to escape neutralising antibodies via epitope alterations (Weiner et 
al., 1991, Kato et al., 2001, Farci et al., 1996, Shimizu et al., 1996, Pantua et al., 
2013).  Some studies have also highlighted that the presence of these HCV 
neutralising antibodies may not be enough to clear the viral infection and that it also 
depends on the functional range of the antibodies, affinity for the highly variable 
binding site and ability to overcome the physical glycan ‘shields’ the virus uses to 
mask antibody binding sites thus escaping antibody neutralisation and viral clearance 
(Ball et al., 2014, Major et al., 2004, Prince et al., 1999, Pestka et al., 2007, Dowd et 
al., 2009, Osburn et al., 2014). 
 
Successful clearance of HCV has been associated with host factors such a robust 
adaptive immune response with HCV-specific CD4+ and CD8+ T cell responses, high 
titres of broadly neutralising antibodies targeting HCV structural proteins, strong 
hepatocellular expression of IFNγ and IL28B gene polymorphisms (or IFNλ3 gene) 
(Lauer et al, 2001; Rauch et al, 2010; Thomas et al, 2009; (Billerbeck et al., 2013, 
Thimme et al., 2001).  Patients with chronic HCV infection tend to have low or 
undetectable CD4+ and CD8+ T cell responses which may be a result of T cell 
exhaustion; however it is still unclear how infection with HCV leads to chronic 
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infection (McMahan et al., 2010).  Chronic HCV disease progression varies in 
individual patients due a several factors previously discussed, which include: use of 
steroids, viral coinfection, age (Svirtlih et al., 2007), ethnic background (Sterling et al., 
2004), and alcohol intake (Gitto et al., 2009).  Polymorphisms of the IL28B gene have 
associated with spontaneous clearance of HCV infection and a better response to the 
standard HCV therapy of pegylated IFNα and ribavirin (Rauch et al., 2010, Tanaka et 
al., 2009). 
 
HCV has other mechanisms that assist in evading the immune response to establish 
a successful chronic infection.  There are several proteins HCV encodes able to 
disrupt various signalling pathways within the host cell, for example; interferon 
signalling can be blocked by either the core protein via modulating the JAK-STAT 
pathway or by NS3-4A via modulating IFNβ production (Foy et al., 2005; Li et 
al.,2005).  HCV encoded proteins, NS5A, E2 and part of the internal ribosome entry 
site (IRES), can inhibit protein kinase receptor (PKR) signalling disrupting type 1 IFN 
signalling (Vyas et al 2003; Sklan et al., 2009).  HCV can utilise cell-cell transmission 
instead of cell free transmission to evade immune responses. A number of other 
mechanisms HCV uses to evade the immune are summarised in Table 1-2 
(Brimacombe et al., 2011, Meredith et al., 2013, Grove et al., 2007, Barretto et al., 
2014, Xiao et al., 2014). 
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Table 1-2 Mechanisms by which HCV evades the host immune responsea 
Viral factor(s) Evasion strategy 
HCV genomic sequence 2,5’ OAS/RNase L pathway: RNase L digests viral 
RNAs.  The genomic sequence of HCV has a paucity 
of RNase L cleavage 
HCV proteins Induces an ER stress response and increase PP2A 
expression, which inhibits the JAK-STAT pathway.  
Suppress ISG56, which normally antagonizes viral 
RNA translation 
HCV IRES Inhibits PKR, which normally antagonizes viral RNA 
translation 
Core Reduces the number of PDCs and decreases their 
ability to produce IFN-α, induces expression of 
SOCS, which down regulates the JAK-STAT pathway 
E2 Inhibits PKR, which normally antagonizes viral RNA 
translation 
NS3-4A Disrupts two independent viral recognition pathways, 
RIG-I and TLR3 
NS5A Inhibits PKR, which normally antagonizes viral RNA 
translation, and activates the transcription factor 
IRF1, induces IL-8 production, which attenuates the 
activity of IFN-α 
aTable adapted from Sklan (2009). ER, endoplasmic reticulum; IFN, interferon; IL-
8, interleukin 8; IRES, internal ribosome entry site; IRF1, interferon response 
factor 1; OAS, oligoadenylate synthetases; PDC, plasmactoid dendritic cell; PKR, 
double-stranded RNA-activated protein kinase; SOCS, suppressors of cytokine 
signalling. 
  
35 
HCV therapies and treatments  
The standard HCV treatment is a combination therapy of ribavirin (a nucleoside 
inhibitor of viral replication) and pegylated interferon-α (Peg-IFN-α) which is toxic, 
costly and only effective in 20-50% of patients (~50% in genotype 1 infected patients) 
with some withdrawing from treatment due to the severe side effects (Lemon et al., 
2010, Appel et al., 2006, Brass et al., 2006, Pezacki et al., 2010, Podevin et al., 2010, 
Lindenbach et al., 2005b, Pawlotsky, 2011).  Responses to treatment can be 
genotype specific, with genotype 1 infected patients often requiring a longer 
treatment time which still results in a lower success rate compared to patients 
genotype 2 and genotype 3 infected patients (Ascione et al., 2010, Rumi et al., 2010; 
Feld and Hoofnagle 2005, Zeuzem, 2004). 
 
There is currently still no vaccine against HCV; however HCV therapy was 
revolutionised when new direct-acting antiviral agents (DAAs) against HCV were 
developed.  This included two new protease inhibitor drugs that target the viral 
NS3/NS4A serine protease, Boceprevir and Telaprevir, which have been licensed.  
These direct-acting anti-viral agents (DAA) can be used in combination with the 
current IFN-α and ribavirin treatment as monotherapy has been shown to result in the 
rapid emergence of drug resistance. They have shown promising results for 
genotype 1 infected patients (cure rates of up to 75%), however are associated with 
increased side effects (Poordad et al., 2011, Kwong et al., 2011, Lin et al., 2004, 
Sarrazin et al., 2007, Backus et al., 2014).  More recently, a number of DAAs have 
been approved which show higher cure rates.  The DAAs Simeprevir (Olysio®, 
Sovriad®) and Faldaprevir are two of the latest protease inhibitors designed to be 
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given once-daily to patients, however they will still be used in combination with the 
current IFN-α and ribavirin treatment.  The cure rates for these newer DAAs are 72-
80%, with the potential for a shorter treatment time if patients respond well 8-12 
weeks after the treatment begins.  In addition, there are fewer side effects with the 
newer DAAs (Welch and Jensen 2014, Manns et al 2014, Zeuzem 2014).  Sofosbuvir 
(Solvaldi®) is the first DAA to be approved which inhibits HCV NS5B polymerase.  
Also a once-daily treatment for patients, Sofosbuvir, in combination with IFN-α and 
ribavirin has shown cure rates of 89% in treatment naïve genotype 1 infected patients 
(Lawitz et al., 2013).  When in combination with ribavirin, Sofosbuvir has shown cure 
rates of 85-100% in treatments naïve genotype 2 and genotype 3 infected patients 
(Jacobson et al., 2013; (Lawitz et al., 2013, Zeuzem et al., 2014). 
 
In general, IFN free HCV therapy for patients would be more ideal and DAA therapies 
would be cheaper and accessible to more patients.  However, we have seen an 
improvement in response to HCV therapies over the last decade by tailoring the 
treatment doses and duration with IFN based treatments for individual patients taking 
into account key baseline factors including HCV genotype, viral load, coinfection, 
level of liver fibrosis, presence of liver steatosis, age, gender, ethnicity, body mass 
index and presence of insulin resistance.   Some of these factors, for example insulin 
resistance, do not alter the treatment outcome when using triple therapy with PEG-
IFN, ribavirin and DAAs (Backus et al., 2011, Veldt et al., 2007, van der Meer et al., 
2012, McHutchison et al., 2009).  A number of recent trials and studies have 
indicated differences in treating patients with different subtypes of the same HCV 
genotype, for example, HCV genotype 1a are at higher risk of developing antiviral 
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resistance than HCV genotype 1b patients (Sarrazin and Zeuzem, 2010).  The 
development of these new DAAs does raise the potential issue of future drug 
resistance as a result of resistance associated amino acid variants of the virus.  
Ensuring patients follow their treatment regimes will be essential in trying to prevent 
antiviral drug resistance and additional measures such as routinely monitoring patient 
HCV sequences before and during therapy may also be helpful.  Treating patients 
with different combinations of DAAs may also be another tactic to prevent drug 
resistance in the future (Schneider and Sarrazin, 2014, Sarrazin et al., 2007, Zeuzem 
et al., 2014, Manns et al., 2014). 
  
Liver transplantation in HCV infected patients still remains a successful treatment, 
particularly for those with severe cirrhosis or hepatocellular carcinoma, even though 
donor livers are limited.  In addition, the new liver can become reinfected with 
circulating HCV particles and in the long term, the prognosis appears to be worse 
with recurrent disease and potential loss of the graft.  Currently, HCV infection is still 
a major burden on liver transplantation and major cause of global mortality.  Taking in 
to account the new DAAs, there is still a need for novel HCV therapies that could 
protect the donor liver from reinfection during liver transplantation.  There is also still 
no vaccine for HCV and novel HCV therapies which can treat more genotypes 
without the need for combination with IFN could be developed following a greater 
understanding of the mechanisms and host-virus interactions involved (Gao et al., 
2010, Lemm et al., 2010, Meredith et al., 2012b, Pawlotsky, 2011). 
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1.4 Model systems to study HCV 
 
HCV replicon systems 
The first in vitro model system to study HCV was a replicon system using cDNA 
clones, developed 10 years after the identification of HCV (Lohmann et al., 1999).  
This system first used RNA derived from HCV infected explants livers to clone the 
entire HCV ORF sequence; however the full length sequences failed to yield viral 
replication following transfection of Huh7 cells.  The system was adapted by 
removing the region of the sequence encoding HCV structural proteins and inserting 
a neomycin resistance gene to create selectable subgenomic replicons (Lohmann et 
al., 1999).  To improve the replication efficiency, cell culture adapted point mutations 
or deletions were introduced to the genome sequence (Blight et al., 2000; Lohmann 
et al., 2001; Bartenschlarger and Lohmann 2000; Krieger et al., 2001).  Huh7 cells 
were used for the replicon system and following prolonged IFNα treatment of the 
transfected Huh7 cells, a sub-clone termed Huh7.5 was established by Blight and 
colleagues.  This subclone appeared more permissive than Huh7 cells and later this 
was shown to be due to a defective retinoic acid inducible gene I (RIG-I), which is 
required for immune sensing of double-stranded RNA.  A schematic diagram 
detailing the production of Huh7 cells containing subgenomic or genomic replicons 
and the generation of the Huh7.5 subclone is illustrated in Figure 1-9A-B (Blight et al 
2002; Sumpter et al 2005; Regeard et al 2007).  The replicon system was developed 
further and a selectable full-length HCV replicon is available, containing the structural 
genes (Kato et al., 2001; Kato et al., 2003). Furthermore subgenomic replicons 
derived from an HCV genotype 2a strain called JFH-1 have been generated with 
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even higher replication efficiency (Date et al., 2004; Kato et al., 2005).  More recently 
the LucA2 subgenomic replicon-luciferase cell line was developed, using Huh7 cells 
expressing HLA-A2 and containing the replicating subgenomic JFH1 HCV strain.  As 
this system contains a luciferase reporter, the level of replication can be easily 
determined by measuring the luciferase activity. 
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Figure 1-9 HCV replicon system   
(A) Schematic diagram illustrating the replicon system from Regeard (2007).  (B) 
Huh7 cells are electroporated with subgenomic or genomic replicon RNA and cells 
successfully replicating the HCV replicons are selected following treatment with G418 
(Ba).  In parallel, Huh7 subclones highly permissive to HCV replication can be 
selected after cells are transfected by first treating cells with G418 and then treating 
with interferon-α (IFN-α) to cure the HCV replicon (Bb)  
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HCV pseudotype virus particles (HCVpp) 
Retroviral particles expressing the HCV glycoproteins E1 and E2 have been created 
and are called HCV pseudoparticles (HCVpp).  This system allows the adsorption 
and entry steps of the HCV life cycle to be investigated, in contrast to the replicon 
system which bypassed entry steps by transfecting the HCV RNA into Huh7 or 
Huh7.5 cells.  The pseudoparticles consist of HCV E1E2 glycoproteins, the gag-pol 
gene of HIV or murine leukaemia virus (MLV) and a reporter gene, as shown in 
Figure 1-10.  The reporter gene allows easy detection of HCV entry and can be 
either a luciferase reporter or green fluorescent protein (GFP) (Bartosch et al 2003a, 
Hsu et al 2003, Zhang et al 2004; Drummer et al 2003). 
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Figure 1-10 HCV pseudotype virus particle (HCVpp) system  
A cartoon illustrating the generation of HCVpp, which can be used to quantify the 
level of HCVpp entry by luciferase activity within the target cells. 
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HCV particles derived in cell culture (HCVcc) 
Several research groups have developed infectious HCV particles in cell culture 
(HCVcc), allowing the full HCV lifecycle to now be investigated.  The development of 
HCVcc particles was first possible due to a unique clone isolated from a Japanese 
patient suffering severe acute HCV genotype 2a infection.  The clone was termed 
Japanese Fulminant Hepatitis 1 (JFH-1) and it can infect cell lines such as Huh7 and 
Huh7.5 cells, however it is also infectious in chimeric mice with human liver cells and 
in chimpanzees (Wakita et al 2005; Zhong et al 2005; Lindenbach et al 2005).  The 
system was developed further and chimeric viruses were produced expanding the 
range of genotypes.  This system was a key breakthrough for HCV research allowing 
the full lifecycle of various HCV genotypes to be studied, including mechanisms of 
HCV pathogenesis and screening for HCV-specific antiviral compounds (Gottwein et 
al 2009; Lai et al 2010; Mancone et al 2011).  HCVcc infection can also be monitored 
via luciferase activity by taking the complete HCV J6 viral strain containing a Gaussia 
luciferase reporter gene (HCVcc-gLuc) or the polymerase defective control HCV virus 
that is unable to replicate (HCVcc-gLuc) and transfecting both virus into hepatoma 
cells separately.  The Gaussia luciferase signals can be detected by sampling the 
supernatants which contain de novo full length HCVcc particles and therefore allow 
the levels of replication to be quantified (Koutsoudakis et al 2012). 
 
Small animal models 
The only species naturally susceptible to HCV are humans and chimpanzees.  
Although chimpanzees have previously been used to research HCV and been a 
valuable model, studies using this model are hampered by increasingly limited 
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access to chimpanzees for research due to ethical concerns, high costs, small cohort 
sizes and genetic heterogeneity (Houghton 2009; Bukh 2004).  The lack of small 
animal models that support HCV infection has limited research into virus-host 
interactions, immunity, and drug and vaccine candidates.  Recently, two genetically 
humanized mouse models have been established which both show potential for 
future HCV research.  However these model systems require improvement if they are 
going to be successfully used to study the complete HCV viral lifecycle, as they can 
not yet replicate HCV successfully.  Table 1-3 summarises the advantages and 
limitations of a number of animal models available to study HCV infection (Dorner 
2011; Washburn 2011;Reeves and Manickam 2014).  There is a need for small 
animal models to study HCV as the current animal models have a number of 
limitations, with the main issue being a lack of progressive HCV disease, which 
ultimately impacts the ability to study HCV immunity and therapeutics (Manickam and 
Reeves 2014). 
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Table  1-3 Summary table of animal models used in HCV researcha 
Model Advantages Limitations 
Chimpanzee HCV discovery; in vivo 
virus replication 
 
Expensive; limited 
availability; lack of liver 
fibrosis; low chronicity 
rate; ethical concerns 
Tree shrew Small animal susceptible 
to HCV infection 
Lack of chronicity; only 
transient viremia 
Humanized mouse 
model 
Useful for immunisation 
and challenge studies 
 
Low level of viral 
replication; lack of 
progressive liver pathology 
GBV-B infection of New 
World Monkeys 
GBV-B closely related to 
HCV; analogous disease 
course to HCV 
Low frequency of chronic 
infection 
Chimeric GBV-B 
infection of New World 
monkeys  
Antiviral testing Inability to cause chronic 
infection 
aTable summarizing the various animal models available for studying HCV 
infection, plus the advantages and disadvantages of each animal model.  Adapted 
from Reeves and Manickam (2014). 
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1.5 HCV lifecycle 
 
The exact mechanism(s) of the full hepatitis C viral lifecycle is yet to be fully 
understood due to several reasons including a limited number of physiologically 
relevant in vitro models which mimic the multi-cellular, complex liver 
microenvironment (Meredith et al., 2012b).  In order for a virus to gain access to the 
host cell and establish infection, it must first bind to specific receptors or attachment 
factors expressed on the cell surface.  Once the virus is bound to the cell membrane, 
it can be internalised via endocytosis or fusion of the viral envelope with the host 
plasma membrane.  HCV entry is thought to be initiated by low affinity interactions 
with the attachment factors low density lipoprotein receptors (LDL-R), C-type lectins 
and glycosaminogylcans (GAGs) before the virus interacts with the four key HCV 
receptors essential for HCV entry; Scavenger Receptor Class B member I (SRBI), 
Tetraspanin CD81, Claudin-1 and Occludin (Meredith et al., 2012a).  HCV is 
internalised via clathrin-dependant endocytosis and the viral genome is released 
following pH dependant fusion of the viral and endosomal membranes.  The 
uncoated viral RNA can then undergo replication, which is a complicated process 
involving various viral and host proteins, the viral RNA and a membranous web 
structure which is the site of replication.  Successful replication leads to the assembly 
and packaging of the replicated viral RNA and maturation of virions, which can be 
released from the cell to transmit infection to other host cells and new hosts 
(Blanchard et al 2006; Meredith, Wilson et al. 2012; Moradpour et al 2007; 
Bartenschlager et al 2011).  
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Despite the recent advances in HCV therapies with the latest DAAs, there are still 
issues with regards to successfully treating patients with different genotypes, 
potential for antiviral drug resistance, cost and availability of these therapies 
especially as many of the drugs are given as combination therapies.  There is still a 
need to develop novel therapies and a vaccine, and so given the essential and 
conserved nature of the HCV entry step, there has been and currently still is a great 
deal of research in developing novel therapeutics which targets the HCV entry step.  
The HCV entry step in a complicated process, the mechanism of which we still do not 
fully understand, involving a number of entry attachment factors and receptors which 
are detailed below. 
 
1.5.1 HCV attachment factors 
  
HCV entry into hepatocytes is a complicated, multistep process for which the exact 
mechanism(s) is still unknown.  Recently, a number of host factors involved in HCV 
entry have been identified in addition to the four key HCV receptors: tetraspanins 
CD81 (Hsu et al 2003) and scavenger receptor BI (SR-BI) (Grove et al 2007) and the 
two tight junction proteins claudin-1 (Kapadia et al 2007) and occludin (Ploss et al 
2009), illustrated in Figure 1-11.  When HCV first contacts hepatocytes, it is 
hypothesized that the virus is captured by low-density lipoprotein receptors (LDL-R), 
C-type lectins or heparin sulphate glycosaminoglycans.  Although these interactions 
are low affinity and do not initiate the entry process, they do potentially concentrate 
the virus at the cell surface, tethering the virus before it interacts with the receptor 
molecules. 
  
48 
 
 
 
Figure 1-11 Key HCV receptors   
The four key host HCV receptor molecules involved in HCV entry: tetraspanin CD81, 
scavenger receptor B I (SR-B1) and tight junction proteins Claudin-1 and Occludin.  
CD81, Claudin-1 and Occludin play a role in HCV internalisation and the extracellular 
loops 1 and 2 (EC1 and EC2), large extracellular loop (LEL) and small extracellular 
loop (SEL) are labelled.  SR-B1 plays a role in HCV attachment.  Adapted from 
Lemon and McKeating (2010). 
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Low density lipoprotein receptors 
HCV particles in vivo in human sera are associated with LDL, very low density 
lipoproteins (VLDL) and high density lipoproteins (HDL).  As a result of this 
association, several studies have suggested LDL-R found on hepatocytes are 
involved in HCV attachment and uptake (Agnello et al 1999; Monazahian 1999; 
Wunschmann 2000; Nahmais 2006; Molina 2007; Germi et al 2002) 
 
C-type lectins  
Although the C-type lectins, DC-SIGN and L-SIGN are not expressed on hepatocytes 
they are expressed on liver sinusoidal endothelial cells (LSEC) and dendritic cells 
and have been shown to bind many viruses including HCV.  These molecules are 
thought to capture HCV particles and transfer them to the target hepatocytes (Lozach 
et al 2004; Cormier et al 2004; Pohlmann et al 2003). 
 
Glycosaminoglycans (GAGs)  
GAGs are polysaccharides present on the surface of many cell types and highly 
sulphated GAGs, such as heparin sulphate, have been shown to bind HCV via 
interactions with the HCV E2 glycoprotein.  As heparin sulphate GAGs can bind 
many viruses this interaction is not specific for HCV and is thought to play more of a 
role in facilitating the interactions between HCV particles and the key receptors rather 
than act as a viral receptor itself (Germis 2002; Barth 2003; Basu 2004; Heo 2004; 
Jiang 2012). 
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1.5.2 HCV entry factors 
 
Once HCV has interacted with the various attachment factors and become tethered 
to the hepatocyte cell membrane, the viral particle can then interact with entry factors 
that will facilitate uptake of the virus particle into hepatocytes.    HCV is thought to 
interact with SR-BI first, then CD81-claudin-1 complexes followed by occludin, 
however the sequence of virus-receptor interactions is not yet fully understood 
(Meredith et al 2012).   
 
Scavenger Receptor Class B member I (SRBI) 
SR-BI is a multi-function lipoprotein receptor expressed on the cell surface of most 
mammalian cells, with high expression in hepatic and steroidogenic tissues.  It is a 
509 amino acid long glycoprotein with a large extra cellular loop between the N-
terminal and C-terminal transmembrane domains, and also has a short cytoplasmic 
extension.  It is expressed in areas of high blood flow where it is involved in 
mediating cholesterol ester uptake from HDL, LDL, and VLDLs, along with 
maintaining lipid homeostasis (von Hahn et al., 2006, Rhainds and Brissette, 2004, 
Rhainds et al., 2003, Dreux et al., 2006).  Initially SR-B1 was identified as a HCV 
receptor with functional studies that showed SR-B1 binds soluble HCV E2 
glycoprotein, later confirmed using the HCVpp and HCVcc systems.  Later it was 
discovered that HDLs and oxidised LDLs can enhance or inhibit virus infection in an 
SR-BI dependent manner (Scarselli et al 2002; Meredith et al 2012).  This interaction 
between HCV and SR-BI is complicated and it may lead to membranous or 
cytoplasmic rearrangements to help bring the HCV-SR-B1 complex closer to the 
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other factors required for virus entry. HCV binding SR-BI is required for it to interact 
with CD81 (Eyre et al., 2010, Meredith et al., 2012b, Brimacombe et al., 2011). 
 
Tetraspanin CD81 
CD81 is a tetraspanin, ubiquitously expressed in the body that is thought to play a 
role in various cell signalling pathways such as immune cell activation. However, the 
functions of CD81 are not fully defined.  CD81 was identified as a potential HCV 
receptor following functional studies that showed CD81 binds soluble HCV E2 
glycoprotein (Pileri et al 1998). It was later found that this interaction and subsequent 
HCV infection could be blocked using anti-CD81 antibodies and soluble CD81, using 
the HCVpp and HCVcc systems (Bartosch 2003a; Lindenbach 2005; Wakita 2005; 
Zhong 2005).  Studies have also shown that non-permissive cell lines could become 
permissive to HCV infection following the expression of CD81 (Zhang 2004; Lavillette 
2005; Akazawa 2007).  However, CD81 alone is not sufficient for HCV entry as it 
requires co-factors such as SR-BI and claudin-1 to facilitate entry, and it appears 
CD81 is also involved in post entry steps and may promote endocytosis and particle 
internalisation (Bartosch 2003b; Hsu 2003 Cormier 2006; Bartaud 2006; 
Koutsoudakis 2006; Farquhar 2012).   
 
Claudin-1  
The role of claudin-1 is not as well defined as CD81, whose interaction with HCV 
induces a conformational change in the HCV E1 and E2 glycoproteins which go on to 
aid the pH-dependent fusion and endocytosis of HCV  (Sharma et al., 2011, Meredith 
et al., 2012b).  The tight junction protein, Claudin-1, is highly expressed in the liver 
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particularly around the bile canaliculi of hepatocytes and is thought play a role in a 
late step of virus entry (Fofana et al., 2010, Krieger et al., 2010).  Recent data 
suggests that CD81 and claudin-1 may work together to assist HCV entry and that a 
direct interaction between the molecules is essential for HCV entry.  It is thought 
CD81 and claudin-1 together have a role in virus internalisation and fusion, as they 
both co-endocytose and fuse with early endosomes (Meredith et al., 2012b, Farquhar 
et al., 2011, Farquhar and McKeating, 2008).  Claudin-1 has also been shown to play 
a role in cell-cell transmission of HCV, independently of CD81 (Timpe 2007), 
furthermore, two other members of the claudin family, claudin-6 and claudin-9, may 
play a role in HCV infection (Zheng 2007; Meertens 2008). 
 
Occludin 
Occludin is a four-transmembrane domain tight junction protein, similar to claudin-1.  
It is essential for HCV infection, as demonstrated when cells expressing SR-BI, CD81 
and claudin-1 were not susceptible to infection, compared to cells expressing all four 
key receptors; which were then susceptible to HCV (Evans 2007; Liu 2009; Ploss 
2009).  The role of occludin in entry and whether it interacts with HCV directly via E2 
glycoproteins or indirectly via the CD81 and claudin-1 complex is yet to be 
determined (Thorley et al., 2010, Harris et al., 2010, von Hahn and Rice, 2008). 
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1.5.3 HCV replication, assembly and release 
 
HCV RNA replication is a complex process which requires several cellular factors, in 
addition to viral factors, to form the HCV replication complex.  The HCV NS5B protein 
has been identified as a RNA-dependant RNA polymerase and is responsible for viral 
RNA replication (Behrens et al., 1996).  The HCV NS4B protein was later identified 
as the protein which induces the endoplasmic reticulum (ER) derived membranous 
web structure, the site of HCV replication, also containing other HCV non-structural 
proteins (Egger et al., 2002).  The positive strand of HCV RNA released into the 
cytosol is used as a template by the NS5B RNA polymerase to synthesize the 
intermediate minus strand RNA.  The HCV NS3 protein has helicase function and is 
thought to assist the RNA polymerase in synthesising minus strand RNA, by 
unwinding the template RNA.  The NS3 helicase also unwinds the intermediate anti-
sense RNA which then becomes the template for synthesis of numerous positive-
stranded RNA to be used as either genomic RNA for HCV progeny or for polyprotein 
translation (Jin et al., 1995; Kim et al.,1995). 
 
Research into HCV particle assembly and release has been limited as the in vitro 
models that could allow these processes to be studied have only been developed 
recently.  The latest studies suggest that virus assembly occurs within the ER 
(Gastaminza et al., 2008) and that particle formation involves lipid droplets 
associating with various HCV proteins.  The core protein, when associated with lipid 
droplets, has the ability to target viral structural proteins and HCV RNA from the ER 
to lipid droplets.  NS5A associated with lipid droplets, together with apolipoprotein E 
(apoE), is thought to play a key role in forming infectious viral particles (Miyanari et 
  
54 
al., 2007; Appel et al., 2008; Benga et al., 2010).  Based on current research 
highlighting the association of various HCV proteins with lipid droplets and spherical 
virus-like particles containing core protein and E2 found associated with membranes 
close to lipid droplets, it has been suggested that lipid droplet associated membranes 
may be the site of HCV particle assembly (Miyanari et al., 2007).  The current model 
for the viral lifecycle is summarised in Figure 1-12 (Feneant 2014). 
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Figure  1-12 HCV lifecycle   
HCV initiates infection following non-specific attachment to glycosaminoglycans 
(GAG) and Low Density Lipoprotein-Receptor (LDL-R).  The HCV particle then 
interacts with SR-BI, CD81 and claudin-1 complexes and then occludin which leads 
to virus entry via clathrin-mediated endocytosis.  HCV translation and replication 
occurs at the endoplasmic  reticulum membrane, followed by assembly of viral 
particles associated with lipid droplets (Feneant 2014). 
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1.6 Role of aLMF in HCV pathogenesis 
 
In developed countries alone, fibrotic diseases account for 45% of the total deaths 
but currently there are no anti-fibrotic therapies available for established cirrhosis.  
Therefore, there is a need to understand the molecular mechanisms of liver 
fibrogenesis in order to help develop new therapies for fibrotic diseases (Su et al 
2014).  Worldwide, chronic HCV infection is one of the leading causes of liver fibrosis 
progressing to cirrhosis.  Several studies have shown the progression of fibrosis can 
be stopped and even reversed following successful antiviral therapies which treat the 
underlying cause of fibrosis.  As there are no anti-fibrotic therapies available, we do 
not know whether combination therapy of antivirals and anti-fibrotic therapies would 
be beneficial for patients, and if this would lead to more successful therapies 
especially as the fibrosis is actually the liver’s mechanism of repair in response to 
HCV infection and is a positive factor which becomes a negative issue if prolonged 
leading to irreversible damage (Su et al 2014; Wynn et al 2008; Friedman et al 2008; 
Friedman et al 2007).      
 
The main driving force behind liver fibrosis is hepatic inflammation caused in 
response to liver injury such as HCV infection; however, host factors such as single 
nucleotide polymorphisms, in addition to viral factors such as viral load, mutations, 
and viral proteins are associated with fibrosis progression.  The key characteristics of 
liver fibrosis include the activation of quiescent HSC into aLMF cells, proliferation of 
aLMFs, loss of hepatocytes, destruction of hepatic microarchitecture and excess 
ECM accumulation.  In chronic viral hepatitis, HSCs are activated as a result of the 
host immunological response to initiate antiviral mechanisms, designed to clear 
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virally infected hepatocytes thus attempting to clear the viral infection (Friedman et al 
2007; Su et al 2014; Wang et al 2013).  A number of profibrogenic factors, including 
transforming growth factor beta (TGF-β) are released by HCV infected hepatocytes, 
which act on HSC modulating the expression of several genes associated with 
fibrosis (Schulze-Krebs et al 2005).   
 
The role of HSCs in liver fibrosis is well known, however more recently, data is 
emerging that HSCs also play a role in liver immunity and could therefore impact 
HCV disease progression via this additional mechanism.  During chronic HCV 
infection, infected hepatocytes can undergo apoptosis induced by the viral infection 
generating apoptotic bodies, which are cleared by phagocytosis as part of the innate 
immune response.  HSCs have the ability to phagocytose these apoptotic bodies and 
this process leads to a profibrogenic response (Zhan et al 2006; Jiang et al 2008; 
Deng et al 2008; Wang et al 2013).  HSCs have been reported to function as liver 
resident antigen-presenting cells (APC), responsible for displaying foreign antigens in 
order to stimulate T cells production, and are also thought to enhance the 
differentiation and accumulation of regulatory T cells.  The innate immune response 
also recognises pathogens such as HCV via toll-like receptors (TLRs) and HSCs 
express TLRs, in particular TLR-3, TLR-4 and TLR-9.  Pathogen sensing via TLR-3 
leads to the activation of the IFN signalling pathway and production of Type I and 
Type III IFNs which act to limit HCV infection in hepatocytes (Wang et al., 2013a, 
Wang et al., 2013c, Winau et al., 2007, Ichikawa et al., 2011, Seki et al., 2007, 
Watanabe et al., 2007, Kumar et al., 2006, Kawai and Akira, 2006).  
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Recent studies have suggested HCV particles and some HCV proteins can also 
directly interact with HSC inducing liver fibrosis and possibly the innate immune 
response.  For example, the HCV E2 protein has been shown to bind directly to 
CD81 expressed on HSCs which induces fibrosis pathways such as the up regulation 
of MMP-2.  MMP-2 is responsible for degrading ECM, including the degradation and 
remodelling of normal ECM in areas infected with HCV to allow the penetration of 
inflammatory cells for repair.  However, HCV has been shown to utilise this 
inflammatory repair mechanism to its advantage, creating an environment which 
actually favours HCV virus replication and spread (Mazzocca et al 2002; (Mee et al., 
2009).  Other recombinant HCV proteins thought to interact directly with HSCs and 
induce fibrosis and inflammation include HCV core and non-structural proteins NS3-
N5 (Bataller et al 2004; Wang et al 2013).  The role HCV infection in inducing 
profibrogenic HSCs and fibrosis is summarized in Table 1-4. 
 
These studies have highlighted an additional role for HSCs and aLMFs other than 
causing fibrosis in response to HCV infected hepatocytes and suggest that these 
cells may also be acting as a key regulatory bystander cell involved in the livers 
innate immune response against HCV infection and disease progression.  A greater 
understanding of viral-host interactions is required here in order to determine the 
role(s) of HSC/aLMF in HCV disease progression and implications for treating HCV 
which may potentially help identify new targets for novel therapeutics. 
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Table 1-4 HCV mediated liver fibrosisa    
HCV/HCV proteins HSC 
HCV Induces liver injury, which activates HSC. 
E2 Engulfs apoptotic bodies through phagocyotosis triggers 
a profibrogenenic response in HSC. Up regulates matrix 
metalloproteinase-2 expression, increasing degradation 
of the normal hepatic extracellular matrix in HSC. 
Core Induces fibrogenic actions and stimulates intracellular 
signalling pathway in HSC. 
NS3-N35 Induces pro-inflammatory cytokines in HSC. 
aTable detailing how HCV and its proteins can interact with HSC and induce liver 
fibrosis, adapted from Wang et al (2013). HSC, hepatic stellate cells. 
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1.7 Project Aims 
 
The overall aim of this study was to understand the role of aLMF cells in hepatitis C 
virus (HCV) infection of the liver.  Firstly, we wanted to investigate whether aLMF 
could support HCV infection and the impact of aLMF cells on the various steps of the 
HCV lifecycle in hepatocytes.  Secondly, we wanted to investigate the complex cell-
cell interactions between aLMF and hepatocytes to increase our understanding of the 
mechanisms of host-viral interactions, and to potentially determine new pathways 
that can be targets for novel therapies.   
 
  
61 
Chapter 2 Materials and methods 
2.0 Tissue culture, Cell lines and primary cells 
2.0.1 Tissue culture  
 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, CA, USA) was used to 
maintain all cells, unless otherwise stated, and was supplemented with varying 
quantities of foetal bovine serum (FBS), 1% non-essential amino acids, 1% L-
Glutamine and 50 units/mL penicillin/streptomycin (Gibco, CA, USA) at 37ºC, 20% O2 
and 5% CO2.  Cells under hypoxic conditions were maintained at 37ºC, 1% O2 and 
5% CO2.  The different FBS quantities used and other supplements required for cells 
used in this study are detailed in Table 2-1.   
 
Cells were stored in liquid nitrogen, briefly; cells were dissociated using trypsin, 
centrifuged at 1500 rpm for 5 minutes  and resuspended in freezing media (95% FBS 
and 5% DMSO (Sigma-Aldrich)).  The cells were stored in cryovials and  placed into a 
-80ºC freezer overnight and then transferred to liquid nitrogen the following day.  To 
thaw cells, cryovials were incubated at 37ºC, suspended in media, centrifuged at 
1500 rpm for 5 minutes and resuspended in fresh media before transferring to tissue 
culture flasks for propagation. 
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Table 2-1 Cell lines and primary cells with details of cell growth medium 
Cell Type Source Medium % 
FBS 
Supplied by 
Huh 7.5 Human 
hepatoma  
DMEM  10 Charles Rice, 
Rockerfellar University, 
NY, USA 
Huh 7 Human 
hepatoma 
DMEM  10 American Type Culture 
Collection, VA, USA 
HepG2  Human 
hepatoblastoma 
DMEM  10 American Type Culture 
Collection, VA, USA 
HepG2-CD81 Human 
hepatoblastoma 
DMEM 10 In house 
HepG2-CD81-GFP Human 
hepatoblastoma 
DMEM 10 In house 
HepG2-EGFR-GFP Human 
hepatoblastoma 
DMEM 10 In house 
HepG2-DPP IV Human 
hepatoblastoma 
DMEM 10 In house, UMCG 
A2-HCV replicon-
luciferase Huh 7 cells  
Human 
hepatoma 
DMEM  10 Robert Thimme, 
University of Freiburg, 
Germany 
293-T (HEK 293T/17) Human 
Embryonic 
Kidney 
DMEM  3 American Type Culture 
Collection, VA, USA 
Chinese Hamster Ovary 
(CHO) cells 
Chinese 
Hamster Ovary 
cell line 
DMEM  10 American Type Culture 
Collection, VA, USA 
Lieming Xu-2 (LX-2) 
stellate cell line 
Human cell line DMEM  2.5 Centre for Liver 
Research, UoB, UK 
Activated liver 
myofibroblasts (aLMF) 
Donor liver 
tissue 
DMEM  16 Centre for Liver 
Research, UoB, UK 
Primary Human 
Hepatocytes (PHH) 
Human liver 
tissue 
Williams E  10 HS Ragai Mitry, Kings 
College London, UK 
Dermal fibroblasts (DM) Human tissue  DMEM 16 Rheumatology 
Research Group, UoB, 
UK 
Synovial fibroblasts 
(SY) 
Human tissue DMEM 16 Rheumatology 
Research Group, UoB, 
UK 
Bone marrow 
fibroblasts (BM) 
Human tissue DMEM 16 Rheumatology 
Research Group, UoB, 
UK 
UoB, University of Birmingham; HS, human serum. 
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2.0.2 Liver tissue samples  
 
All human liver tissue samples used to isolate various liver cell types were obtained 
from patients attending the Queen Elizabeth Hospital, Birmingham.  The samples 
were collected with the consent from the patients or their relatives, and according to 
local research ethics committee approval.  These samples were at various end stage 
chronic liver disease aetiologies, including patients undergoing liver transplantation 
for cryptogenic cirrhosis, primary biliary cirrhosis, alcoholic liver disease or 
hemochromatosis.  Tissues were processed promptly after collection to ensure a high 
yield of viable cells, with each sample used to isolate activated liver myofibroblasts 
(aLMF), liver sinusoidal endothelial cells (LSEC) and biliary epithelial cells (BEC). 
 
2.0.3 Isolation of primary aLMF 
 
The liver tissue samples were processed by enzymatic digestion, differential density 
centrifugation and immunomagnetic separation in order to recover a variety of liver 
cell types.  Firstly, the liver tissue was cut into smaller pieces and digested using 
type-1A collagenase (Sigma Aldrich, UK) at 0.4µg/mL.  After enzymatic digestion for 
25-45 minutes at 37ºC, the tissue mixture was sieved using a sterile fine mesh to 
remove any undigested tissue, washed with PBS several times and centrifuged at 
2000rpm for 5 minutes.  The pellet was resuspended in PBS and separated by 
centrifugation using a 33/77 wt/vol Percoll gradient (Amersham, Biosciences, GE) at 
2300rpm for 20 minutes.  Biliary epithelial cells (BEC) were isolated first, using an 
antibody targeting a glycoprotein specifically expressed on the surface of epithelial 
cells, HEA-125 (10µg/mL, Progen Biotechnik), followed by a sheep anti-mouse 
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secondary antibody conjugated to magnetic beads (Dynal, Invitrogen), allowing 
separation using a magnet.  Subsequently LSEC were then isolated using an 
antibody targeting CD31 (10µg/mL, Progen Biotechnik) and magnetic bead 
separation as described above.  aLMF were remaining in the cell suspension and 
thus purified by negative immunomagentic selection, following the removal of BEC 
and LSEC.  The viability of each cell type was confirmed by trypan blue exclusion 
(Holt et al., 2009, Joplin et al., 1990).   
 
Isolated cells were routinely assessed for cell morphology and purity to ensure 
cultures used were >95% pure.  To assess purity, cells were stained and imaged by 
immunofluorescence microscopy using a number of lineage specific markers: for 
aLMF (CD90, desmin, vimentin or αSMA), hepatocytes (albumin, α-feto-protein, CK7, 
CK18), biliary epithelial cells (CK17, CK18, CD19, and EpCAM) and liver sinusoidal 
endothelial cell (CD31).  The morphology was assessed by phase contrast 
microscopy and aLMF cells were kept in culture until at least passage 6.  Primary 
cells were routinely isolated and supplied by Gill Murihead, Janine Youster and 
Elizabeth Humpreys (Centre of Liver Research, University of Birmingham). 
 
2.0.4 Isolation and cryopreservation of primary human hepatocytes 
 
Primary human hepatocytes (PHH) used in this study were a kind gift from Dr Ragai 
Mitry (King’s College, London).  These were isolated according to published protocols 
from donor liver tissue (Mitry, 2009; Hughes et al 2010).  Once isolated, PHH were 
cryopreserved, stored in a liquid nitrogen tank and transported on dry ice.  In order to 
thaw the PHH, briefly; the primary human hepatocytes were incubated at 37ºC, 
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centrifuged at 50xg, 4ºC for 5 minutes and resuspended in Minimal Essential Medium 
containing 20% human serum albumin (Baxter AG, UK), 25mM HEPES without 
phenol red and calcium (1:100 dilution) (Lonza, UK) plus 25% Percoll (GE Healthcare, 
UK).  This cell suspension was then centrifuged at 50xg, 4ºC for 20 minutes to 
separate non-viable and viable cells.  The viable cell pellet was resuspended in 
Minimal Essential Medium containing 20% human serum albumin (Baxter AG, UK), 
25mM HEPES without phenol red and calcium (1:100 dilution) (Lonza, UK) and 
viability further assessed using trypan blue exclusion, then seeded accordingly in 
mono- and co- culture with aLMF, LX-2 and CHO cells (at a 1:1 ratio) in Williams 
Essential Eagles Medium (Sigma, UK) containing 10% human serum, 1% non-
essential amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin (Gibco, 
CA, USA), 1M HEPES, 1% Insulin (Sigma, UK).  Cells were maintained at 37ºC, 20% 
O2 and 5% CO2, and the media replaced 24 hours post seeding to DMEM containing 
10% FBS, 1% non-essential amino acids, 1% L-Glutamine and 50units/mL 
penicillin/streptomycin (Gibco, CA, USA), then infected with high titre HCVcc as 
detailed in section 2.1.3.   
 
2.0.5 Isolation of primary fibroblasts from different sites 
 
The fibroblasts from different sites used in this study were kind gifts from Professor 
Chris Buckley (University of Birmingham, UK).  Dermal fibroblasts (DM), synovial 
fibroblasts (SY) and bone marrow fibroblasts (BM) were all isolated from clinical 
samples as previously described (Salmon et al., 1997), from patients with rheumatoid 
arthritis or osteoarthritis who gave consent according to local research ethics 
committee approval.  Briefly; the tissue samples were cut into smaller pieces, washed 
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in RPMI containing 20mM HEPES and centrifuged at 300g for 6 minutes.  The cells 
were resuspended in digestion buffer (RPMI containing 20mM HEPES and 0.2% 
collagenase type 1A) then incubated for 4-5 hours at 37ºC with vigorous shaking.  
The cell mixture was centrifuged at 300g for 6 minutes, and the pellet containing the 
adherent fibroblast cells was resuspended in DMEM containing 10% FBS, 1% non-
essential amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin (Gibco, 
CA, USA), then incubated at 37ºC, 20% O2 and 5% CO2.  The cells were grown to 
confluency and fresh media replaced weekly.  Fibroblast morphology was assessed 
by phase microscopy over time and the cultures were assessed for contamination by 
staining for markers of the excluded cell populations.  Cultures were routinely stained 
and assessed using endothelial cell markers such as CD31 and von Willebrand factor, 
epithelial cell markers such as cytokeratin and macrophage markers such as CD14 
and CD68 (Zimmermann et al., 2001, Salmon et al., 1997).   
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2.1 Routine techniques 
 
2.1.1 Antibodies and application 
 
Details of all antibodies used in this study, the application, and working 
concentrations used are detailed in Table 2-2 and Table 2-3.
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Table  2-2 Primary Antibodies 
Antibody 
name and 
clone 
Target 
antigen 
Type Specificity Species Application Working 
conc. 
(µg/mL) 
Source 
Anti- claudin-
1 
(polysera) 
Human 
Claudin-1 
Purified 
IgG 
Poly Rabbit IF, WB 1 Zymed, CA, 
USA 
Anti-occludin 
(OC-3F10) 
Human 
Occludin 
Purified 
IgG 
Poly Rabbit IF, WB 1 Zymed, CA, 
USA 
Anti-CD81 
(2s131) 
Human 
CD81 
Purified 
IgG 
Mono Mouse IF, WB 1 In-house 
Anti-SRB1 
(R25) 
Human 
SRB1 
Purified 
IgG 
Mono Mouse WB 1 BD 
Biosciences, 
UK 
Anti-β-actin 
(AC-74) 
Human β-
actin 
Purified 
IgG 
Mono Mouse WB 0.5 Sigma Aldrich 
Anti-NS5A 
(9E10) 
HCV NS5A Hybrido
ma      
supernat
ant 
Mono Mouse IF 2 Rockefellar 
University, 
NY, USA 
Anti-CD90 
(5E10) 
Human 
CD90 
Purified 
IgG1 
Mono Mouse IF 0.25 eBiosciences 
Anti-Desmin 
(DE-R-11) 
Human 
Desmin 
Purified 
IgG1 
Mono Mouse IF 0.5 Vector Labs, 
UK 
Anti- 
Vimentin 
(V9) 
Human 
Vimentin 
Purified 
IgG1 
Mono Mouse IF 0.5 Vector Labs, 
UK 
Anti-VEGF-A 
(293) 
Human 
VEGF-A 
Hybrido
ma 
supernat
ant 
Purified 
IgG2B 
Mono Mouse Neutralising 100  R&D systems 
Anti-CD81 
(2s131) 
Human 
CD81 
Purified 
IgG 
Mono Mouse Neutralising  10 In-house 
Anti-VAP-1 
(BTT1023) 
Human VAP-
1 
Purified 
IgG 
Mono Mouse Neutralising 20 Biotie 
Therapies 
Poly, polyclonal; Mono, monoclonal; IF, Indirect immunofluorescence; WB, Western Blotting. 
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Table 2-3 Secondary Antibodies 
Antibody 
name 
Antigen Type Specificity Species Application Working 
dilution 
Source 
Rabbit 
Alexa Fluor 
488 
Rabbit 
IgG 
Purified 
IgG 
(H+L) 
Poly Goat IF 1/500 Molecular 
Probes, 
Invitrogen, 
CA 
Mouse 
Alexa Fluor 
488 
Mouse 
IgG 
Purified 
IgG 
(H+L) 
Poly  Goat IF 1/500 Molecular 
Probes, 
Invitrogen, 
CA 
Rabbit 
Alexa Fluor 
594 
Rabbit 
IgG 
Purified 
IgG 
(H+L) 
Poly Goat IF 1/500 Molecular 
Probes, 
Invitrogen, 
CA 
Rabbit 
Alexa Fluor 
633 
Mouse 
IgG 
Purified 
IgG 
(H+L) 
Poly Goat IF 1/500 Molecular 
Probes, 
Invitrogen, 
CA 
Anti-Rabbit 
HRP 
Rabbit 
IgG 
Purified 
IgG 
Poly Donkey  WB 1/1000 GE 
Healthcare, 
PA 
Anti-Mouse 
HRP 
Mouse 
IgG 
Purified 
IgG 
Poly Sheep WB 1/1000 GE 
Healthcare, 
PA 
IF, Indirect immunofluorescence; WB, Western Blotting; Poly, polyclonal.  
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2.1.2 List of plasmids  
 
Details of all plasmids used in this study are in Table 2-4 
 
Table  2-4 List of plasmids 
Plasmid details Supplied by 
HCVcc JFH-1 Tajika Wakita, National Institute of Infectious 
Disease, Tokyo, Japan (Wakita et al., 2005a, 
Zhong et al., 2005a) 
HCVcc J6/JFH-1 Charles Rice, Rockefellar University, NY, USA 
(Lindenbach et al., 2005a) 
HCVcc SA13 Jens Bukh, Copenhagen Hospital, Denmark 
(Jensen et al., 2008) 
ISG-56 luciferase reporter Michael Gale, University of Texas Southwestern 
Medical centre, TX, USA 
H77 E1E2 Zie Zhang, Rockefellar University, NY, USA 
(Bartosch et al., 2003, Zhang et al., 2004) 
JFH-1 E1E2 Zie Zhang, Rockefellar University, NY, USA 
(Bartosch et al., 2003, Zhang et al., 2004) 
VSV-G Aaron Diamond, AIDS Research Centre 
HIV gag-pol Aaron Diamond, AIDS Research Centre 
CD81-GFP In house 
EGFR-GFP In house 
TRIP gag-pol  In house 
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2.1.3 HCV cell culture (HCVcc) generation and infection 
 
The HCVcc system is based on a unique clone, termed Japanese Fulminant 
Hepatitis 1 (JFH-1) which can infect hepatoma cell lines and has since been 
used to generate all other HCVcc strains (Wakita et al 2005; Zhong et al 2005; 
Lindenbach et al 2005(Jensen et al., 2008).  SA13 (genotype 5a) HCVcc 
infection was achieved through electroporation of early passage Huh7.5 cells 
with SA13 RNA transcripts, allowing the entry of the RNA transcripts into the 
Huh7.5 cells.  The RNA transcripts encoding the HCV genome SA13 were 
generated using the T7 RNA polymerase kit (Promega, UK) according to the 
manufacturer’s instructions.  The electroporation protocol consists washing 
and resuspending Huh7.5 cells in ice cold PBS, before gently mixing with 
SA13 RNA and transferring into a 0.2cm gap electroporation cuvette (Sigma, 
UK).  Using the BTX Electro Square Porator (Harvard Appartus, USA), the 
cells were electroporated at 815 volts and then allowed to rest in the cuvette 
for 5 minutes at room temperature before gently transferring into IMDM 
containing 10% human serum, 1% L-Glutamine and 50units/mL 
penicillin/streptomycin .  Cells were seeded in a 24 well tissue culture plate 
and taken to the category 3 containment laboratory for culturing and harvest of 
HCVcc particles.  The level of HCV expression after 48 hours was determined 
by staining for NS5A positive cells indicating HCV infected cells, as shown in 
Figure 2-1.  After confirming the level of HCV infected cells 48 hours post 
electroporation, HCVcc particles were harvested by collecting and replacing 
the media every 4 hours throughout the day, for 4 to 7 days post 
electroporation.  Each virus harvest was immediately stored at -80ºC, and then 
pooled and spin clarified by centrifugation at 3000rpm for 5 minutes, and 
  
72 
stored at -80ºC.  The virus stock was titrated by infecting naive Huh7.5 cells 
with varying dilutions to calculate foci forming units per mL (FFU/mL), 
according to NS5A positive staining at 48 hours post infection. 
  
This harvested virus was used in all HCVcc infection assays as follows (unless 
otherwise stated).  Mono- and co- cultures of cells, at a density of 2.5x104 cells 
per well in a 48 well tissue culture plate, were infected 24 hours post seeding 
in the category 3 containment laboratory.  The media was carefully removed 
and replaced with 200µL of the HCVcc particles diluted in complete DMEM 
media containing 10% FBS.  The cells were incubated with the virus inoculum 
for 6 hours at 37ºC, washed with PBS carefully to remove any unbound virus 
particles.  Complete DMEM media, containing 10% FBS, was added to the 
cells and the infection allowed to proceed for 48 hours at 37ºC (unless 
otherwise stated).  Cells were fixed with ice cold methanol then blocked using 
PBS containing 1% BSA with 0.1% saponin or Triton X-100 added to 
permeabilise the cells.  HCV positive cells were determined by staining for 
NS5A positive cells using the primary mouse anti-NS5A mono-clonal antibody 
(clone 9E10), as described in section 2.1.6.  Staining was visualised using a 
fluorescent UV microscope (Nikon eclipse TE2000-5 inverted) and infection 
quantified by counting either the number of foci or total number of infected 
cells. 
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Figure 2-1 Electroporated Huh7.5 cells stained for HCV NS5A 
Immunofluorescence image of Huh7.5 cells fixed and stained for HCV NS5A 
(green), with DAPI nuclear stain (blue), 48 hours post electroporation with 
SA13 RNA, at magnification x10. 
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2.1.4 Pseudoparticle virus generation and infection 
 
Pseudoparticle viruses were generated using 293-T cells and a Fugene 
transfection protocol, according to the method published by Hsu et al (2003).  
Briefly, 293-T cells were seeded at 7x105 cells per well in a 6 well tissue 
culture plate coated with poly-L-lysine at 0.1 mg/mL (Sigma, UK) using DMEM 
containing 10% FBS, 1% non-essential amino acids, 1% L-Glutamine (Gibco, 
CA, USA).  After 24 hours media was replaced with DMEM containing 3% FBS, 
1% non-essential amino acids and 1% L-Glutamine (Gibco, CA, USA).  
Plasmids were delivered to the cells using 6 µg/well Fugene (Roche) and 100 
µL/well optimum (Gibco).  1000 ng/well of the pNL4.3luc plasmid, which 
encodes a HIV virus competent for a single round of replication containing a 
firefly luciferase gene,  was co-transfected with 10 ng/well of the viral envelope 
construct of interest e.g. HCV E1E2, VSV, or the control plasmid encoding no 
envelope (NE).  After incubating the cells with the transfection mixture for 6 
hours at 37ºC, the media was removed and fresh DMEM containing 3% FBS, 
1% non-essential amino acids, 1% L-Glutamine and 50units/mL 
penicillin/streptomycin (Gibco, CA, USA) added to the cells.  The supernatants 
from the transfected cells containing pseudoparticle virus were collected at 48 
and 72 hours post transfection, pooled, spin clarified by centrifugation at 
3000rpm for 5 minutes and stored at -80ºC.  The virus stocks were titrated by 
infecting naive Huh7.5 cells with varying dilutions, the cells were lysed 48 
hours post infection using 1x Cell Culture Lysis Buffer (Promega), prepared 
according to the manufacturer’s instructions, for 2 hours at room temperature. 
The luciferase activity was detected using the Luciferase Assay System 
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(Promega) and a Centro LB960 Luminometer (Berthold Technologies, UK) 
calculate relative light units (RLU) per mL.   
 
The harvested pseudoparticle viruses were used in all pseudoparticle infection 
assays as follows; mono- and co- cultures, seeded at a density of 1.2x104 per 
well in a 96 well plate, were infected 24 hours post seeding with the relevant 
pseudoparticle virus, or NE control, for 8 hours at a dilution defined for each 
batch based on a titration.  Typically HCVpp were diluted 1:2, NEpp diluted 1:2 
and VSVpp diluted 1:100 in DMEM containing 3% FBS, 1% non-essential 
amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin (Gibco, 
CA, USA) and then added to the cells.  After the virus inoculums were 
removed, the cells were lysed and luciferase activity measured after 48 hours 
as described above.   
 
2.1.5 HCVcc-gLuc generation 
 
The HCVcc-gLuc system is based on a HCV J6 viral strain containing a 
Gaussia luciferase reporter gene (HCVcc-gLuc), or the polymerase defective 
control HCV virus that is unable to replicate and thus unable produce Gaussia 
luciferase (HCVcc-GNN) as it encodes two stop codons in the NS5B region 
resulting in a catalytically inactive RNA dependent RNA polymerase.  Both 
HCV viruses were transfected into hepatoma cells to determine the level of 
replication by measuring the Gaussia luciferase activity of Huh7.5 cells 
containing either the HCVcc-gLuc RNA or HCVcc-GNN RNA and then 
comparing the Gaussia luciferase signals.  Gaussia luciferase signals can be 
detected by sampling the supernatants which contain de novo full length 
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HCVcc particles if replication is successful (Koutsoudakis et al 2012(Phan et 
al., 2011).  Huh7.5 cells were transfected with either the HCVcc-gLuc virus, or 
the control HCV-GNN virus and then used in co-culture with stromal cells.  
First, Huh7.5 cells were seeded at 10x104 cells per well in a 6 well tissue 
culture plate using DMEM containing 10% FBS, 1% non-essential amino acids, 
1% L-Glutamine (Gibco, CA, USA).   Cells settled for 24 hours and 1 hour prior 
to the transfection, the media was replaced with DMEM containing 3% FBS, 
1% non-essential amino acids, 1% L-Glutamine (Gibco, CA, USA).  The two 
different viral RNAs were delivered to the cells using Mirus Delivery TransIT®-
mRNA Transfection kit (Mirus Bio LLC, UK).  For each well, 4.5µL Mirus 
Transit mRNA was added to 300µL optimem and mixed well before 3µL Mirus 
Boost reagent was added and incubated at room temperature for 3 minutes.  
Next 1.5µg of RNA (HCVcc-gLuc or the negative control HCVcc-GNN) was 
diluted in 300µL optimem and added to the transfection mixture, then 
incubated at room temperature for 5 minutes before adding to the cells.  After 
incubating for 4 hours at 37ºC, 50µL of supernatant was transferred to a white 
polystyrene 96-well fluorescent assay plate (Corning, USA), mixed with 50µL 
of Gaussia luciferase substrate reagent (Luciferase Assay System, Promega) 
and the Gaussia luciferase activity detected using a Centro LB960 
Luminometer (Berthold Technologies, UK) for 1 second per well, measured as 
RLU, to determine whether the transfection was successful.  Following 
successful transfections for both the HCVcc-gLuc virus and the control HCV-
GNN virus, the transfected Huh7.5 cells were co-cultured with aLMF, LX-2 or 
CHO cells at a 1:1 ratio, at a density of 2.5x104 cell per well in a 24 well plate, 
leading to co-cultures with either the HCVcc-gLuc infected Huh7.5 cells or the 
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replication deficient HCVcc-GNN infected Huh7.5 cells.  The supernatants 
were sampled 24, 48, 72 and 96 hours post co-culturing, mixed with Gaussia 
luciferase substrate and the Gaussia luciferase readings measured using a 
Centro LB960 Luminometer (Berthold Technologies, UK), as previously 
described.  By monitoring the HCVcc-gLuc Gaussia luciferase activity, thus 
monitoring de novo viral replication, and comparing it to the negative HCVcc-
GNN control which is replication deficient, the level of replication was 
monitored in real time from the same cultures without the need to harvest cells 
at each time point.  To determine the level of cell-cell transmission when in a 
co-culture, cells were treated with 10 µg/mL anti-CD81 antibody in order to 
block cell free infection and then the luciferase activity measured as the 
various time points described above. 
 
2.1.6 Indirect immunofluorescence 
 
Cells were seeded for the detection of various cellular proteins or HCV 
infection by immunofluorescence at a density of 0.05 cells per mm2 then fixed 
using either ice cold methanol (Fisher Scientific, UK) for 5 minutes or 3.6% 
para-formaldehyde (PFA) (TAAB, UK) for 20 minutes, at room temperature.  
Cells were blocked using a wash buffer consisting of PBS containing 1% BSA 
and 0.1% saponin or Triton X-100, to permeabilise the cells, for 30 minutes at 
room temperature.  Cells were washed twice with PBS before adding primary 
antibody diluted in wash buffer for 60 minutes at room temperature.  Cells 
were then washed twice with PBS before the addition of the secondary 
fluorescent conjugated antibody diluted in wash buffer and incubated in the 
dark for 60 minutes at room temperature.  Cells were washed twice with PBS, 
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then the nuclei were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI) 
at 10µg/mL (SIGMA, UK) for 5 minutes in the dark and finally PBS was added 
to the wells.  Staining was visualised using fluorescent UV microscope (Nikon 
eclipse TE2000-5 inverted) and imaged with a digital camera (Hammatsu, 
Japan) at magnification x10, unless otherwise stated. 
 
2.1.7 Western blotting  
 
Cells were seeded in a 6 well plate at 4x104 cells per well and 24 hours post 
seeding, lysed for western blotting.  To prepare the cell lysates, media was 
removed and the cells washed carefully with PBS twice.  Then the cells were 
then treated with ice-cold lysis buffer (PBS, 1% Brij97, 20mM/L Tris [pH 7.5], 
300 mM/L CaCl2 and 2nM/L MgCL2) also containing protease and phosphate 
inhibitors (Roche, UK) for 30 minutes and kept on ice for the duration of the 
lysis process.  Cell lysates were centrifuged at 20,000xg for 20 minutes at 4ºC 
and the supernatant was collected and stored at -20ºC.  The protein 
concentration of each cell lysate was determined using a BCA Protein Assay 
Kit (Thermo Scientific, USA) according to the manufacturer’s instructions. 
 
Proteins were separated using 8% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). Cell lysates were diluted in 4x Laemmli 
loading dye (H2O, 6% w/v SDS, 30% Glycerol, 0.02% v/v Bromophenol Blue 
and 0.2M Tris, pH 6.8) under reducing conditions (except for CD81 detection) 
to a final volume of 20µL and equal protein concentrations (20µg) based on 
the BCA Protein Assay Kit results.  The samples were heat denatured at 95ºC 
for 5 minutes and allowed to cool prior to loading.  Protein samples were 
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loaded, with a prestained standard (Novex Sharp, Invitrogen) and 
electrophoresis carried out at 200V for 35 minutes using the Mini Protein 3 
system (Bio-Rad Laboratories, USA) according to the manufacturer’s 
instructions.  Proteins were transferred on to polyvinylidene membranes 
(Milipore, USA) washed in methanol, rinsed with water and in transfer buffer 
(25nM Tris, 0.2M Glycine, 200mL methanol and 10% SDS dissolved in H2O, 
pH 8.3) for approximately 15 minutes. The transfer occurred at 350A for 60 
minutes using a Mini Trans-Blot Electrophoresis system (Bio-Rad Laboratories, 
USA) according to the manufacturer’s instructions.  The membranes were 
blocked in a solution containing 5% Marvel dry milk powder dissolved in 
antibody buffer (10mM Tris, 100nM Sodium Chloride and 10% v/v Tween-20 
dissolved in H2O, pH 7.5) for 60 minutes with agitation.  The blocking buffer 
was removed and the membrane incubated with the primary antibody diluted 
in antibody buffer (see Table 2-2) overnight with agitation at 4ºC.  Following 
overnight incubation, the membranes were washed 5 times using the antibody 
buffer for 5 minutes with agitation, before the membranes were incubated with 
HRP-conjugated antibodies for 60 minutes with agitation.  The membranes 
were washed 5 times and the HRP-conjugated antibodies detected by 
chemoluminescence using an ECL Western Detection System (Amersham, 
UK) according to the manufacturer’s instructions. 
 
2.1.8 Real time quantification PCR (qRT-PCR)   
 
For all cell culture samples used in polymerase chain reactions (PCR), the 
RNA was lysed and extracted using the RNeasy mini kit (Qiagen) according to 
the manufacturer’s instructions, and eluted with 35µL of RNase/DNase free 
  
80 
water at the end step.  A Cells Direct One Step qRT-PCR kit (Life 
Technologies, UK) was used to quantify the sample RNA according to the 
manufacturer’s instructions.  Specific primers were then added to this PCR mix 
to detect on the FAM channel the copies of HCV (primer-unlimited; Applied 
Biosystems), or the relative level of the differentiation markers albumin, α-
fetoprotein (α-FP), hepatocyte nuclear factor 4α (HnF4α) or cytochrome P450 
family 3 - subfamily A, polypeptide 4 (cyp3a4) (Applied Biosystems).  To 
quantify the copies of HCV RNA in the samples, a HCV positive control 
standard (Primer design) was used to produce a standard curve from a dilution 
series (ranging from 100 to 107 copies per µL) which was then used to 
calculate the copies of HCV RNA in the unknown samples.  In all qRT-PCR 
reactions the house-keeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) with VIC was included as an internal endogenous 
control for amplification efficiency and RNA quantification (primer-limited 
endogenous control; Applied Biosystems). 
 
Samples were run in triplicate using a MicroAmp 96 well optical reaction plate 
(ABPrism, Applied Biosciences, USA) and fluorescence was monitored in a 
Stratagene RT-PCR machine (MX3000P, Stratagene, Agilent, UK).  The PCR 
reaction was set up with the following thermal settings:  
 
30 minutes  at 50º 
5 minutes  at 95ºC 
15 seconds  at 95ºC* 
60 seconds  at 60ºC*  *repeated for 50 cycles 
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The PCR data was analysed using the MXpro software with the threshold 
values for the FAM and VIC signals set manually at the exponential phase of 
the amplification plots. 
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2.2 Specific techniques 
 
2.2.1 Co-culture of stromal cells with hepatoma cells 
 
Hepatoma cells were co-cultured with stromal cells: aLMF, LX-2, fibroblasts 
from different sites (dermal, synovial or bone marrow fibroblasts) or the control 
CHO cells.  Mono- and co- cultures were seeded at a density of 2.5x104  cells 
per well in a 48 well tissue culture plate or 10x104 cells per well in a 12 well 
tissue culture plate.  Both cell types were seeded at the same time, allowed to 
settle for 24 hours before being either transferred into the category 3 
containment laboratory for HCVcc infection assays (detailed in section 2.1.3) 
or infected with pseudoparticle viruses (detailed in section 2.1.4).  All co-
cultures were maintained in DMEM containing 10% FBS, 1% non-essential 
amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin (Gibco, 
CA, USA), throughout the duration of the co-culture assays and infection.  Co-
cultures were seeded at a 1:1 ratio, unless otherwise stated and infections 
allowed to proceed for 48 hours, unless otherwise stated.  A schematic 
diagram of a co-culture set up is shown in Figure 2-2. 
 
Co-cultures seeded using the LucA2 subgenomic replicon-luciferase 
hepatoma cell line (section 3.3.3) were seeded at a density of 10x104 cells 
per well in a 48 well plate, at a 1:1 ratio and also maintained in complete 
DMEM containing 10% FBS for the duration of the co-culture assay.  Under 
normal propagation conditions, the LucA2 subgenomic replicon-luciferase cells 
are maintained using DMEM containing 10% FBS supplemented with high 
glucose at 4.5 g/L, 1% non-essential amino acids, 1% L-Glutamine and 
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50units/mL penicillin/streptomycin (Gibco, CA, USA), plus G418 at 1mg/mL 
(PAA Laboratories, GmbH) and blasticidin S hydrochloride at 3µg/mL (Carl 
Roth GmbH+Co, Germany).  Cultures were lysed 24 and 48 hours post 
seeding, using 100µL lysis buffer, to determine changes in replication over 
time.  The luciferase activity was measured and data is expressed as relative 
light units (RLU) of the subgenomic-luciferase reporter activity. 
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Figure 2-2 Schematic diagram illustrating co-culture set up   
Huh7.5 cells were seeded in co-culture with stromal cells (LX-2 or aLMF) or 
the control CHO cells at a 1:1 ratio, and 24 hours post seeding, infected with 
HCVpp or HCVcc.  Infection levels were determined 48 hours post infection by 
immunofluorescence staining for HCVcc infection assays, or luciferase 
readings for HCVpp assays.    Conditioned media samples were collected 
prior to infection, spin clarified and stored at -80ºC for further testing. 
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2.2.2 Transwell assay 
 
Transwell inserts with a pore size of 0.4µm (BD Falcon, USA) were used to 
separate cells but still allow the exchange of soluble secreted factors between 
the two types.  The transwell inserts were placed in a 24 well plate with each 
well containing 800µL of fresh media, then aLMF, LX-2, dermal fibroblasts 
(DM), synovial fibroblasts (SY), bone marrow fibroblasts (BM) or CHO cells 
were seeded inside the transwell inserts at 2.5x104 cells per insert in a volume 
of 300µL media.  Next Huh7.5 cells were seeded in separate 24 well plates at 
2.5x104 cells per well in a volume of 800µL media, thus the number of cells in 
the inserts and tissue culture plates were in a 1:1 ratio.  The cells were 
allowed to settle separately for a few hours before the inserts were carefully 
added to the wells containing Huh7.5 cells.  Then 24 hours post adding the 
transwell inserts to the wells, Huh7.5 cells were infected with either HCVcc 
(detailed in section 2.1.3) or the pseudoparticle viruses (detailed in section 
2.1.4), by carefully lifting the inserts, removing the media, adding the virus 
inoculums diluted in fresh media to give an end volume of 800µL and then 
adding back the transwell inserts carefully.  The infection proceeded for 48 
hours at which point the inserts were removed and discarded, and the Huh7.5 
cells either fixed (if infected with HCVcc) or lysed (if infected with 
pseudoparticle viruses) to determine the level of infection. 
 
2.2.3 Conditioned media  
 
Conditioned media was collected from various mono- and co –culture 
conditions 24 hours post seeding but prior to infection, to ensure all samples 
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were virus free.  Conditioned media samples were spin clarified by 
centrifugation at 3000rpm for 5 minutes and stored at -80ºC.  Conditioned 
media samples were routinely collected from various co-culture assays and 
the volume of conditioned media necessary to achieve an equal ratio of co-
culture cells to target cells was calculated.  Naïve Huh7.5 mono-cultures were 
treated with a 1:1 mix of conditioned media and fresh media on the day of 
seeding and 24 hours later infected with either HCVcc (detailed in section 
2.1.3), or pseudoparticle viruses (detailed in section 2.1.4), for  48 hours in 
the presence of the conditioned media, with naïve Huh7.5 cells cultured in 
normal media as a control. 
 
2.2.4 ISG56 detection 
 
Huh7.5 cells were transfected with an ISG56 luciferase reporter plasmid and 
co-cultured with stromal cells.  Briefly, Huh7.5 cells were seeded at 10x104 
cells per well in a 6 well tissue culture plate using DMEM containing 10% FBS, 
1% non-essential amino acids and 1% L-Glutamine (Gibco, CA, USA).   Cells 
settled for 24 hours and 1 hour prior to the transfection, the media was 
replaced with DMEM containing 3% FBS, 1% non-essential amino acids and 
1% L-Glutamine (Gibco, CA, USA).  The ISG56 plasmid was delivered to the 
cells using Lipofectamine Delivery (Life technologies, UK); per well, 4µL of 
lipofectamine was mixed with 250µL optimem and incubated at room 
temperature for 5 minutes.  Then 4µg of the ISG56 plasmid was mixed with 
250µl optimem, added to the transfection mixture and incubated at room 
temperature for 20 minutes before adding to the Huh7.5 cells.  After incubating 
the cells with the transfection mixture for 6 hours at 37ºC, the media was 
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removed and fresh DMEM containing 3% FBS, 1% non-essential amino acids, 
1% L-Glutamine and 50 units/mL penicillin/streptomycin (Gibco, CA, USA) was 
added to the cells.  After 24 hours the cells were re-seeded into co-culture with 
the stromal cells at a 1:1 ratio or seeded in mono-culture in order to screen the 
conditioned media for potential ISGs. 
 
To screen the conditioned media, samples were added to reporter plasmid- 
transfected cells at a 1:1 ratio with fresh media.  Exogenous IFNα (1, 10, 100 
IU), IFNβ (1, 10, 100 units), IFNλ1 (0.3, 1, 3 ng/ml) and IFNλ2 (1, 10, 30 ng/ml) 
(Peprotech) were also added alongside conditioned media as positive controls.  
Type I IFN (IFNα and IFNβ) doses were based on previous concentrations 
used by our group and others, which have shown maximal inhibition of HCV 
replication at > or =50 U/ml (Meredith et al., 2014, Marcello et al., Marcello et 
al., 2006, Macejak et al., 2001).  Type III IFN (IFNλ1 and IFNλ2) doses were 
based on concentrations shown by other research groups to have maximal 
inhibition on HCV genotype 2a replication at 10 ng/ml (Marcello et al., 2006) 
and ranges between 0.2-0.5 ng/ml showing 50% inhibition of HCV replication 
(Park et al., 2012, Pagliaccetti et al., 2008).  The cells were lysed 24 hours 
post the addition of the samples with 50µL of 1x Cell Culture Lysis Buffer 
(Promega), prepared according to the manufacturer’s instructions, for 2 hours 
at room temperature.  Then 45µL of each cell lysate was transferred to a white 
polystyrene 96-well fluorescent assay plate (Corning, USA), mixed with 45µL 
of luciferase substrate reagent (Luciferase Assay System, Promega) and then 
the luciferase activity detected using a Centro LB960 Luminometer (Berthold 
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Technologies, UK) as relative light units (RLU) of the plasmid signal relative to 
the untransfected control Huh7.5 cells containing no plasmid (Luc:no plasmid). 
 
In co-culture HCVcc infection assays, the transfected Huh7.5 cells were re-
seeded with the stromal cells at a 1:1 ratio in a 96 or 48 well plate, as 
previously described in section 2.2.1, along with mono-cultures for positive 
controls.  Once the cells had settled, mono-cultures of transfected Huh7.5 
cells were either left untreated or treated with the positive control of 100 IU of 
IFNα.  In parallel, the Huh7.5 co-cultures with aLMF, LX-2 and CHO cells were 
infected with a high titre HCVcc virus (detailed in section 2.1.3).  The cells 
were lysed 24 hours post the addition of HCVcc virus and the positive IFNα 
control with 50µL (96 well plate) or 100µL (48 well plate) of 1x Cell Culture 
Lysis Buffer (Promega), prepared according to the manufacturer’s instructions, 
for 2 hours at room temperature.   Then 45µL of each cell lysate was  
transferred to a white polystyrene 96-well fluorescent assay plate (Corning, 
USA), mixed with 45µL of luciferase substrate reagent (Luciferase Assay 
System, Promega) and then the luciferase activity detected using a Centro 
LB960 Luminometer (Berthold Technologies, UK) as relative light units (RLU).   
 
2.2.5 Human anti-viral Response PCR array  
 
Huh7.5 cells were seeded in mono- and co- culture with aLMF as described in 
section 2.2.1 then left uninfected or infected with a high MOI of HCVcc (MOI 
10) to be lysed for RNA extraction, resulting in the following samples: Huh7.5 
mono-culture uninfected, Huh7.5 mono-culture infected, Huh7.5+aLMF co-
culture uninfected and Huh7.5+aLMF co-culture infected.  The level of HCV 
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infection was detected using qRT-PCR (as described in section 2.1.8).  To 
run the samples in the Human anti-viral Response PCR array, cDNA was first 
synthesized with the RNA as template, using the RT2 First Strand Kit 
(SABiosciences, USA), according to the manufacturer’s instructions.  The PCR 
array constituted a 384-well plate (SABiosciences, USA) divided into 4 x 96 
well formats, 1 for each sample.  The gene expression was then measured 
according to the manufacturer’s instructions using the Absolute Quantity RT-
qPCR program monitored in a Stratagene RT-PCR machine (MX3000P, 
Stratagene, Agilent, UK).  The array contains 84 key anti-viral genes and the 
control housekeeping genes: GAPDH, actin, B2M, RPLP0 and HPRT.  Data 
were analysed using the online RT2 Profiler PCR Array Data Analysis Program 
(www.sabiosciences.com/pcrarraydataanalysis.php, SABiosciences), by 
normalising the target genes to the housekeeping control genes, then 
comparing all four samples in pair wise comparisons, calculating the 2^ΔΔ Ct 
levels for each target gene.  The data are presented in the form of heat-maps 
that display the fold-differences. 
 
2.2.6 Inhibition of nitric oxide (NO) pathway and detection of NO in 
extracellular media  
 
To inhibit the NO pathway, Huh7.5 cells were seeded in co-culture with aLMF, 
LX-2 and CHO cells (as detailed in section 2.2.1) at a 1:1 ratio for HCVcc 
infection and immediately treated with the anti-nitric oxide compound L-
monoethlyl arginine (L-NMMA) (Sigma, UK) at 1 mM, and then seeded into co-
culture.  The L-NMMA compound can inhibit the NO pathway for 
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approximately 72 hours, and so cultures were infected with HCVcc 24 hours 
post seeding, in the presence or absence of L-NMMA.  The cells were 
methanol fixed 48 hours post infection (detailed in section 2.1.3), to 
enumerate the foci.  The supernatants removed from these cultures were 
collected and screened using the Griess assay (Promega) to determine the 
level of NO, following manufacturer’s instructions.  In order to test these 
supernatants using the Griess assay, they were removed from the category 3 
containment laboratory; this involved treating them with 1% empigen (Sigma 
Aldrich Ltd, UK) at room temperature for 30 minutes to inactivate any HCVcc 
virus present. Then samples were spin clarified by centrifugation at 3000rpm 
for 5 minutes.  This treatment did not interfere with results from the Griess 
assay. 
 
2.2.7 Matrigel 3D cultures 
 
To establish a 3D liver organoid Matrigel sandwich culture, I undertook a 
research visit to UMCG, The Netherlands, where under the guidance and help 
of Prof. Sven van Ijzendoorn and his research group; I learnt how to establish 
3D liver organoid Matrigel sandwich cultures.  Upon return to The University of 
Birmingham, the 3D Matrigel™ culture technique was adapted to grow Huh7.5 
cells and HepG2 cells in co-culture with aLMF, LX-2 and CHO cells for HCV 
infection assays.  BD Matrigel™ Basement Membrane Matrix (BD 
Biosciences) was stored in aliquots at -80ºC to avoid repeated freeze-thawing.  
Required aliquots were thawed on ice for approximately 30 minutes and then 
used to coat a Nunc™ Lab-Tex™ II 8 well Chambered Coverglass (Thermo 
Scientific, USA).  Each chamber was coated with 5µL of BD Matrigel™ and 
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incubated at 37ºC for 30 minutes to set.  Cells were then seeded to a total of 
5000 cells per chamber in 300µL media.  Huh7.5 and HepG2 cells were 
seeded in mono- and co- culture with aLMF, LX-2 and CHO cells at a 4:1 ratio 
of hepatoma to stromal cells.  As a control, cultures were also seeded in 
Labtex Chambers without the BD Matrigel™ to give 2D cultures with the same 
number of cells.  The 3D cultures were assessed 72 hours post seeding for 
the formation of organoid cultures using phase microscopy and if required, the 
cultures were given an additional day to form organoids before the cultures 
were infected.  Once the organoids had formed, they were infected alongside 
the 2D control cultures with either HCVcc (detailed in section 2.1.3) or 
pseudoparticle viruses (detailed in section 2.1.4) for 48 hours. 
 
2.2.8 Cell IQ live cell imaging 
 
Huh7.5 cells were seeded in mono- and co- culture at a 1:1 ratio with aLMF, 
synovial, bone marrow and dermal fibroblasts as previously described in 
section 2.2.1, on glass bottomed tissue culture plates.  The fibroblasts were 
labelled using CMFDA green cell tracker dye (Invitrogen, USA) prior to co-
culturing. Briefly; cells were incubated with 5µM CMFDA in complete DMEM 
containing 3% FBS at 37ºC for 30 minutes.  Cells were then carefully washed 
with PBS twice, fresh complete DMEM containing 3% FBS added and 
incubated at 37ºC for 30 minutes before seeding in co-culture with unlabelled 
Huh7.5 cells.  After 24 hours the cultures were placed in a Cell-IQ® SLF 
(single-label fluorescence) machine.  This maintained normal tissue culture 
conditions and imaged multiple points in each well every 30 minutes over night, 
on both the phase channel and green fluorescence channel, obtaining images 
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of unlabelled Huh7.5 cells and CMFDA labelled fibroblasts over time.  These 
images were used to create time lapse movies showing the cells migrating 
from which representative images were taken at approximately 1, 4, 7 and 10 
hours.  The time lapse movies were also used to track individual CMFDA 
labelled fibroblasts over time using ImageJ software frame by frame (tracking 
data performed by Dave Mason). 
 
2.2.9 Virus binding to cell membrane and ECM assay 
 
Huh7.5, Huh7, HepG2, aLMF, LX-2 and the non-permissive control CHO cells 
were seeded in mono-culture in duplicate wells to assess the level of virus 
binding to the cells and also virus binding to the ECM produced by each cell 
type.  Cells were seeded at 4x104 cells per well in a 24 well plate.   To remove 
the cells and leave behind the ECM produced on the tissue culture plate, 24 
hours post seeding, the cells were treated with a lysis buffer consisting of PBS 
containing 0.5% Triton X (v/v) and 20mM ammonium hydroxide (NH4OH) until 
they detached, which was observed by phase microscopy (Butler 2005).  The 
remaining ECM was washed carefully with PBS three times.  HCVcc inoculum 
was added to wells containing either cells or ECM alone for one hour, the 
remaining virus inoculum was removed, spin clarified and transferred to naïve 
Huh7.5 mono-cultures seeded at 2.5x104 cells per well in a 48 well plate to 
determine the level of infection compared to a control virus inoculum incubated 
in an empty well to control for potential static or non-specific binding caused by 
the tissue culture plate, as detailed in section 2.1.3. 
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2.2.10 Generation of TRIP virus 
 
The TRIP virus system is used to generate retrovirus gene expression vectors 
that allow us to transduce cells to express a protein of interest.  The retrovirus 
gene expression vector is formed using a replication deficient gag-pol core 
bearing vesicular stomatitis virus (VSV-G) envelope glycoproteins.  These 
TRIP virus particles can then be used to enclose the RNA transcript of the 
gene of interest to be delivered to the target cells by transduction (Gottwein et 
al 2009, Zennou et al).  In this study, transduced cells were maintained under 
normal tissue culture conditions without selection and typically maintained 
exogenous gene expression for up to 4 weeks, at which point cells were 
discarded.  The TRIP virus system was used to transduce Huh7.5 cells with 
plasmids encoding CD81-GFP or EGFR-GFP.  Briefly, TRIP virus particles 
were generated in 293-T cells using a Fugene transfection protocol.  First, 
293-T cells were seeded at 7x105 cells per well in a 6 well tissue culture plate 
coated with poly-L-lysine at 0.1 mg/mL (Sigma, UK) using DMEM containing 
10% FBS, 1% non-essential amino acids and 1% L-Glutamine (Gibco, CA, 
USA).  After 24 hours the media was replaced with DMEM containing 3% FBS, 
1% non-essential amino acids and 1% L-Glutamine (Gibco, CA, USA).  The 
TRIP gag-pol plasmid encoding a HIV virus deficient of replication (600ng/well) 
was transfected with VSV-G envelope plasmid (600ng/well) and the target 
gene of interest (600ng/well), using 6µL Fugene in 100 µL optimem on a per 
well basis, as described previously in section 2.2.4. As the target genes 
express GFP, the transfection efficiency was assessed using UV microscopy.  
The supernatants from the transfected cells, containing TRIP virus particles, 
were collected at 48 and 72 hours post transfection, pooled, spin clarified by 
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centrifugation (at 3000rpm for 5 minutes) and used to transduce the target 
cells immediately.  The target Huh7.5 cells were seeded 24 hours prior to 
transduction at 4x104 cells per well in a 6 well plate.  To transduce the Huh7.5 
cells, the supernatants containing TRIP virus were diluted 1:2 in DMEM 
containing 3% FBS, 1% non-essential amino acids, 1% L-Glutamine, 
50units/mL penicillin/streptomycin (Gibco, CA, USA) and 1.6µg/mL polybrene 
(Sigma, UK), then added to the cells and incubated overnight.  The following 
day the media was replaced with fresh DMEM containing 3% FBS, 1% non-
essential amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin 
(Gibco, CA, USA). 
 
2.2.11 Fluorescence recovery after photobleaching (FRAP)  
 
Real-time fluorescence recovery after photobleaching (FRAP) was used to 
investigate the effects of aLMF cells in co-culture with Huh7.5 cells transduced 
with either CD81-GFP or EGFR-GFP (transduction protocol detailed in 
section 2.2.10).  The transduced Huh7.5 cells were seeded, in mono- and co- 
culture with aLMF cells at a 1:1 ratio, onto glass bottomed 24 well tissue 
culture plate at 4x104 cells per well in DMEM containing 10% FBS, 1% non-
essential amino acids, 1% L-Glutamine and 50units/mL penicillin/streptomycin 
(Gibco, CA, USA).  After 24 hours the cells were imaged using a Zeiss LSM 
780 Confocal microscope at a 100x Plan Apochromat 1.4NA oil immersion 
objective.  The media was replaced 1 hour prior to imaging with phenol red 
free DMEM/IMDM containing 10% FBS, 1% non-essential amino acids, 1% L-
Glutamine and 50units/mL penicillin/streptomycin and 1M HEPES (Sigma, UK).  
In order to determine the impact of heterotypic cell-cell contact on membrane 
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dynamics of Huh7.5 cell expressed CD81 and EGFR, Huh7.5 cells in co-
culture and direct contact with aLMF cells were selected for FRAP and 
compared to Huh7.5 cells in contact with other Huh7.5 cells in mono-culture.  
Also, 16-bit images were obtained with optimal pixel resolution.  The GFP-
tagged CD81 and EGFR proteins were excited using an argon 488 laser, 
photobleached using full laser power on circular regions of interest (ROI) 
selected in the planar membrane.  FRAP measurements were taken prior to 
and after photobleaching at 0.08 s per frame, for approximately 2 minutes until 
the ROI recovery reached a plateau.  The mean fluorescent intensity over time 
for the photobleached ROIs and a background ROI (containing no cells) were 
acquired, and then analysed using the Zeiss Zen analysis software.  Data 
were normalised for potential fluctuations in laser strength, image capture and 
overall loss of fluorescence in the cells by subtracting the background ROI 
from the photobleached ROIs.  To calculate the relative fractional recovery for 
each photobleached ROI, the values acquired before the bleaching were set 
as 100% and then post-bleaching calculated as relative to the mean 
fluorescence intensity prior to photobleaching for that ROI.  Graphpad Prism 
software was used to fit the data to a single exponential decay algorithm Y = 
span (1-exp (-K*X)) + plateau.  The mobile fraction (MF) was calculated from 
the span and plateau.  The diffusion coefficient (D) was calculated using the 
equation D = 0.224 x (radius2/t½) for each circular bleached ROI in a two-
dimensional diffusion model.  In each independent experiment, a minimum of 
10 cells and 100 ROIs were selected for each condition.  
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2.3 Statistical analysis 
 
Statistical analysis was conducted using PRISM software (Graphpad).  Non-
parametric statistical tests were used when assumptions of a normal or 
Gaussia distribution could not be tested, allowing statistical significance to be 
determined without assuming normal distribution of data.  This included all 
HCVcc based assays which were tested using the Mann-U-Whitney test 
followed by Wilcoxson test with multiple corrections (small sample sizes) or 
the Kruskal-Wallis test with Dunn’s corrections (larger sample sizes).  These 
non-parametric tests were used to compare the median infection levels across 
the different co-culture conditions and data are shown as the median ± 
standard deviation unless otherwise stated.  Parametric tests were used for 
data which passed the normality test (D’Agostino-Pearson omnibus test in 
Graphpad) indicating a Gaussia distribution.  This included all luciferase based 
assays such as pseudoparticle infections or luciferase reporter plasmids, 
which were tested using a One way ANOVA test with Bonferroni’s corrections.  
Data are shown as the mean ± standard deviation unless otherwise stated. 
 
  
97 
Chapter 3 aLMF are non-permissive to HCV but have the 
ability to inhibit HCV infection in co-culture 
3.0 Introduction 
 
The liver contains multiple types of cells with the parenchymal cells, also 
referred to as hepatocytes, occupying the majority of the total volume.  
Additional types of cells include the non-parenchymal cells, which provide 
many important functions.  One such cell type is hepatic stellate cells (HSC) 
which store vitamin A and become activated in response to liver injury, such 
as viral infection, into activated liver myofibroblast cells (aLMF) (Yoshida et al 
2012; Ishibashi et al 2009; Pertoft 1987).  Several potential sources are 
thought to give rise to aLMF cells however HSCs have been identified as the 
main source.  aLMF cells are the key players in liver fibrosis, a dynamic 
process designed to heal the liver however in response to chronic 
inflammation, which can cause liver scarring and progress further to cirrhosis 
or advanced scarring (Su et al 2014; Mederacke et al 2013).  Fibrosis, or 
scarring of the liver, is a result of the excess ECM produced by the aLMF 
which is not degraded, particularly collagen (types I, III, IV and V), elastin, 
laminin, fibronectin and proteoglycans (Schulze-Krebs et al 2005).  HCV 
infection of hepatocytes induces a profibrogenic response, stimulating the 
HSCs to become activated and driving fibrosis via a number of mechanisms 
(Su et al 2014; Wang et al 2013). 
 
Although hepatocytes are the primary target for HCV in the liver, the role of 
HSC or aLMF in the viral lifecycle is poorly understood.  HSCs have been 
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reported to express the HCV receptor CD81 and the attachment factor, low 
density lipoprotein receptor (LDL-r) (Bataller et al 2004).  We wanted to 
determine if HSCs and primary aLMF are permissive to HCV infection and 
then given their close proximity to hepatocytes in the liver, establish a co-
culture system to study the role these cells plays in HCV infection of the liver. 
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3.1 Isolation and phenotyping of primary activated liver myofibroblasts  
 
aLMF cells were isolated from human liver samples obtained from patients 
attending the Queen Elizabeth Hospital Birmingham for a range of liver 
diseases as listed in Table 3-1.  These human tissues were at various end 
stage chronic liver disease aetiologies providing the opportunity to examine 
and interpret the function in vivo of the aLMF.  Many of the human tissues 
were obtained from patients undergoing liver transplantation for various 
diseases or occasionally obtained from tissue rejected for use as a donor liver 
due to damage from illness or disease.  These tissues all have underlying 
disease aetiologies and normal healthy tissue is only obtained if there is 
surplus tissue to requirements at transplant which is often very limited 
amounts.  The tissue was processed by enzymatic digestion, differential 
density centrifugation and immunomagnetic separation in order to recover 
cells from the liver tissue and generate a single cell suspension, see materials 
and methods (section 2.0.3) (Joplin et al 1990; Holt et al 2009).  The aLMF 
were only used when they were 95% pure as assessed by staining for lineage 
specific markers for aLMF, hepatocytes, biliary epithelial cells (BEC) and liver 
sinusoidal endothelial cell (LSEC), which is also detailed in the materials and 
methods (section 2.0.3).  After isolation, these cells maintained classical 
aLMF elongated morphology in culture until at least passage 6 (Fig.3-1A) and 
the expression of the characteristic aLMF phenotype markers cluster of 
differentiation 90 (CD90), desmin, and vimentin were monitored over 6 
passages in culture by immunofluorescence microscopy (Fig.3-1B).  
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Table  3-1 Disease aetiologies of patient derived aLMFa 
Abbreviation Disease 
ALD Alcoholic Liver Disease 
Donor Tissue from rejected donor liver 
HCC Hepatocellular Carcinoma 
NASH Non-alcoholic Steatohepatitis 
NAFLD Non-alcoholic fatty liver disease 
PBC Primary Biliary Cirrhosis 
PSC Primary Sclerosing Cholangitis 
Seronegative Negative reaction to serological tests for 
viral infections including HIV and hepatitis 
viruses 
  
aTable summarising the different disease aetiologies of the human tissues 
obtained and routinely used to isolate aLMF cells by the Centre for Liver 
Research, University of Birmingham. 
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Figure 3-1 Phenotype of primary isolated aLMF  
(A) Representative phase contrast image of aLMF morphology under tissue 
culture, taken at magnification x10.  (B) aLMF were fixed and stained for 
fibroblast specific markers including CD90, vimentin and desmin (green) with 
the mouse anti-human IgG isotype control.  Cell nuclei were stained using 
DAPI (blue).   
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3.2 aLMF do not support HCV infection 
 
HCV primarily targets the liver and due to the location of aLMF within the liver 
and given their role in fibrosis progression, we first wanted to determine 
whether aLMF could support HCV infection.  To ascertain whether aLMF 
primary cells and the Lieming Xu-2 (LX-2) stellate cell line can support HCV 
infection, mono-cultures were infected with high titre high titre hepatitis C 
virus derived from cell culture (HCVcc) inoculum with mono-cultures of 
Huh7.5 included as a positive control and the Chinese Hamster Ovary (CHO) 
cell line included as a non-permissive control.   Mono-cultures of the various 
cell types were incubated with a high Multiplicity of Infection (MOI) of HCVcc 
(MOI of 1 on Huh7.5) for 6 hours before the cells were washed, fresh media 
added and cells incubated for a further 48 hours.  The supernatant was then 
removed, clarified of cell debris by centrifugation (20,000 g, 5 minutes) and 
incubated with naïve Huh7.5 “target” cells for 48 hours in order to determine 
whether or not infectious Hepatitis C viral particles were being produced by 
the mono-cultures.  The mono-cultures incubated with the high titre virus 
inoculum and the naïve Huh7.5 “target” cells incubated with the supernatants 
were then assessed for HCV infection using immunofluorescence and staining 
for non-structural 5A (NS5A) protein of HCV. 
 
As expected, high levels of HCVcc infection were detected in the control 
Huh7.5 cells incubated with the high virus infection and in the naïve Huh7.5 
target cells treated with the supernatant collected from these cells (Fig.3-2).  
This confirmed that the Huh7.5 cells are highly permissive to the HCVcc 
inoculum used and highly supportive of HCVcc infection as the supernatant 
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transferred to the naïve Huh7.5 target cells also produced high levels of 
HCVcc infection.  In the negative control CHO cells, there was no detectable 
HCVcc infection by immunofluorescence, similarly there was no detectable 
virus in their supernatant when incubated on the naïve Huh7.5 target cells.  
Notably, there was no detectable HCVcc infection in the aLMF and LX-2 
mono-cultures or in the target cells treated with supernatants collected from 
these cells.  Taken together, these results indicate that aLMF and LX-2 cells 
are not permissive to HCVcc infection.   
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Figure 3-2 aLMF do not support HCVcc infection 
(A) Representative immunofluorescence images of Huh7.5, aLMF, LX-2 and 
CHO mono-cultures infected with a high MOI of HCVcc followed by incubation 
with fresh media for a further 48 hours.  Cells were fixed and stained for NS5A 
(green) and also stained with DAPI to show nuclei (blue).  NS5A alone 
staining is shown alongside (grey).  (B) Representative immunofluorescence 
images of naive Huh7.5 target cells treated with supernatants (sup) 
transferred from the Huh7.5, aLMF, LX-2 and CHO mono-cultures infected 
with a high MOI of HCVcc. Cells were fixed 48 hours post treatment with the 
supernatants and stained for NS5A (green) and with DAPI nuclei (blue).  
NS5A alone staining is shown alongside (grey) (magnification x10).  Data 
representative of n=2 independent repeats (n=2 aLMF donors).  
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3.3 Key receptors mediating HCV entry are not present on aLMF 
 
HCV entry into the cell is mediated by four well-established HCV receptors: 
CD81, Claudin-1, Occludin, and the human scavenger receptor class B type I 
(SR-BI) (Hsu et al 2003; Kapadia et al 2007; Ploss et al 2009; Grove et al 
2007).  Several studies have identified other possible entry factors which HCV 
may also utilise to enter cells, including epidermal growth factor receptor 
(EGFR), low-density lipoprotein receptor (LDLR), Neimann-Pick C1-like 
cholesterol absorption receptor (NPC1L1), and ephrin receptor A2 (EphA2) 
(Meredith et al 2012; Lupberger et al 2011).  As aLMF and LX-2 cells were 
unable to support HCV infection, we therefore investigated if these cell types 
expressed the four well-established HCV receptors: CD81, Claudin-1, 
Occludin, and SR-BI which mediate HCV entry into the cell (Meredith et al 
2012).  Receptor expression was investigated using Western blot analysis of 
the aLMF and LX-2 cells.  As a positive control the Huh7.5 cell line was 
included because they have previously been shown to express all four 
receptors.  As a negative control the Chinese Hamster Ovary (CHO) cell line 
was included because they do not express any of the human receptors.  As 
expected, the controls stained for their respective receptors (Fig.3-3A).  
Analyses revealed that aLMF express CD81, but showed no expression of 
Claudin-1, SR-BI, or Occludin.  In contrast, the LX-2 cell line expresses all 
receptors except Claudin-1. 
 
We then used immunofluorescence to characterize the expression levels and 
localisation of the receptors on aLMF.  Using Confocal microscopy, cells were 
imaged at 24 hours post adherence to a glass-bottomed tissue culture plate.  
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A representative image for CD81, Occludin, and Claudin-1 staining of aLMF is 
shown in Fig.3-3B. For both Claudin-1 and Occludin, a staining pattern was 
constant over time but very faint, indicating very low levels of detectable 
expression.  The staining which was seen appeared to be localised mainly in 
the cytoplasm, with some nuclear staining.  These faint staining patterns could 
also be due to some autofluorescence or background noise.  aLMF often 
appear autofluorescent under microscopy due to the vitamin A stored within 
the cells and exacerbated by the high FBS content in the culture medium.  At 
the time, we were unable to visualise SR-BI by immunofluorescence as there 
was no access to SR-B1 antibodies for this method.   
 
Together these two independent experimental methods, western blot analysis 
and immunofluorescence, show that aLMF do not express all four key HCV 
receptors required for viral entry.  This lack of receptor expression explains 
why aLMF cells failed to support HCV infection. 
 
  
107 
 
 
Figure 3-3 aLMF lack expression of key HCV receptors 
(A) Cell lysates from Huh7.5, aLMF, LX-2 and CHO cell mono-cultures were 
prepared for Western blot detection of the four key HCV receptors; CD81, 
Claudin-1, SRB1 and Occludin. β-Actin is used as a loading control.  Data is 
representative of n=3 independent repeats (n=3 aLMF donors).  (B) aLMF 
were seeded on glass cover slips in a 48 well tissue culture plate at a seeding 
density of 2.5x104 cells per well and stained for CD81, Occludin and Claudin-1 
staining (green).  Imaging was done by Confocal microscopy (Zeiss 510 
inverted using a 100x Plan Apochromat 1.4NA oil immersion objective).  The 
cells were left for 48 hours to adhere before being fixed at 24, 48 and 72 
hours post adherence.  A representative image from 24 hours post adherence 
is shown. 
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3.4 The role of aLMF on HCV infection in a co-culture system 
 
The interactions of different cells in the liver are of crucial importance for 
tissue formation and homeostasis (Taub, 2004a). The majority of work done in 
laboratories involves studying cells of one origin and therefore lacks the 
dimension introduced by heterotypic cell-cell interactions found in vivo.  Within 
the liver, aLMF are found in close proximity to hepatocytes which support 
HCV infection (Taub, 2004a).  We have demonstrated aLMF do not support 
HCV infection.  Therefore, to further investigate if aLMF have a role in 
modulating hepatocellular HCV infection and lifecycle we developed a co-
culture model. 
 
3.4.1 Establishing a co-culture system to investigate the effects of aLMF 
on hepatocellular HCV infection 
In order to establish a co-culture system, initially Huh7.5 cells were seeded 
45-60 minutes before the addition of the secondary cells: aLMF, LX-2 or CHO 
cells.  In addition both cell types were seeded together at the same time in co-
culture.  Both methods of seeding resulted in the same pattern with the two 
cells types separating to form islands of matched cell types which resemble 
“rivers” and “islands” (Fig.3-4A).  This separation was clearly visible by phase 
microscopy due to the differences in morphology and is possibly mimicking 
the cell arrangements in the liver environment.  This separation is seen when 
other secondary cell types are co-cultured with Huh7.5 cells, including liver 
sinusoidal endothelial cells (LSEC) (Rowe et al 2014).  Given that the various 
cell types are propagated in DMEM containing different levels of bovine serum 
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(FBS), see materials and methods (section 2.0.1), it was decided to maintain 
all co-cultures in DMEM containing 10% FBS.  Typically 3% FBS is used 
during HCV infection assays, however the higher level of FBS helps maintain 
the aLMF at optimal density and aids aLMF adherence in co-culture. 
 
Next, the effect of varying the number of target cells was investigated by 
varying the number of target cells on HCV infection.  Using Huh7.5 cells as 
the target cells because they have previously been shown to be highly 
permissive to HCV infection, we seeded a full well of target cells, 2.5x104 cells 
per well in a 48 well tissue culture plate giving a density of 0.05 cells per mm2.  
Huh7.5 cells were then seeded a half, a fourth and an eighth of the number of 
target cells in the full well, infected with the same virus inoculum and cells 
fixed 48 hours post infection.  Cells were stained for NS5A positive cells and 
the level of infection determined by counting the number of foci per well.  
Altering the number of target Huh7.5 cells and infecting the mono-cultures 
with the same virus inoculum led to a decreasing level of HCV infection in 
proportion with the number of target cells present (Fig.3-4B).  By altering the 
number of Huh7.5 target cells in the same sized tissue culture wells, we were 
of course also altering the density and previous studies have previously 
shown hepatoma density impacts HCV infection via HCV receptor expression 
levels (Schwarz et al., 2009, Grove et al., 2007, Koutsoudakis et al., 2007).  
HCV entry is dependent on the target cell density due to the increased level of 
claudin-1 and SRB1 expression at the points of cell-cell contact.  Therefore, 
as the target cell density increases, the level of HCV entry for both HCVpp 
and HCVcc particles also increases (Schwarz et al 2009; Grove et al 2007; 
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Koutsoudakis et al 2007).  Based on these observations, the non-permissive 
CHO cell line was included in co-culture assays as a control in order to take 
up space controlling for cell density by cell contact inhibition of cell 
proliferation.  Thus, comparing aLMF or LX-2 containing co-cultures to the 
CHO containing co-cultures is more accurate than comparing to the half 
density well of Huh7.5 cells alone.     
 
We next co-cultured target Huh7.5 cells:stromal cells (aLMF, LX-2 or the 
control CHO cells) in both a 1:1 and 2:1 ratio condition.  We wanted to model 
the ratio of hepatocytes to liver myofibroblasts at a more physiologically 
relevant level and therefore wanted to test aLMF seeding at a range of ratios.  
However there are always a small number of aLMF cells which do not adhere 
due to the nature of primary cells being more difficult to maintain in culture 
compared to cell lines.  The lower the number of aLMF present in the culture 
the less likely they were to adhere and therefore the increased cell death in 
the aLMF would distort the final ratio.  Based on this observation we decided 
not to seed the ratio of Huh7.5 cells to aLMF at any less than a 2:1 ratio.  
aLMF, LX-2 and the control CHO cells were then co-cultured with Huh7.5 
cells at a 1:1 and 2:1 hepatoma:stromal cell ratio, then infected with HCVcc.  
The level of HCV infection observed in the co-cultures seeded at a 1:1 and 
2:1 ratio were comparable but there was an overall modest increase in HCV 
infection in the 2:1 ratio co-culture.  This modest increase in HCV infection 
supports our prediction that the level of HCV infection is proportional to the 
number of target hepatoma cells present and the cell density.  Interestingly, in 
co-culture the aLMF from three separate donors and LX-2 cells reduced the 
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level of HCV infection to a greater extent than the control CHO cells.  
Furthermore, the ability of aLMF cells to significantly reduce the levels of HCV 
infection in co-culture was not restricted to any specific disease aetiology or 
passage number, as demonstrated over n=4 independent experiments and 
n=7 aLMF donors at different passages as detailed in Table 3-2 for co-
cultures seeded at a 1:1 hepatoma:stromal cell ratio.  The data indicates the 
aLMF can reduce the level of HCVcc infection in neighbouring Huh7.5 cells by 
93.5%±5.7 when compared to Huh7.5 mono-cultures or by 65.3%±43.4 when 
compared to the control CHO co-cultures.  LX-2 cells can reduce HCVcc 
infection in neighbouring Huh7.5 to lesser extent of 59.4%±29.1 when 
compared to Huh7.5 mono-cultures or by 71.9%±15.2 when compared to the 
control CHO co-cultures.   
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Figure 3-4 The effects of aLMF on hepatocellular HCV infection in co-
culture 
(A) Phase image of Huh7.5 cells and aLMF cells in co-culture 24 hours post 
seeding (magnification x10).  (B) In a 48 well tissue culture plate, Huh7.5 
target cells were seeded in mono-culture at 2.5x104 cells per well in the full 
well, then a half, a fourth and an eighth of the number of target cells in the full 
well.  Huh7.5 cells were also seeded in co-culture with either three separate 
aLMF donors (numbered 1-3), LX-2 or CHO cells at both a 1:1 and 2:1 
hepatoma:stromal cell ratio.  24 hours post seeding, the cultures were 
infected with HCVcc for 48 hours after which the cells were fixed and stained 
for NS5A and the number of NS5A positive cells counted as foci to determine 
the level of infection.  Data representative of n=4 independent repeats (n=7 
aLMF donors).  Statistical comparison was made using the Kruskal-Wallis test 
and Dunn’s corrections were applied. 
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Table 3-2 Hepatitis C viral inhibition by aLMF in co-culture with 
Huh7.5 cellsa 
Disease Passage HCVcc viral inhibition (%) relative to 
  Huh7.5 mono-culture CHO co-culture 
Donor 6 98.7 95.0 
Donor 5 93.7 77.0 
PBC 3 97.5 90.8 
ALD 6 90.6 0.0 
PBC 6 100.0 100.0 
NASH 3 89.7 89.2 
ALD 6 84.1 5.4 
    
aTable summarising data from n=4 independent co-culture experiments 
seeded at a 1:1 hepatoma:stromal cell ratio, infected with HCVcc 24 hours 
post seeding and infection levels counted as either foci or total number of 
infected cells per well, 48 hours post infection.  Data is expressed as 
percentage viral inhibition relative to either the full Huh7.5 mono-culture 
(stromal cell co-culture infection calculated as a percentage relative to Huh7.5 
mono-culture expressed as 100% infection) or the CHO control co-culture 
(stromal cell co-culture infection calculated as a percentage relative to 
Huh7.5+CHO co-culture expressed as 100% infection) from a total of n=7 
aLMF donors at different passages and of different disease aetiologies.   
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3.4.2 aLMF can limit HCV entry in co-culture  
After observing that the aLMF can reduce the level of HCV infection in 
neighbouring hepatoma cells, we wanted to determine at which stage in the 
virus lifecycle the aLMF are acting to reduce the level of viral infection.  We 
first started by investigating whether or not this reduction in infection was due 
to an effect on HCV virus entry.  For this approach, we used the HCV 
pseudoparticles (HCVpp) system to determine whether or not the aLMF can 
inhibit HCVpp entry into the Huh7.5 cells when in co-culture (Bartosch et al 
2003a, Hsu et al 2003, Zhang et al 2004; Drummer et al 2003).   
 
As before, Huh7.5 cells were first seeded in mono-culture at target cell 
number varying from a full well of target cells (1.2x104 cells per well in a 96 
well tissue culture plate), then a half, a fourth and an eighth of the density of 
the full well.  Cultures were allowed to adhere for 24 hours before infecting 
with the same virus inoculum for the indicated pseudoparticles; HCVpp strain 
H77, Vesicular Stomatitis virus pseudoparticles (VSVpp), and the negative 
control of no envelope pseudoparticles (NEpp).  VSVpp were included as a 
control for HCVpp specificity.  The infections proceeded for 48 hours before 
the cells were lysed for the detection of the luciferase reporter gene activity, 
which indicates the level of pseudoparticle entry.  A 48 hour infection period 
was used instead of the standard 72 hours as this matches the infection time 
used in previous experiments with HCVcc (detailed in section 3.4.1).  By 
matching the infection time, we sought to ensure that both experimental set 
ups are matched for infection duration and cell density throughout the assays.  
The luciferase signals from the negative NEpp control give the background 
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level of relative light units (RLU), which is then used to normalise the data for 
the pseudoparticle infections.  The level of pseudoparticle virus entry for both 
the HCVpp and VSVpp, showed a decreasing entry in proportion with the 
number of target cells present (Fig.3-5A).  This indicates that the target cell 
number of Huh7.5 cells present determines the level of HCV entry and is 
comparable to the results seen with the full length HCVcc virus in section 
3.4.1. 
 
Before co-culturing the hepatoma and stromal cells and infecting with HCVpp, 
monocultures were first infected with HCVpp and VSVpp (Fig.3-5B.i).  
Cultures were allowed to adhere for 24 hours before infecting for 48 hours 
with the same virus inoculum for the indicated pseudoparticles: HCVpp, 
VSVpp, and negative control NEpp.  Huh7.5 cells served as a positive control 
and CHO cells as a negative control.  The results for the mono-cultures 
indicate aLMF, LX-2, and CHO cells alone were non-permissive to HCV and 
VSV pseudoparticle viruses reaffirming our observations in section 3.2 
(Fig.3-5B.i).   
 
Afterwards, Huh7.5 cells were seeded in co-culture with aLMF, LX-2 and CHO 
cells at a 1:1 ratio, allowed to adhere for 24 hours, and then infected for 48 
hours (Fig.3-5B.ii).  In co-culture with Huh7.5 cells, aLMF, LX-2 and CHO 
cells significantly reduced the level of HCVpp entry in the Huh7.5 cells (Fig.3-
5B.ii).  These results indicate that stromal cells can impact HCV infection at 
the entry stage.  Interestingly, stromal cells also significantly reduced VSV 
(Fig.3-5B.ii) and the murine leukaemia virus (MLV) (data not shown) 
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pseudoparticle entry in Huh7.5 cells, which suggests stromal cells can inhibit 
multiple viral entry pathways, and not just HCV in hepatoma cells. The 
percentage inhibition of HCVpp and VSVpp entry and the details of the 
various aLMF donors tested are summarised in Table 3-3.   
 
Based on the previous results indicating that stromal cells have the ability to 
modulate viral entry, we wanted to determine whether they are modulating the 
pseudoparticle’s ability to enter the cell or the transcription of the luciferase 
reporter plasmid after it has entered the cell.  To test this, the luciferase 
reporter plasmid, pNL4.3luc, was transfected into Huh7.5 cells alone.  The 
transfected cells were trypsinised and reseeded in co-culture with the stromal 
cells at a 1:1 ratio as done previously; 24 hours post transfection.  Then 24 
hours after co-culture, the cells were then lysed to allow for the detection of 
the luciferase reporter gene activity.  The luciferase readings for the 
transfected Huh7.5 cells in co-culture with three different aLMF donors, LX-2 
and the control CHO cells were compared to transfected Huh7.5 cells alone to 
assess the effect of the stromal cells on pNL4.3luc transcription (Fig.3-5C).  
Important to realize, is that when the Huh7.5 cells are co-cultured with stromal 
cells there are 50% less Huh7.5 cells compared to the mono-culture.  
Therefore, the approximate 50% decrease in luciferase signals in all the co-
culture compared to mono-culture condition is relative to the number of 
Huh7.5 cells.  As a result, this indicates that there is no modulation of the 
luciferase reporter plasmid in co-culture and supports the hypothesis that co-
culture with stromal cells modulate the pseudoparticle entry. 
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Figure 3-5 aLMF can limit HCVpp entry in co-culture  
(A-B) Cells were seeded in a 48 well tissue culture plate, allowed to adhere 
for 24 hours, infected with HCVpp, VSVpp, and NEpp for 48 hours, then lysed, 
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and the luciferase activity measured. For each sample, data is expressed as 
RLU of luciferase activity normalised to the negative NEpp control (Luc:No 
env).  (A) Huh7.5 cells were seeded at 2.5x104 cells per well in a full well, then 
at a half, a fourth and an eighth of the number of cells in the full well.  Data is 
representative of n=4 independent repeats.  (B.i) aLMF, LX-2, and CHO cell 
were seeded in mono-culture and (B.ii) in co-culture with Huh7.5 cells at a 1:1 
ratio.  Data is representative of n=4 independent repeats (n=7 aLMF donors). 
(C) Huh7.5 cells were transfected with the luciferase reporter gene, pNL4.3luc, 
for 24 hours then seeded either in mono- or co-culture with aLMF, LX-2, and 
CHO cells at a 1:1 ratio.  Cells were lysed and luciferase activity measured 24 
hours after seeding.  Data is expressed as RLU of pNL4.3luc luciferase 
activity normalised to the untransfected control Huh7.5 cells (Luc:untreated).  
Data representative of n=3 independent repeats (n=7 aLMF donors).  
Statistical comparison was made using one way ANOVA tests to compare 
groups of data and Bonferroni’s corrections (parametric) were applied for pair 
wise comparisons of all data where * P<0.05, **P<0.01 and *** P<0.001. 
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Table  3-3 Pseudoparticle entry inhibition by aLMF in co-culture 
with Huh7.5 cellsa 
Disease Passage HCVpp viral inhibition (%) relative to 
  Huh7.5 mono-culture CHO co-culture 
NASH 4 82.1 69.8 
ALD 3 84.0 74.0 
 4 91.6 39.0 
Donor 3 67.9 64.0 
 4 89.3 42.0 
Seronegative 3 92.0 48.7 
NAFLD 5 87.6 73.8 
    
aTable summarising data from n=3 independent co-culture experiments 
seeded at a 1:1 hepatoma:stromal cell ratio, infected with either HCVpp, 
VSVpp or the negative NEpp control 24 hours post seeding, cells were lysed 
and luciferase activity measured 48 hours post infection to determine 
pseudoparticle entry.  Data is expressed as percentage viral inhibition relative 
to either the full Huh7.5 mono-culture (stromal cell co-culture infection 
calculated as a percentage relative to Huh7.5 mono-culture expressed as 
100% infection) or the CHO control co-culture (stromal cell co-culture infection 
calculated as a percentage relative to Huh7.5+CHO co-culture expressed as 
100% infection) from a total of n=7 aLMF donors at different passages and of 
different disease aetiologies.   
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3.4.3 aLMF can reduce HCV replication over time in co-culture 
 
After observing that the aLMF reduce HCV entry in neighbouring hepatoma 
cells, we next sought to determine if they also modulate HCV replication.  For 
this approach, we first decided to use a subgenomic replicon-luciferase cell 
line, Huh7A2HCV, in co-culture with aLMF.  This cell line is a human 
hepatoma Huh7 cell line containing the replicating subgenomic JFH1 HCV 
strain encoding luciferase.  The cell line is under selection and allows for easy 
and accurate quantification of HCV RNA replication over time (Jo et al 2009).  
 
Huh7A2HCV replicon cells were seeded in mono- and co- culture at a 1:1 
ratio with aLMF, LX-2 and CHO cells as previously done so.  Huh7.5 cells 
were also included in co-culture to control for density because density is 
critical in maintaining optimal luciferase plasmid activity within the 
Huh7A2HCV replicon cells.  It has previously been observed that at higher 
densities there is a loss of luciferase activity.  Cells were lysed 24 and 48 
hours post seeding to determine changes in HCV RNA replication over time.  
The luciferase activity was measured and data expressed as relative light 
units (RLU) of the subgenomic-luciferase reporter activity (Fig.3-6). 
 
At 24 hours post seeding, the cell density control, Huh7.5 cells, in co-culture 
had slightly lower replication levels (39.5%+/-2.5) than expected (50%) when 
compared to the Huh7A2HCV mono-culture. Given that there is 50% less 
Huh7A2HCV in the co-culture compared to the mono-culture control, we 
would have expected approximately 50% of the replication.  This suggests 
there is a low level reduction in replication when the Huh7A2HCV cells are in 
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contact with Huh7.5 cells and possibly other cell types.  Nevertheless, the co-
cultures with Huh7A2HCV cells appeared to reduce the level of replication in 
the Huh7A2HCV cells further than the co-culture of stromal cells with the 
Huh7.5 cells, with levels at 24.1%+/-2.9 for the aLMF and 23.7%+/-4.8 for the 
LX-2 in co-culture with Huh7A2HCV cells.  Both of these reductions are lower 
than the level of replication in the Huh7.5 or CHO containing control co-
cultures (35.7+/-13.3) (24 hour time point Fig.3-6).  The percentages of 
replication in co-culture conditions for each time point were calculated relative 
to the Huh7A2HCV cell mono-cultures for the appropriate time point.  In some 
conditions, high standard deviations were observed which may be as a result 
of the high sensitivity in detection for the luciferase based system.    
 
At 48 hours post seeding, the level of HCV RNA replication in the 
Huh7A2HCV mono-culture and Huh7.5 co-culture increased compared to 24 
hours, which indicates successful HCV replication over time.  The control 
CHO cells slightly reduce the level of replication to 66.9%+/-21.9 of the 
Huh7A2HCV mono-culture.  The stromal cell containing co-cultures 
significantly reduce the levels of replication in the Huh7A2HCV cells, when 
compared to the Huh7.5 containing co-culture with aLMF containing co-
cultures at 20.5%+/-5.7 and LX-2 at 26.1%+/-14.0 (48 hour time point Fig.3-6).  
Interestingly, the levels of replication detected in both the aLMF and LX-2 
containing co-cultures at 48 hours are comparable to the levels at 24 hours.  
This suggests that little replication has occurred in the Huh7A2HCV cells over 
time as a result of co-culturing with stromal cells which leads us to 
hypothesize that the stromal cells are also inhibiting HCV replication over time.  
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Figure 3-6 aLMF can reduce HCV replication over time in co-culture 
Huh7A2HCV cells were seeded in either mono- or co-culture with Huh7.5, 
aLMF, LX-2, or CHO cells at a 1:1 ratio.  Cultures were lysed and luciferase 
activity measured at 24 and 48 hours post-seeding.  Data is expressed as 
HCV RNA replication (RLU) and is representative of n=2 independent repeats 
(n=2 aLMF donors).  Statistical comparison was made using one way ANOVA 
tests and Bonferroni’s corrections (parametric) were applied where * P<0.05.   
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3.4.4 Co-culture of aLMF with Huh7.5 cells inhibits HCVcc spread at 48 
hours  
While counting the level of HCVcc infection as foci per well in the previous co-
culture assays, it was observed that the foci size could vary from foci 
containing as little as 1-6 infected cells to foci greater than 25 infected cells. 
These observations lead us to conclude that counting HCVcc foci was a 
subjective way to count the level of HCVcc infection and that there were 
clearly differences in HCV spread.  These differences in HCVcc foci size are 
visible in the representative immunofluorescence images of HCV NS5A 
positive stained Huh7.5 cells in mono- and co-culture conditions, with very 
small foci detected in the co-culture conditions compared to the Huh7.5 mono-
cultures (Fig.3-7A).  In co-culture conditions, we observed very small foci 
compared to the Huh7.5 mono-culture.  The number of individually infected 
cells per foci was counted to determine the changes in HCV spread over time 
in Huh7.5 mono-culture (Fig.3-7B).  There was a significant increase in the 
number of infected cells per foci for the Huh7.5 mono-culture from 24 to 48 
hours.  This indicates that the virus has established in the initial infected cells 
by 24 hours, and then by 48 hours it has successfully replicated and spread to 
neighbouring Huh7.5 cells, thus increasing the number of HCVcc infected 
cells per foci.  However, part of this increased infection is also due to cell 
division occurring between the 24 to 48 hour time points. 
 
When the aLMF, LX-2 and CHO cells were co-cultured with Huh7.5 cells at a 
1:1 ratio, the number of HCVcc infected cells per foci after 48 hours was 
moderately decreased in the aLMF co-culture, but significantly decreased in 
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the LX-2 co-culture compared to the Huh7.5 mono-culture (Fig.3-7C).  The 
control CHO cells also appear to inhibit HCV spread however to a lesser 
extent than the stromal cell containing conditions.  These data suggest the 
presence of stromal cells in co-culture inhibit HCVcc spread in the Huh7.5 
cells. 
 
In order to bypass the entry step and only measure replication post viral entry, 
Huh7.5 cells were transfected with either the RNA of the complete HCV virus 
(J6 strain) containing a Gaussia luciferase reporter gene (HCVcc-gLuc) or the 
RNA of the polymerase defective control HCV virus (HCVcc-GNN).  The 
HCVcc-GNN control is unable to replicate and thus unable to produce 
Gaussia luciferase as it encodes two stop codons in the HCV RNA dependent 
RNA polymerase (NS5B) region which results in a catalytically inactive RNA 
polymerase (Koutsoudakis et al., 2012, Phan et al., 2011).  This system 
allows de novo full length HCVcc virus particles to be detected by sampling 
the supernatants periodically over time to detect the levels of Gaussia 
luciferase following successful HCV replication and thus measure replication 
in real time without having to set up cultures at each time point.  Supernatants 
were sampled 4 hours post transfection in order to first determine whether or 
not the transfection was successful by reading the luciferase activity of de 
novo virus released into the supernatant following replication (Fig.3-7D.i).  
The transfected cells were then trypsinised and re-seeded into co-culture with 
aLMF, LX-2 or CHO cells from which point on, supernatants were sampled 
every 24 hours in order to measure HCV replication in real time, and 
expressed as HCVcc-gLuc luciferase activity over HCVcc-GNN luciferase 
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activity.  The results indicate that the aLMF and LX-2 cells can strongly inhibit 
HCVcc-gLuc replication when in co-culture over the course of 96 hours.   
 
In addition, the mono- and co- culture conditions were treated with mouse IgG 
control (Fig.3-7D.i), and parallel cultures were treated with anti-CD81 
antibody (Fig.3-7D.ii) in order to inhibit cell free infection and cell-cell 
transmission.  These results indicate the level of HCVcc-gLuc virus in Huh7.5 
mono-culture conditions can be significantly inhibited in the presence of the 
anti-CD81 antibody; however there is very little difference in the level of 
infection in co-culture conditions with or without the anti-CD81 antibody.  This 
data suggests the aLMF and LX-2 cells may be able to inhibit HCV spread in 
a similar manner to the anti-CD81 antibody via cell free and cell-cell 
transmission however further work would be required to confirm this and 
establish which mode of transmission is impacted when Huh7.5 cells are in 
co-culture with stromal cells.   
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Figure  3-7 Co-culture of aLMF with Huh7.5 cells inhibits HCVcc spread 
at 48 hours 
(A) Microscopy images 48 hours post infection (magnification x10).  HCVcc 
foci in Huh7.5 cells were visualised using anti-NS5A antibody detected by a 
secondary antibody conjugated to Alexa594 (red) and nucleus detected by 
DAPI (blue).  (B-C) Cells were fixed, stained for NS5A positive cells and the 
number of NS5A positive cells per foci of infection counted.  (B) Huh7.5 cells 
were seeded in mono-culture.  24 hours post seeding, they were infected with 
HCVcc and the infection proceeded for 24 and 48 hours.  (C) Huh7.5 cells 
were seeded in either mono- or co-culture with aLMF, LX-2, or CHO cells at a 
1:1 ratio. Then 24 hours post seeding, they were infected with HCVcc and the 
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infection proceeded for 48 hours.  Data is representative of n=4 independent 
repeats (n=6 aLMF donors).  Statistical comparison was made using the 
Mann-U-Whitney test where * P<0.05 and *** P<0.001.  (D) Huh7.5 cells were 
transfected with either HCVcc-gLuc or HCVcc-GNN. After measuring 
transfection success at 4 hours post transfection, cells were reseeded into 
mono- and co-culture conditions with aLMF, LX-2, or CHO cells at a 1:1 ratio.  
Cultures were treated with control mouse IgG antibody (D.i) or treated with an 
anti-CD81 antibody at 5µg/mL  (D.ii) for the duration of the infection.  Data is 
expressed as the luciferase activity measured from the HCVcc-gLuc 
transfected cells over the HCVcc-GNN transfected cells.  Data representative 
of n=3 independent repeats (n=3 aLMF donors). 
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3.8 Discussion 
In this chapter, we first characterized primary aLMF and established they are 
non-permissive to HCV infection, using both the HCVcc and pseudoparticle 
systems to confirm that the stromal cells tested do not support HCV infection 
or entry.  Primary human HSCs have been reported to express the HCV 
receptor CD81 and the attachment factor, low density lipoprotein receptor 
(LDL-r) by mRNA expression (Bataller et al 2014).  So we demonstrated that 
aLMFs isolated from patients express CD81 however they do not express the 
other key HCV receptors, Claudin-1, SRB1, and Occludin as confirmed by 
Western blot analysis and immunofluorescence.  Interestingly, the LX-2 cell 
line expresses all receptors except Claudin-1, which illustrates there are 
differences between the two stromal cell types tested in this thesis.  
Nonetheless, aLMF and LX-2 cells are non-permissive to HCV infection as 
they do not express the full set of HCV receptors required for successful entry 
of the viral particles. 
 
We then wanted to design a co-culture system to study if stromal cells, in 
particular fibroblasts could impact the HCV lifecycle in hepatocytes, the cells 
that can support HCV infection.  When establishing this co-culture model to 
study the role of fibroblasts on hepatocellular HCV infectivity, there were 
many factors to take into consideration and so the co-culture model under 
went a series of optimisation steps.  The primary aLMF cells gave us a great 
opportunity to study how these primary human liver derived cells may impact 
HCV infection in the liver in vivo however working with primary cells poses a 
number of challenges in itself with care needed to be taken during the 
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isolation process to avoid contamination of the aLMF cell cultures with other 
liver cell types, as well as monitoring the phenotype of the cells over time to 
ensure they still maintained aLMF function and differentiation.  Some of the 
major issues faced whilst working with aLMF cells were the limited availability 
and the slow proliferation rate, often requiring time to expand the aLMF cells 
to ensure there were enough cells to perform the required assays.  The 
delicate nature of the aLMF cells also lead to a very small proportion of the 
cell death occurring upon each trypsination of these cells, with an increased 
level of aLMF cell death observed as the number of aLMF in co-culture was 
reduced lower than a 2:1 ratio (hepatoma:fibroblast) in order to more 
accurately represent the proportion of aLMF in vivo.  This increased level of 
cell death could be due to a number of factors such as the cultured aLMF 
cells may require a certain level of homotypic cell-cell contact in order for 
successful adherence to occur.  Under normal propagation of aLMF, there are 
soluble secreted factors produced by the aLMF cells which help these cells to 
proliferate and maintain phenotype in culture.  So another possible 
explanation could be that the lower levels of soluble secreted factors as a 
result of fewer aLMF cells present could be leading to increased aLMF cell 
death.  Despite the 1:1 ratio not accurately representing the 
hepatocyte:stellate cell ratio found in a normal healthy liver which is 
approximately 11:1, this ratio could be used to mimic the level of fibroblasts 
present in a highly fibrotic liver (Pertoft and Smedsrod, 1987, Taub, 2004b, 
Ishibashi et al., 2009).  However the major advantage of a 1:1 ratio is that not 
only does it help ensure sufficient cell-cell contacts between the two cells 
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types are established, but it also helps maintain the aLMF cells in culture as 
well as making the interpretation of the data easier. 
 
One of the other issues with using aLMF cells is that they represent the 
activated liver myofibroblasts found in the liver during fibrosis, and not the 
quiescent stellate cells typically found in a healthy liver prior to liver injury, for 
example by viral infection.  Unfortunately this is an artefact of culturing these 
primary cells.  When primary HSCs are isolated from the liver and cultured on 
normal plastic tissue culture surfaces, molecular signals are triggered, similar 
to those during activation in response to liver injury, leading to their gradual 
activation into liver myofibroblasts or aLMF.  Once the cultured HSCs are 
activated, they undergo a number of phenotypic and functional differences 
associated with their role in fibrosis including an increased cellular contractility, 
increased cell mobility, elongated cell morphology, increased expression and 
deposition of ECM including collagens.  Once activated, HSCs also lose the 
stored vitamin A, down-regulate a number of neural markers and up-regulate 
mesenchymal markers such as aSMA and fibronectin, therefore it is not 
surprisingly that the LX-2 cells and aLMF cells demonstrated differential 
expression of HCV receptors in section 3.3 (Herrmann et al 2007; Taub 
2004; Iredale et al 2007; Geerts et al 2001; Kisseleva et al 2008).   
 
In terms of developing a system which mimics the role of fibroblasts in the 
liver microenvironment and HCV infection, the use of primary fibroblasts 
would be physiologically more relevant compared to immortalized cell lines, 
which as mentioned often display altered phenotypes and differentiation gene 
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expression compared to primary cells (Herrmann et al 2007). However, if we 
wanted to understand virus-host mechanisms occurring in the earlier stages 
of infection in healthy livers which could trigger liver disease progression, then 
aLMF may not be suitable as they already display a fairly activated phenotype.  
This is of course assuming that when patients are initially infected with HCV, 
their livers are healthy with no signs of mild or acute fibrosis from other 
underlying health problems such as alcoholic liver disease or unhealthy diets 
leading to fatty liver related diseases.  This is very difficult to determine as 
patients often do not know when they acquired the virus as the infection 
caused by HCV is often asymptomatic with symptoms of liver end stage liver 
disease being the only indication after the virus has established infection for a 
considerable number of years (Lindenbach et al., 2005b, Blight et al., 2003a, 
Farquhar and McKeating, 2008, Lemon et al., 2010, Meredith et al., 2012b).  
However, understanding the role of aLMF on HCV infection would prove very 
valuable when trying to treat patients with HCV as therapies are given to 
patients with varying levels of fibrosis during which time there is an increased 
number of aLMF in the liver.  Therefore, to address these issues and the aims 
of this study, both the LX-2 cell line and primary aLMF were used in parallel 
representing the quiescent HSC and liver myofibroblasts, respectively.  The 
LX-2 cell line was characterised by Xu and colleagues in 2005 and has since 
been described as the stellate cell line which is the most similar to primary 
HSC, hence is a commonly used in studies investigating liver fibrosis (Xu et al 
2005; Herrmann et al 2007).  Despite the potential issues surrounding the pre-
activated stated of the aLMF prior to infection in our system, we were keen to 
still investigate these cells as they represent what we are faced with clinically, 
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which is HCV patients with chronic fibrosis.  By focusing slightly more on the 
role of aLMF in HCV infection and disease we hoped to increase over 
understanding of the mechanism(s) of host-viral interactions, potentially 
leading to new pathways which can be targeted for novel and improved 
therapies.  
 
Generally aLMF cells grow significantly slower than the Huh7.5 hepatoma cell 
line used in these co-culture assays and so there is a certain degree of 
competition between the two cells type for space and nutrients when cultured 
together, with the more rapidly dividing Huh7.5 having more space when there 
are fewer aLMF present.  For consistency across the entry, replication and 
spread assays, cultures were generally infected for 48 hours and maintained 
in DMEM containing 10% FBS for the duration of the assay.  Normally for the 
duration of HCV infections cells are grown the DMEM containing 3% FBS in 
order to control the growth rate of the cells which avoid over confluent mono-
layers, but I found that reducing the FBS content to such a low level 
compared to the DMEM containing 16% FBS plus 33% conditioned media 
used to propagate fibroblasts affected their adherence and growth which 
overall impacted the experiment negatively.  These factors may contribute to 
fewer aLMF settling when lower numbers are seeded.  This difference in 
proliferation rates was taken into consideration when optimising this co-culture 
system and attempts were made to arrest cell growth of all the cell types in 
order to help maintain the initial ratio throughout the assay and help with 
interpreting the impact of infection under arrested cell growth.  Two methods 
were used to arrest cell growth, gamma irradiation of cells in suspension 
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before seeding and mitomycin C treatment post seeding however both 
methods were unsuccessful for a number of reasons including cell growth was 
not completely arrested for some of the cell types including the aLMF and LX-
2 cells, but also there was a high level of aLMF cell death and so given the 
limited availability of these cells and wanting to maintain both their function 
and phenotype it was decided to continue co-culturing without arresting cell 
growth.  HCV entry is dependant on the target cell density due to the 
increased level of claudin-1 and SRB1 expression at the points of cell-cell 
contact.  Thus cultures were seeded at a slightly higher seeding density than 
normal (at 2.5x104 cells per well in a 48 well tissue culture plate) adjusted 
according to the surface area of different sized tissue culture plates as this 
higher density would lead to contact inhibition cell growth thus assisting in 
controlling the cell growth of these different cell types in culture. 
 
Having established the co-culture system, we assessed the impact of co-
culturing aLMF cells with the highly permissive Huh7.5 cells, on various 
stages of the HCV lifecycle.  The data demonstrated that in co-culture, the 
aLMF can limit HCV infection at multiple stages of infection; entry, replication 
and spread.  Interestingly, we saw no difference in the level of inhibition at any 
stage of infection when testing aLMF isolated from various different end stage 
liver disease aetiologies or the passage at which the fibroblasts were used.  
Also, the level of aLMF mediated inhibition was comparable to the LX-2 cells, 
which probably became activated in response to the virus infection leading to 
similar wound healing mechanisms as the already activated primary aLMF.  
When enumerating the level of HCVcc inhibition using immunofluorescence 
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microscopy, I noticed the variability in the size of the focus forming units 
(FFUs) typically counted when assessing HCVcc infection.  Further 
microscopy analysis highlighted the subjectiveness of counting FFUs to 
assess the overall level of HCV infectivity in co-culture.  I noticed the Huh7.5 
mono-cultures produced a greater number of large foci compared to the co-
cultures which produced a greater number of smaller foci.  As a result, the 
number of foci does not accurately reflect the infectivity as a foci made up of 
10-15 cells can not be compared to a foci of 2-3 cells.  Consequently, I 
counted the total number of individually infected cells when assessing overall 
levels of HCV infection, and counted the number of cells per foci when 
assessing the level of HCVcc spread. 
 
Having demonstrated that stromal cells can impact HCV infection of 
hepatocytes at various stages of the viral lifecycle, we wanted to investigate 
the anti-viral mechanism but wanted to first investigate the role of cytokines 
and other soluble factors in our system.  During HCV infection, a number of 
profibrogenic factors, including transforming growth factor (TGF-β) are 
released by HCV infected hepatocytes.  These secreted factors act on 
fibroblasts modulating the expression of several genes associated with 
fibrosis thus initiating the wound healing and innate immune response which 
could be limiting HCV infection (Schulze-Krebs et al 2005; Wang et al 2013; 
Friedman et al 2007; Su et al 2014).  The fibroblasts could also be responding 
directly to interaction with the virus.  Some recent studies have artificially 
stimulated LX-2 cells and shown anti-viral properties of the conditioned media 
collected post stimulation on Huh7 cells infected with HCV (Wang et al., 
  
135 
2013b, Wang et al., 2013c).  Whilst other studies have shown HCV or 
recombinant HCV proteins can act via a range of mechanisms which could 
potentially contribute towards the anti-viral activity observed in our co-culture 
system.  Some of these mechanisms include the induction of pro-
inflammatory cytokines in HSC, stimulation of intracellular signalling pathways 
in HSC, or the activation of HSC leading to fibrogenic action (Wang et al 
2013; Friedman 2008; Mazzocca 2005; Coenen et al 2011).   
 
Overall, there could be multiple pathways or mechanism by which the stromal 
cells can inhibit HCV infection in neighbouring hepatocytes.  In summary, I 
have shown aLMF have the ability to significantly limit the level of HCV entry, 
replication and spreading infection in neighbouring hepatoma cells when in 
seeded together in co-culture. 
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Chapter 4 Pathways and mechanisms not contributing to the 
anti-viral activity of aLMF in co-culture 
4.0 Introduction  
We have determined that aLMF limit hepatocellular HCV infection at multiple 
stages in the virus lifecycle: entry, replication, and spread (Chapter 3).  In 
order to better characterize HCV and host cell interactions, we sought to 
define the mechanism leading to aLMF facilitated anti-viral activity.  A 
complex crosstalk of cell membrane interactions and signalling pathways exist 
between hepatocytes and stromal cells, which are responsible for creating the 
liver microenvironment (Taub, 2004b, Gomez-Aristizabal et al., 2009).  
Therefore, we hypothesized that there would be crosstalk between the 
hepatoma and aLMF upon co-culturing and further crosstalk in response to 
viral infection.  For this approach, we first established if the anti-viral 
mechanism required cell-cell contact or soluble secreted factors.  Next, we 
wanted to investigate which signalling pathways were activated during the 
hepatoma innate immune response when aLMF were present.  To determine 
if the aLMF could be modulating the immune response in neighbouring 
hepatoma cells, HCV infected Huh7.5 cell mono-cultures were compared to 
aLMF containing co-cultures.   
 
Given the lack of small animal models to study HCV infection in the liver, our 
co-culture system could provide a physiologically relevant cell culture model 
for studying HCV lifecycle.  Thus, it was important to determine the 
physiological relevance of our model by testing the aLMF limitation of 
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hepatocellular HCV infection in different hepatoma cells, particularly primary 
human hepatocytes (PHH), and under low oxygen levels that mimic the liver 
environment in vivo.  By using this co-culture system to understand the 
mechanism by which aLMF limits HCV infection, the knowledge we obtain 
could provide new therapeutic avenues for treating viral infection and the 
underlying inflammatory response in chronic hepatitis.   
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4.1 Stromal cell anti-viral activity is mediated primarily via a cell contact 
dependant mechanism 
To begin characterizing HCV and host cell interactions that lead to aLMF 
facilitated anti-viral activity, we first established if the anti-viral mechanism 
required cell-cell contact or soluble secreted factors.  For this approach, 
transwell inserts (0.4µm pore size) were used to physically separate the 
stromal and Huh7.5 cells but still allow the cells to exchange soluble secreted 
factors.  The different cell types were seeded at a 1:1 ratio and allowed to 
settle separately for 2 hours before the inserts were added to the wells. Then 
24 hours post adding the inserts to the wells, the co-culture conditions were 
infected with HCVcc (Fig.4-1A).  Infecting with HCVcc allowed us to 
investigate the effect of cell separation on the complete viral lifecycle.  CHO 
cells were included as a control for cell numbers and to act as a non-stromal 
cell control.  When aLMF, LX-2, and CHO cells were in co-culture but 
separated from hepatoma cells using transwells there was minimal reduction 
in HCVcc infection compared to the Huh7.5 mono-culture control which 
suggests stromal cells mediate their effects mainly via cell contacts.   
 
In order to investigate the effects of cell separation on viral entry alone, 
pseudoparticles HCVpp (Fig.4-1B.i), VSVpp (Fig.4-1B.ii), and the negative 
control NEpp were used to infect the same transwell system and were then 
compared to co-culture conditions where the cells were in contact and 
infected with that same pseudoparticle viral inoculums.  The HCVpp and 
VSVpp data both show a decrease of approximately 50% infectivity in all 
transwell co-culture conditions compared to a decrease of approximately 80% 
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in all contact co-culture conditions.  This indicates that although some 
inhibition of HCV and VSV entry can be detected in transwell, cell contact is 
required in order to see a significant reduction in viral entry. 
 
To confirm that aLMF facilitated anti-viral activity required cell-cell contact, 
virus free conditioned media clarified (section 2.3.3) and frozen from previous 
Huh7.5 co-culture assays was used to further investigate the role of soluble 
secreted factors on HCV infectivity.  Mono- and co- culture conditioned media 
was collected to establish whether or not cell contact in co-culture versus 
mono-culture produces soluble secreted factors that have anti-viral activity.  
Huh7.5 mono-cultures were treated with a 1:1 mix of conditioned and fresh 
media on the day of seeding.  Cultures were infected 24 hours after seeding 
with HCVcc, and the infection proceeded for 48 hours in the presence of the 
1:1 conditioned:fresh media mix.  The level of HCV infection was quantified by 
counting NS5A positive foci per well in order to determine the effects of mono- 
or co- culture conditioned media on full length HCV infection (Fig.4-1C).  A 
Huh7.5 mono-culture treated with fresh media was used as a control.  The 
difference in the level of HCVcc infection when Huh7.5 cell were treated with 
conditioned media was not significant when compared to the normal media 
control.  This indicates that the conditioned media from both mono- and co- 
culture conditions does not impact overall HCV infectivity.   
 
To compare to the observations seen with HCVcc, we next investigated the 
effects of conditioned media on viral entry alone by using pseudoparticles.  
Huh7.5 cells treated with 1:1 conditioned:fresh media mix for 24 hours were 
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then infected with HCVpp, VSVpp, or the negative control NEpp for 48 hours 
(Fig.4-1D).  Again the difference in the level of HCVpp or VSVpp infection 
when Huh7.5 cells were treated with conditioned media compared to the fresh 
media control was not significant.  However, there was one exception where 
aLMF donor 1 mono-culture conditioned media showed a significant decrease 
in the level of VSVpp entry (Fig.4-1D, right panel; *p<0.05).  Together with the 
transwell data, the modest decreases in the number of HCVcc foci and 
HCVpp entry levels when treated with conditioned media indicates a minimal 
role for soluble secreted factors on HCV infectivity.  Therefore, we 
hypothesize that the mechanism by which the aLMF reduce HCV infectivity is 
a cell contact dependant mechanism.   
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Figure 4-1 Stromal cells mediate their anti-viral effect primarily via cell 
contact  
(A-B) Stromal cells were seeded in the transwell inserts and Huh7.5 cells 
seeded in the tissue culture plates.  After adhering, the inserts were added to 
the tissue culture plate.  After 24 hours, the cells were infected with (A) 
HCVcc virus or (B.i) HCVpp or (B.ii) VSVpp for 48 hours.  (A) HCVcc infected 
Huh7.5 cells were fixed, stained, and counted for NS5A positive foci.  Data 
representative of n=2 independent repeats (n=4 aLMF donors).  Statistical 
comparison was made using the Kruskal-Wallis test and Dunn’s corrections 
were applied.  (B) Cells infected with pseudoparticles were lysed and 
luciferase activity measured.  Data is expressed as RLU of HCVpp (left panel) 
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or VSVpp (right panel) luciferase activity normalised to the no envelope 
control by subtracting the no envelope signals from the pseudoparticle virus 
signals (Luc:No env).  Data representative of n=2 independent repeats (n=4 
aLMF donors).  Statistical comparison was made using one-way ANOVA tests 
and Bonferroni’s corrections (parametric) were applied for pair wise 
comparisons of all data.  (C-D) Huh7.5 mono-cultures were treated with 1:1 
conditioned:fresh media.  The source of the conditioned media is as indicated. 
After 24 hours, they were infected with (C) HCVcc or (D) HCVpp, VSVpp, or 
NEpp for 48 hours in the presence of the 1:1 conditioned:fresh media.  (C) 
HCVcc infected Huh7.5 cells were fixed, stained, and counted for NS5A 
positive foci.  Data representative of n=4 independent repeats and aLMF 
conditioned media n=8 in both mono- and co-culture.  Statistical comparison 
was made using the Kruskal-Wallis test and Dunn’s corrections were applied.  
(D) Cells infected with pseudoparticles were lysed and luciferase activity 
measured.  Data is expressed as RLU of HCVpp (left panel) or VSVpp (right 
panel) luciferase activity normalised to the no envelope control by subtracting 
the no envelope signals from the pseudoparticle virus signals (Luc:No env).  
Data representative of n=3 independent repeats and aLMF conditioned media 
n=6 in both mono- and co-culture.  Statistical comparison (B-D) was made 
using One-way ANOVA tests with Bonferroni’s corrections to compare the 
treatment groups of data and Bonferroni’s corrections (parametric) were 
applied for pair wise comparisons of all data.  * P<0.05, **P<0.01 and *** 
P<0.001.  All error bars show SD. 
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4.2 Stromal cell anti-viral activity is also mediated via a cell contact 
dependant mechanism in cytokine sensitive hepatomas 
Huh7.5 cells are highly permissive to HCV infection when compared to other 
hepatoma cell lines commonly used in the study of HCV infection.  This high 
permissivity is due to a defective RIG-1 pathway in Huh7.5 cells.  Huh7.5 cells 
have also been shown by our group to be less responsive to cytokines 
compared to other hepatoma cells lines, such as Huh7 and HepG2 cells 
(unpublished data; Wang et al., 2013).   Therefore, we decided to also test the 
role of soluble secreted factors in aLMF facilitated anti-viral activity on a more 
sensitive hepatoma cell line.  We decided to use Huh7 as this cell line still 
provides a level of permissivity that will allow a countable level of HCVcc 
infection instead of HepG2 cells which would potentially produce too low and 
uncountable levels of HCVcc infection.  
 
As previously detailed in section 4.1, Huh7 mono-cultures were treated with a 
1:1 mix of conditioned and fresh media on the day of seeding.  The 
conditioned media was collected from previous Huh7.5 containing co-culture 
assays, from both the mono- and co- culture conditioned, spin clarified and 
stored as described in section 2.3.3.  Then 24 hours after seeding and 
adding the conditioned media, the cultures were infected with HCVcc for a 48 
hour infection in the presence of the 1:1 conditioned:fresh media mix.  The 
level of HCVcc infection was quantified by counting NS5A positive foci per 
well in order to determine the effects of mono- and co- culture conditioned 
media on full length HCV infection (Fig.4-2A).  As a control, Huh7 mono-
cultures were also treated with fresh media only.  The difference in the level of 
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HCVcc infection when Huh7 cells were treated with conditioned media was 
not significant when compared to the normal media control.  This indicates 
that the conditioned media  collected from the previous Huh7.5 assays, mono- 
and co- culture conditions, does not impact overall HCV infectivity even in 
cytokine sensitive hepatoma cells. 
 
We next investigated the effects of the conditioned media collected from 
previous Huh7.5 assays on the entry of viruses into the cytokine sensitive 
Huh7 hepatoma cell line using pseudoparticles.  Huh7 cells were treated with 
1:1 mix of conditioned:fresh media mix on the day of seeding and 24 hours 
after, were infected with HCVpp, VSVpp, or the negative control NEpp for a 
48 hour infection in the presence of the 1:1 mix of conditioned:fresh media 
mix (Fig.4-2B).  Again the difference in the level of HCVpp or VSVpp infection 
when Huh7 cells were treated with conditioned media compared to the fresh 
media control was not significant and consistent with the HCVcc infection data 
(Fig.4-2A).  Overall these data indicate that any soluble secreted factors 
found in conditioned media do not impact HCV infection.  Therefore, we 
conclude that the mechanism controlling aLMF facilitated anti-viral activity 
requires cell-cell contact. 
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Figure 4-2 Testing conditioned media using cytokine sensitive hepatoma 
cells 
(A-B) Huh7 mono-cultures were treated with 1:1 conditioned:fresh media.  
The source of the conditioned media is as indicated.  After 24 hours, they 
were infected with (A) HCVcc or (B) HCVpp, VSVpp, or the negative control 
NEpp for 48 hours in the presence of the 1:1 conditioned:fresh media.  (A) 
HCVcc infected Huh7 cells were fixed, stained, and counted for NS5A positive 
foci.  Data representative of n=3 independent repeats and aLMF conditioned 
media n=6 in both mono- and co-culture.  Statistical comparison was made 
using the Kruskal-Wallis test and Dunn’s corrections were applied.  (B) Cells 
infected with pseudoparticles were lysed and luciferase activity measured.  
Data is expressed as RLU of HCVpp (left panel) or VSVpp (right panel) 
luciferase activity normalised to the no envelope control by subtracting the no 
envelope signals from the pseudoparticle virus signals (Luc:No env).  Data 
representative of n=3 and aLMF conditioned media n=6 in mono- and co-
culture.  Statistical comparison was made using one-way ANOVA tests to 
compare the treatment groups of data and Bonferroni’s corrections 
(parametric) were applied for pair wise comparisons of all data.  All error bars 
show SD. 
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4.3 Stromal cell anti-viral activity is not mediated through an interferon 
dependent pathway 
Production of interferons is a key defence against viral infection as part of the 
innate immune response.  After the detection of viruses, the signalling 
pathway leads to the phosphorylation of IRF3 and subsequent translocation 
into the nucleus where it initiates the production of interferons (IFNs) and 
numerous interferon stimulated genes (ISGs), including ISG56 (!!! INVALID 
CITATION !!!, Horner and Gale, 2009, Marukian et al., 2011).  We wanted to 
establish whether or not the interferon signalling pathway played a role in 
stromal cell anti-viral activity.  For this approach, we decided to use the ISG56 
luciferase reporter to measure the level of IFN activation in hepatocytes when 
in co-culture with stromal cells compared to mono-culture.    
 
The ISG56 luciferase reporter allows the detection of interferon pathway 
activation by a luciferase assay.  We have confirmed that the ISG56 luciferase 
reporter is sensitive enough to detect IFNα, IFNβ, IFNλ1, and IFNλ2 as shown 
by the dose response graphs (Fig.4-3A).  Exogenous Type I IFN (IFNα and 
IFNβ) doses were based on previous concentrations used by our group and 
others, which have shown maximal inhibition of HCV replication at 
concentrations greater then or equal to 50 U/ml (Meredith et al., 2014, 
Marcello et al., 2006, Macejak et al., 2001).  Type III IFN (IFNλ1 and IFNλ2) 
doses were based on concentrations shown by other research groups to have 
maximal inhibition on HCV genotype 2a replication at 10 ng/ml (Marcello et al., 
2006) and ranges between 0.2-0.5 ng/ml showing 50% inhibition of HCV 
replication (Park et al., 2012, Pagliaccetti et al., 2008).  Time course assays 
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were used to investigate the ISG56 reporter response after the addition of 
exogenous IFNα and the data indicated that the luciferase activity increases 
over 8 to 24 hours, with the peak signals achieved 24 hours post addition of 
IFNα (100 IU) even when the time course was extended beyond 24 hours up 
to 48 hours (Fig.4-3B).  Based on the results of the time course and high 
sensitivity of the assay, 24 hours post addition of interferon was chosen as the 
end time point for the ISG56 reporter assays. 
 
Alternative reporters which also detect the interferon pathway were tested 
alongside the ISG56 reporter however the ISG56 reporter showed the highest 
sensitivity and consistency in dose and time response assays, and is capable 
of detecting both Type I and III interferons.  The other luciferase reporter 
plasmids tested included: PRDII (the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) dependent region of the IFNβ promoter 
which induces a proinflammatory response following induction by pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) that 
recognise and respond to virus associated pathogen-associated molecular 
patterns or PAMPS), pConA (an artificial reporter construct with NF-κB 
responsive sequence taken from the concanavalin A promoter induced by 
virus infection), pIFNβ (a full length IFNβ promoter), pISRE (binds to the IRF3 
transcription factor) and pNIFTY (artificial construct of the NF-κB region from 
the ELAM-1 promoter which is induced by PRRs such as TLRs that recognise 
and respond to PAMPS) (data not shown) (Macdonald 2003; Richards and 
Macdonald 2011; Wu et al 2012; Singhi et al 2004; Leblanc 1990; (Mogensen, 
2009). 
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The ISG56 luciferase reporter plasmid was transfected into Huh7.5 cells with 
an average transfection efficiency of approximately 12%.  Then 24 hours after 
transfection, Huh7.5 cells were seeded in mono-culture and co-culture with 
the stromal cells at a 1:1 ratio as done previously (section 3.4).  After 4-6 
hours, the co-cultures were infected with high titre HCVcc virus.  Huh7.5 
mono-cultures were treated with IFNα as a positive control.  As a negative 
control, cells were untransfected or left untreated after transfection.  After 24 
hours, the cells were lysed and the ISG56 expression determined by 
measuring luciferase activity (Fig.4-3C).  In the aLMF and LX-2 containing co-
cultures, the levels of ISG56 activation were comparable to the no IFN control.  
This suggests there is no IFN being produced in co-culture and therefore it 
has no role in the inhibition of HCVcc when aLMF or LX-2 cells and hepatoma 
cells are in co-culture.   
 
Taking into account the 12% transfection efficiency, we wanted to 
demonstrate that the levels of HCVcc infection were sufficient to induce the 
ISG56 reporter.  After transfection and infection as done above, we fixed co-
cultures for immunofluorescence staining.  Representative images of NS5A 
positive cells in mono- and co- culture conditions indicate high levels of 
HCVcc infection (Fig.4-3D). Therefore, despite high levels of HCVcc infection, 
IFN stimulated pathways leading to ISG56 activation were not activated in co-
culture, which suggests no role for them in stromal cell anti-viral activity.    
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Figure  4-3 Measuring ISG56 activation in co-culture 
(A-D) 24 hours after Huh7.5 cells were transfected with the ISG56 luciferase 
reporter plasmid or untransfected as a negative control, they were re-seeded 
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in mono-culture or co-culture and allowed to adhere for 4-6 hours before 
treatment.  (A-C)  Cells were lysed 24 hours after the indicated treatment and 
luciferase activity (RLU) measured.  ISG56 activity is expressed as RLU 
normalised to the untransfected Huh7.5 cells by subtracting the no plasmid 
signals (Luc:no plasmid).  (A) Huh7.5 mono-cultures were treated with IFNα 
(1, 10, 100 IU), IFNβ (1, 10, 100 units), IFNλ1 (0.3, 1, 3 ng/ml), or IFNλ2 (1, 
10, 30 ng/ml).  Data representative of n=7 independent repeats.  (B) Huh7.5 
mono-cultures treated with IFNα (100 IU) were collected at 1, 2, 4, 8, and 24 
hours post treatment.  (C) Mono-cultures of Huh7.5 cells were either 
untreated or treated with IFNα (100 IU).  Huh7.5 co-cultures with aLMF, LX-2, 
or CHO cells were infected with a high titre HCV virus.  Data representative of 
n=3 independent repeats (n=4 aLMF donors).  Statistical comparison was 
made using one-way ANOVA tests to compare and Bonferroni’s corrections 
(parametric) were applied for pair wise comparisons of all data where *** 
P<0.001.  All error bars show SD.  (D)  Microscopy images, 24 hours after 
infection with HCVcc, foci in mono- and co-cultures were visualised using anti-
NS5A antibody detected by a secondary antibody conjugated to Alexa488 
(green) and nucleus detected by DAPI (blue) (magnification x10).  Data 
representative of n=3 independent repeats (n=4 aLMF donors). 
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4.4 Anti-viral response PCR array shows no significant contribution to 
stromal cell anti-viral activity 
In order to investigate further the reduction in HCV infectivity when hepatoma 
cells are co-cultured with stromal cells, we used a Human Antiviral Response 
PCR array from SABiosciences.  The human antiviral response PCR array 
allowed us to determine the expression of 84 key genes involved in the innate 
antiviral immune response.  The genes are a mixture of receptors, 
chaperones, downstream signalling effectors, genes responsive to these 
pathways and signalling pathways belonging to the following functional 
groups; Toll-Like receptor (TLR) signalling, Nod-Like receptor (NLR) signalling, 
RIG-I-Like receptor signalling and Type-I-Interferon signalling and response.  
TLRs, NLRs and RIG-I-like receptors are different groups or pattern 
recognition receptors (PRRs) which can initiate the innate immune response 
following the detection of common pathogens including viruses, leading to a 
cascade of immune signalling pathways.  Type-I interferon signalling leads to 
the activation of natural killer cells and dendritic cells but can also activate the 
adaptive immune response (Foy et al., 2005; Wang et al., 2013a; Wynn 2008). 
 
Huh7.5 cells were seeded in mono-culture or in co-culture with aLMF.  After 
24 hours, the cells were infected with a high level of HCVcc (MOI 10) or left 
uninfected.  First, the infection was confirmed by reverse transcription 
polymerase chain reaction (RT-qPCR) detecting copies of HCV over GAPDH 
(Fig.4-4A).  Once the infection was confirmed, the cDNA was isolated and 
used in the antiviral PCR array.  The antiviral PCR array includes a number of 
controls in addition to the 84 key genes of interest involved in the innate 
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antiviral immune response, as shown in the plate map (Fig.4-4B).  The 
controls included: housekeeping genes (wells H1-H5), human genomic DNA 
contamination control (HGDC) (well H6), reverse transcription controls (RTC) 
for testing the efficiency of the RT2 First strand kit (wells H7-H9) and positive 
PCR controls (PPC) for testing the efficiency of the polymerase chain reaction 
itself using an artificial DNA sequence and primer set pre-dispensed (wells 
H10-12).  The controls for each sample were checked and passed.  The data 
was analysed and heat maps used to display the fold-difference in gene 
expression when making pair wise comparisons of the samples for example 
the fold-difference in expression levels between the uninfected co-culture and 
infected co-culture (Fig. 4-4C).  To investigate the reduction in HCV infectivity 
when Huh7.5 cells are co-cultured with aLMF cells, the relative level of genes 
in mono-culture and co-culture samples were compared.  Gene differences 
above two fold were considered significant and genes with a cycle threshold 
value (Ct) above 30 classed as undetectable for all pair wise comparisons 
made, summarised according to functional family in Table 4-1.  A large 
number of genes for all four samples were classified as undetectable, and 
many more genes classified as non-significant and so were not included in the 
summary table.  The genes classified as undetectable were not due to issues 
with RNA or cDNA as the controls to test for the RT2 First strand kit (wells H7-
9) and positive PCR controls (PPC) (wells H10-12) passed confirming there 
were no issues with RNA or cDNA and that there was enough genomic 
material added to the array.  When comparing the effect of HCVcc infection 
on Huh7.5 cells by comparing the Huh7.5 mono-culture uninfected vs the 
Huh7.5 mono-culture infected, there were no significant gene changes 
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suggesting the viral infection did not initiate any of the anti-viral pathways 
included on the array.  The same was true when comparing the effect of 
HCVcc infection on the Huh7.5 and aLMF co-cultures.  Significant gene 
changes of 2-fold, either up-regulated or down-regulated genes were only 
detected when a comparisons were made between either; Huh7.5 mono-
culture uninfected vs Huh7.5 and aLMF co-culture uninfected or Huh7.5 
mono-culture infected vs Huh7.5 and aLMF co-culture infected.  There were 
some similarities in the genes change across these two comparisons, 
however, it is difficult to interpret some gene changes are a result of the aLMF 
being present in co-culture or the viral infection of mono-culture compared to 
the co-culture conditions.  In order to interpret this data better and understand 
the effect of HCVcc infection on the aLMF, additional antiviral response PCR 
array kits should have been used to run the following samples: aLMF mono-
culture uninfected and aLMF mono-culture infected.  As a result, it was 
difficult to conclude whether the mechanism of stromal cell anti-viral activity is 
likely to be associated with an anti-viral mechanism used in this PCR array, 
especially given the large number of genes which were undetermined due to a 
high Ct value (>30).  However, there were also a number of genes which 
remained unchanged when comparing the uninfected vs infected co-culture 
conditions, and taken together with the ISG56 data in this chapter, it is likely 
that the mechanism of anti-viral activity does not involve the IFN pathway, 
TLR, NLR or RIG-1 signalling pathways but further work may be required to 
confirm this data. 
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Figure 4-4 Human anti-viral response PCR array  
Huh7.5 cells were seeded in mono-culture and in co-culture with aLMF donor 
at a 1:1 hepatoma:stromal cell ratio.  The cultures were infected 24 hours post 
seeding with a high titre HCVcc (MOI 10) or left uninfected.  After 48 hours 
post infection, the cells were lysed for RNA extraction. (A) RT-qPCR detecting 
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copies of HCV over GAPDH.  (B) Plate map with gene names and locations of 
the genes included in the 2-step RT2 profiler SABiosciences human anti-viral 
mirco array.  There were 84 key genes involved in the innate immune 
response and the controls: housekeeping genes (wells H1-H5), human 
genomic DNA contamination control (HGDC) (well H6), reverse transcription 
controls (RTC) (wells H7-H9) and positive PCR controls (PPC) (wells H10-12).  
(C)  Data analysed using the RT2 profiler SABiosciences software and 
displayed as heat maps showing the fold-difference in gene expression when 
making pair wise comparisons of the samples labelled beneath the heat map.  
The colour represent the magnitude of log2 (fold changes) with green 
representing decreased expression and red representing increased 
expression. 
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Table  4-1 Summary of anti-viral array data.  
Table summarising anti-viral array data obtained as the gene differences 
above two fold that were considered significant and genes with a cycle 
threshold value (Ct) above 30 classed as undetectable for all pair wise 
comparisons made,  and grouped according to functional family. A large 
number of genes for all four samples were classified as undetectable, and 
many more genes classified as non-significant and so were not included in the 
summary table  
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4.5 Blocking the VEGF pathway does not suppress stromal cell anti-viral 
activity 
Previous work in our group, identified bone morphogenetic protein 4 (BMP4) 
as a pro-viral molecule expressed by liver sinusoidal endothelium cells 
(LSEC) in chronic liver diseases including HCV (Rowe et al 2014).  BMP4 was 
negatively regulated by vascular endothelial growth factor A (VEGF-A).  
Based on these observations and having ruled out other anti-viral pathways, 
we wanted to investigate whether or not VEGF-A contributes to the reduced 
HCV infectivity observed in aLMF and hepatoma cell co-cultures.   
 
For this approach, Huh7.5, aLMF, LX-2, and CHO cells were treated with anti-
VEGF-A antibody to block VEGF-A activity or left untreated while in 
suspension.  Then Huh7.5 cells were seeded in co-culture with aLMF, LX-2, 
or CHO cells at a 1:1 ratio.  24 hours after seeding, the cultures were infected 
with HCVcc and cultured in the absence or presence of the anti-VEGF-A 
antibody for 48 hours.  The cultures were then fixed, stained for NS5A, and 
the level of HCV infection quantified by counting the number of NS5A positive 
cells per foci, which indicates the spread of the infection (Fig.4-5A) and total 
number of infected cells (Fig.4-5B).  There was no difference in the level of 
HCV spread or overall number of HCV infected cells between mono-cultures 
and co-cultures in the absence or presence of anti-VEGF-A antibody.  This 
anti-VEGF-A antibody has been extensively used by our group and we have 
previously shown it can inhibit the pro-viral action of BMP4, however, 
additional positive controls which could have been included here are: BMP4 
alone at doses of 1, 10, 100 ng/ml  (which would demonstrate a dose 
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dependant increase in HCV infection of Huh7.5 cells) and BMP4 doses with 
anti-VEGF-A antibody (which would show the anti-VEFG-A antibody can 
inhibit the increased HCV infection caused by BMP4 increasing hepatocyte 
permissivity to support HCV infection) (Rowe et al., 2014).  Under these 
circumstances, this data indicates that VEGF-A does not contribute towards 
stromal cell anti-viral activity as blocking VEGF-A did not restore HCV 
infection in co-culture.  
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Figure 4-5 Blocking the VEGF pathway does not restore HCV infection in 
co-culture  
After cells were either treated with anti-VEGF-A antibody (1000µg/mL) or left 
untreated, Huh7.5 mono-cultures were seeded alone and in co-cultures with 
aLMF, LX-2, or CHO cells at a 1:1 ratio.  Cells were infected 24 hours post 
seeding and left for 48 hours in the absence or presence of anti-VEGF-A 
antibody.  The level of HCVcc infection was determined by counting the 
number of NS5A positive cells per foci (A) and the total number of infected 
cells (B).  Data representative of n=1 (n=1 aLMF donor).  Statistical 
comparison was made using the Kruskal-Wallis test and Dunn’s corrections 
were applied *** P<0.001.  All error bars show SD. 
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4.6 Stromal cell anti-viral activity is independent of the nitric oxide 
pathway 
After investigating various anti-viral pathways, we were left to explore other 
pathways not traditionally classified as anti-viral, but may in this model 
contribute to the anti-viral mechanism of aLMF.  One potential pathway that 
could account for the inhibition of HCVcc infection is the nitric oxide (NO) 
pathway, which is activated following induction by interferons and thought to 
play a role in controlling viral infection but can also act independent to the IFN 
pathway (Ibrahim M, et al 2010; Mehta D R et al 2012; (Mehta et al., 2012).  
An increase in NO production as a result of HCV infection has been reported 
as well as its links to oxidative stress, carcinogenesis, and vascular thickening 
(Bruckdorfer, 2005a, Ren et al., 2008, Lukacs-Kornek et al., 2011).  To 
investigate if this pathway could explain the mechanism of stromal cell anti-
viral activity, the NO pathway was blocked using the chemical inhibitor L-
monomethyl arginine (L-NMMA) (Bruckdorfer, 2005b).  The NO inhibitor L-
NMMA was added to the cells in suspension (1mM working concentration) 
and then the cells were seeded in mono- and co- culture.  Then 24 hours after 
seeding, the cells were infected with HCVcc and cultured in the absence or 
presence of L-NMMA for 48 hours.  The cultures were fixed, stained for NS5A, 
and the level of HCV infection quantified by counting the number of NS5A 
positive cells per foci, indicating spread (Fig.4-6A), and total number of 
infected cells (Fig.4-6B). 
 
When comparing the level of HCVcc infection in mono-cultures of Huh7.5 
cells to co-cultures as cells per foci, there appeared to be a significant 
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difference (*** P<0.001)  in each co-culture condition when compared to the 
mono-culture conditions (Fig.4-6A).  This is expected as we have previously 
shown that stromal cells can limit HCVcc infection in Huh7.5 cells when in co-
culture.  When the infection level of HCVcc was compared as total number of 
infected cells, there was statistically minimal difference in the co-culture 
conditions compared to the Huh7.5 mono-cultures (untreated or treated with 
anti-NO inhibitor) however there is clearly a reduction in infection levels in the 
co-culture conditions (Fig.4-6B).  Moreover, there was no difference in HCVcc 
infection between the untreated cultures compared to the cultures infected in 
the presence of the NO pathway inhibitor L-NMMA (Fig.4-6A-B).  If the NO 
pathway was required for stromal cell anti-viral activity, we would have 
expected to see the levels of infection in the L-NMMA treated co-cultures to 
be higher than the untreated, which we did not.   
 
In parallel to this assay, as a control, supernatants from cells in mono- and co-
culture were collected after 48 hours of HCVcc infection.  Using the Griess 
assay, the supernatants were screened for the presence of any NO produced 
by the cells in response to infection.  The Griess assay indicated the 
supernatants were negative for NO (data not shown).  By measuring the 
production of NO in the supernatants and by blocking the production of NO 
using L-NMMA, it is clear NO production plays no role in control of HCV 
infection.  Additional controls which could be added to future NO assays 
include using poly I:C to stimulate NO production which should lead to an 
reduction in HCV infection, or adding exogenous NO to the cultures and then 
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using exogenous NO and the L-NMMA inhibitor in combination to show the L-
NMMA inhibitor does block the NO pathway (Mehta et al., 2012).   
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Figure 4-6 Blocking the NO pathway does not restore HCV infection in 
co-culture   
After cells were either treated with the NO inhibitor, L-NMMA (1mM), or left 
untreated, Huh7.5 mono-cultures were seeded alone and in co-cultures with 
aLMF, LX-2, or CHO cells at a 1:1 ratio.  24 hours post seeding, cells were 
infected and left for 48 hours in the absence or presence of L-NMMA.  The 
level of HCVcc infection was determined by counting the number of NS5A 
positive cells per foci (A) and the total number of cell infected (B).  Data 
representative of n=1 (n=1 aLMF donor).  Statistical comparison was made 
using the Kruskal-Wallis test and Dunn’s corrections were applied *** P<0.001.  
All error bars show SD. 
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4.7 aLMF limit HCVcc infection in PHH  
The ideal in vitro physiological model to study the human liver uses primary 
human hepatocytes (PHH), which are the closest system we have available to 
study hepatocytes in vivo.  PHH are metabolically and phenotypically more 
similar to hepatocytes in the liver than the Huh7 cell lines.  PHH express 
various hepatocyte differentiation markers and do not divide in culture like 
hepatocytes in vivo.  The highly differentiated phenotype of PHH means these 
cells have an anti-viral response that is more intact compared to immortalised 
hepatoma cell lines.  Therefore to investigate the physiological relevance of 
our Huh7.5 co-culture model, we used the PHHs in the co-culture system 
established in section 3.4 and looked for aLMF anti-viral activity. 
 
The caveat of this model is that the differentiation status of PHH in culture 
declines over time along with metabolic activity.  Therefore, we first monitored 
the differentiation status of the PHH by using qRT-PCR to measure the 
expression levels of hepatocyte differentiation markers: alpha-fetoprotein 
(αFP), hepatocyte nuclear factor 4α (HnF4α), albumin, and a cytochrome 
P450 enzyme called CYP3a4.  The PHHs maintained all four differentiation 
markers at a consistent level of expression over a period of 96 hours, 
observed using three different PHH donors (Fig.4-7A). 
 
Our research group first characterised the PHH donors provided by Dr Ragai 
Mitry (King’s College, London), comparing the PHHs to hepatoma cells, 
examining HCV receptor expression and location, and testing the ability of 
PHHs to support HCV entry and replication over time, in assays performed by 
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Garrick Wilson.  We determined the time it takes for PHHs to de-differentiate 
in culture, which were monitored over a period of 12 days.  The hepatocyte 
morphology was monitored by phase microscopy and samples collected every 
24 hours to investigate albumin secretion and differentiation status in assays 
performed by myself.  We found that the PHHs maintained their differentiation 
status for 10 days, at which point the morphology had changed from a 
hepatocyte like shape (a unique polygonal shape) to a more elongated 
fibroblast like shape.  The level of albumin secretion decreased slowly over 
time, starting at approximately 350ng/mL on the day of seeding down to 
approximately 20ng/mL after 10 days in culture, thus indicating the PHH were 
de-differentiating (unpublished data).  This data correlates with reports from 
other groups, highlighting the difficulties in culturing PHH and maintaining the 
phenotype and morphology in culture (Bhogal 2011; Yang 2011; Podevin 
2010; Ploss 2010). 
 
Next, we investigated the effect aLMF would have on HCV infection of PHH in 
co-culture.  As established in section 3.4, PHHs were seeded in mono- and 
co- culture with aLMF, LX-2 and CHO cells at a 1:1 ratio.  In mono-culture, the 
PHHs were seeded varying the number of target cells by starting with a full 
well of target cells (2.5x104 cells per well in a 48 well tissue) then a half the 
number of target cells in the full well.  Cultures were allowed to adhere for 24 
hours before infecting HCVcc.  48 hours post infection, cells were lysed for 
RNA extraction and RT-PCR used to detect the levels of HCV RNA.  qRT-
PCR was used to quantify infection because of the difficulties we found with 
staining and detecting HCV positive cells due to the autofluorescent nature of 
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PHH in immunofluorescence.  In the PHH mono-cultures seeded at a full and 
half well of target cells, the level of HCV copies per GAPDH was higher when 
half the number of target cells are available (Fig.4-7B).  This is in contrast to 
the Huh7.5 mono-culture where the level of infection is proportional to the 
number of target hepatoma cells available (section 3.4.1).  However, this 
discrepancy could be due to PHH donor variability, as previous work by 
Garrick Wilson indicated that donor variation in PHHs did affect HCVcc 
replication in PHHs.  Moreover, this initial data shows that HCVcc infection of 
PHHs is inhibited when they are in co-culture with aLMF, LX-2, and CHO cells.   
 
Given the difficulties in isolating and culturing PHH, plus the limited availability, 
repeat assays were not feasible at this time and there weren’t enough PHHs 
from a single donor to split the culture in order to set up two experiments in 
parallel.  Under these circumstances, the data indicates that aLMF reduce 
HCV infection in both Huh7.5 cells and the physiologically relevant PHH, thus 
supporting the above conclusions made with our co-culture model.   
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Figure 4-7 aLMF limit HCVcc infection in PHH 
(A) Mono-cultures of PHHs were lysed at 24, 48, 72 and 96 hours post 
seeding for RNA extraction and qRT-PCR detection of the differentiation 
genes αFP, HnF4α, albumin, and CYP3a4 and the control house keeping 
gene GAPDH.  The expression levels were quantified and normalised relative 
to the level of GAPDH detected at each time point.  Data representative of 
n=3 independent repeats (n=3 PHH donors).  (B) PHHs were thawed and 
seeded in mono-culture or co-culture with aLMF, LX-2, or CHO cells at a 1:1 
ratio.  24 hours post seeding, cells were infected with high titre HCVcc.  Then 
48 hours post infection, cells were lysed for RNA extraction and gene 
expression of HCV RNA and GAPDH detected by qRT-PCR with data 
expressed as copies of HCV per GAPDH.  Data representative of n=1 
independent repeats (n=1 PHH donor and n=1 aLMF donor).  Statistical 
comparison was made using the Kruskal-Wallis test and Dunn’s corrections 
were applied * P<0.05.  All error bars show SD. 
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4.8 The differentiation status of hepatoma cells in co-culture with aLMF 
remain unchanged 
The role of aLMF within the liver is to support the hepatocytes in cell growth 
and survival.  Therefore, we hypothesized that the aLMF may push the 
Huh7.5 cells to become more differentiated when in co-culture.  More 
differentiated hepatomas would ultimately lead to a decrease in infection, 
similar to the lower levels of infection seen when using highly differentiation 
PHH.   
 
To investigate the level of differentiation of the Huh7.5 cells in mono- and co- 
culture, the expression levels of hepatocyte differentiation genes α-FP (Fig.4-
8A), albumin (Fig.4-8B), HnF4α (Fig.4-8C), and CYP3a4 (Fig.4-8D) was 
assessed using qRT-PCR.  The results indicate that the expression level of 
the hepatocyte differentiation genes was not significantly different when 
comparing Huh7.5 cells in mono-culture to Huh7.5 cells in co-culture with 
aLMF.  Therefore, the differentiation status of the Huh7.5 cells is not a 
potential mechanism for the stromal cell anti-viral activity.   
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Figure 4-8 The differentiation status of hepatoma cells when in co-
culture with aLMF remains unchanged  
Huh7.5 cells were seeded in mono- or co- culture with aLMF (two donors, 
denoted 1 and 2), LX-2, or CHO cells at a 1:1 ratio.  72 hours post seeding, 
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cells were lysed for RNA extraction and qRT-PCR used to detect the 
expression level of the differentiation markers and the control house keeping 
gene GAPDH.  The expression levels of α-FP (A), albumin (B), HnF4α (C), 
and CYP3a4 (D) were normalised relative to the level of GAPDH detected at 
each time point.  Data representative of n=3 independent repeats.  Statistical 
comparison was made using the Kruskal-Wallis test and Dunn’s corrections 
were applied.  All error bars show SD. 
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4.9 HepG2 polarity is altered when in co-culture with aLMF 
The differentiation status and polarity of hepatocytes is key to maintaining 
their phenotype and function.  After showing that aLMFs do not alter the 
differentiation status of Huh7.5 cells in co-culture, we next investigated if they 
could alter the polarity.   
 
For this approach, we used HepG2 cells because this hepatoma cell line has 
the ability to polarize whereas Huh7.5 cells do not polarize in culture.  
Hepatocyte polarity is key in the ability of hepatocytes to function and is 
described as the distinct distribution of lipids and proteins in the sinusoidal 
and bile canaliculi membranes (Chiu et al 1990; Wang and Boyer 2004).  
HepG2 expressing DPP IV (tagged with red fluorescent protein) were seeded 
in mono- or co- culture with aLMF, LX-2 and CHO cells.  DPP IV is a 
membrane expressed protein which is trafficked to the bile canaliculi in 
hepatocytes and so can be used to visualise the formation of bile canaliculi in 
HepG2 cells when polarised (Wojtal et al 2006; Ait Slimane et al 2003).  The 
cells were allowed to settle for 3 days after seeding to give them time to 
polarize, after which the cultures were assessed for polarity using 
immunofluorescence (Fig. 4-9).  We did not observe significant differences in 
polarity when the LX-2 or CHO cells were in co-culture with the HepG2-DPP 
IV cells.  However we did observe a noticeable difference in polarity when 
aLMF (green) were co-cultured with HepG2-DPP IV cells (red) compared to 
the HepG2-DPP IV cells alone by immunofluorescence (Fig. 4-9).  The 
aLMFs appeared to be causing the HepG2-DPP IV cells to form larger lumens 
that were more cis like in structure, compared to when the HepG2-DPP IV 
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cells are alone or in co-culture with LX-2 or CHO cells, thus appearing to have 
altered the polarity.  The cis like lumens observed in the aLMF containing co-
cultures can be described as larger lumens than normal, appearing bright 
which indicates there is a high level of DPP IV located around the lumen 
labelled with red fluorescent protein.  There were also some lumens in the 
aLMF containing co-culture, which had not formed very well as a result of the 
HepG2-DPP IV cells being in direct contact with the aLMF, and sometimes, 
the long spindly extensions of the aLMF appeared to be running across where 
the lumen should have formed, disrupting the formation.     
 
This data suggest that the aLMF are altering the polarity of the hepatocytes 
when in co-culture.  The role of the altered hepatocyte polarity requires further 
functional assays in order to investigate the potential impact on viral infection 
and hepatocyte function.  
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Figure 4-9 HepG2 polarity is altered when in co-culture with aLMF  
Representative immunofluorescence images of HepG2-DPP IV cells (red) 
seeded in mono- or co- culture with aLMF.  Cells were fixed 3 days post 
seeding, the nuclei stained using DAPI (blue) and the immunofluorescence 
visualised by immunofluorescence microscopy (magnification x50).  Data 
representative of n=2 independent repeats (n=2 aLMF donors).  BC - bile 
canaliculi structures.   
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4.10 aLMF may reduce HCVcc infection at physiologically relevant 
oxygen levels  
Metabolic, vascular, and secretory functions of the liver are regulated by 
oxygen concentration, with a 3-9% oxygen gradient across the liver 
parenchyma.  Therefore, hepatocytes are exposed to different levels of 
oxygen depending on their location within the liver (Wilson et al 2014; Wilson 
et al 2012).  The oxygen level found in normal tissue incubators is 20% so the 
role of stromal cell anti-viral activity at physiologically relevant oxygen 
concentrations is unknown.  Previous studies have shown that hypoxic 
conditions significantly increase HCV infection of hepatocytes and that under 
normal tissue culture conditions; HCV infection can induce a pseudohypoxic 
state by stabilizing HIF-1a expression (Nasimuzzaman et al 2007; Hassan 
2009; Vassilaki 2013).  Therefore it is hypothesized that HIF-dependent 
changes in hepatocyte metabolism and permeability can actually promote 
HCV replication and transmission (Wilson et al 2014; Vassilaki 2013; Mee et 
al 2009; Wilson 2012). 
 
To investigate the role of oxygen concentration, Huh7.5 cells were seeded in 
mono-culture and co-culture with aLMF, LX-2, or CHO cells at a 1:1 ratio.  
Then 24 hours after seeding and incubating in the normal 20% oxygen 
incubator, the cultures were infected with HCVcc and immediately transferred 
to the 1% oxygen incubator (hypoxia) or left at 20% (normoxia conditions).  
The cells were fixed 48 hours post infection and the level of infection 
determined by staining for NS5A positive cells and counting the number of 
foci per well.  The level of HCV infection under normoxia (Fig.4-10; left 
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panel) compared to hypoxia (Fig.4-10; right panel) was comparable in this 
preliminary data.  The level of infection in the Huh7.5 mono-culture condition 
was unexpected as under hypoxia, the level of HCVcc infection in Huh7.5 is 
supposed to be significantly higher than under normoxia, however in this 
preliminary data, there appeared to be a slight decrease in the level of HCVcc 
infection of Huh7.5 mono-cultures which can not be explained but could be 
due to possible technical issues with the hypoxic incubator.  Given that in this 
data the level of infection in both conditions is comparable it is difficult to 
establish whether or not hypoxia does play a role in stromal cell anti-viral 
activity but this potential mechanism warrants further investigation. 
  
176 
 
 
 
Figure 4-10 aLMF can still reduce HCVcc infection at physiologically 
relevant oxygen levels 
Huh7.5 cells were seeded alone or in co-culture with aLMF, LX-2, or CHO 
cells at a 1:1 ratio in the normal 20% oxygen incubator.  Then 24 hours post 
seeding, cells were infected with HCVcc and immediately transferred to the 
1% oxygen incubator (hypoxia) or left at 20% (normoxia).  Cells were fixed 48 
hours after infection, stained for NS5A positive cells, and the number of foci 
per well counted.  Statistical comparison was made using the Mann-U-
Whitney test.  All error bars show SD. 
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4.11 Discussion 
There are limited studies investigating HCV infection of hepatoma cells that 
also take into account the complex nature and diverse cell types found within 
the liver.  Previous work in our group from Rowe et al (2014) investigated the 
role of liver sinusoidal endothelium cells (LSEC) in regulating HCV replication 
and identified a secreted factor that promoted HCV infection within other cells.  
LSEC do not support HCV infection but do secrete bone morphogenetic 
protein 4 (BMP4), a soluble secreted factor that promotes HCV infection of 
hepatoma cells and increases HCV replication.  However, when both cell 
types are in contact co-culture, there is actually an overall reduction in HCV 
infectivity of hepatoma cells when compared to mono-culture despite the 
LSEC producing the pro-viral BMP4 factor.  Further research identified that 
although recombinant BMP4 increased hepatoma permissivity to HCV, 
hepatoma cells can actually negatively regulate BMP4 at the transcriptional 
level via vascular endothelial growth factor A (VEGF-A) activation, a factor 
known to protect the liver from injury (Rowe at el, 2014). 
 
In chapter 3, we demonstrated that when aLMF, LX-2 and CHO cells were co-
cultured with Huh7.5 cells at a 1:1 ratio, there were clearly less infected cells 
per foci after 48 hours in co-culture indicating that stromal cells can inhibit 
HCVcc spread.  Despite the clear decrease in the level of spread in co-culture, 
there was only a moderate decrease in the aLMF co-culture, but a reasonable 
decrease in the LX-2 containing conditions (P<0.05) (Fig.3-7C).  By using the 
various systems available to study HCV lifecycle, we were able to 
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demonstrate that stromal cells can limit HCV infection at various stages of the 
viral lifecycle including entry, replication and spread.   
 
The data in this chapter demonstrates that the mechanism by which aLMF 
can limit HCV infection in neighbouring hepatoma cells is mediated via cell 
contacts determined by separating the cells in co-culture and testing the 
conditioned media from both mono- and co- culture conditions for potential 
soluble secreted factors with anti-viral properties.  Huh7.5 cells are known to 
have a defective RIG-1 pathway due to a mutation in the RIG-1 gene, which is 
involved in regulating the interferon pathway (Yao et al 2011; Feigelstock et al 
2010; Blight et al 2002; Sumpter et al 2005; Regeard et al 2007).  This 
defective pathway means the Huh7.5 cells are more permissive to viral 
infection, which works well in our co-culture system as it allows us to achieve 
higher infection levels and a better dynamic range in co-culture conditions.   
However, when trying to understand if the mechanism by which aLMF are 
inhibiting viral infection involves the innate immune response, this defective 
pathway means the system does not accurately mimic hepatocytes within the 
liver, which do have intact innate immune responses.  On the other hand, 
even with this defective pathway in Huh7.5 cells we still observed a decrease 
in HCV infectivity, which could be suggesting that the mechanism is 
independent of this pathway.  Interestingly, previous studies have shown that 
poly I:C stimulation of LX-2 cells in mono-culture leads to TLR-3 activation in 
the LX-2 which induces IFN-λ production Huh7 cells (which have an intact 
RIG-I pathway) when treated with conditioned media collected from the LX-2 
cells.  As a result, Huh7 cells pre-infected with HCV were treated with the 
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conditioned media collected from the stimulated LX-2 cells, which was shown 
to be anti-viral.  In a similar manner, conditioned media collected from LX-2 
cells stimulated with a RIG-I ligand were also shown to suppress HCV 
replication of pre-infected Huh7 cells, indicated RIG-I signalling of LX-2 cells 
can inhibit HCV infection via the production of IFN-β and IFN-λ (Wang et al., 
2013b, Wang et al., 2013c).  With such questions surrounding the 
physiological relevance of the Huh7.5 co-culture system, we wanted to 
validate the system and in this chapter we have shown data using PHH in co-
culture demonstrating a similar level of viral inhibition in PHH co-culture to the 
Huh7.5 co-culture system.   
 
A human anti-viral array was then used to screen the contribution of a vast 
number of anti-viral pathways and this data, combined with the ISG56 data, 
was key in concluding that anti-viral mechanisms do not contribute to the 
reduction in HCV infectivity.  When comparing the effect of HCVcc infection 
on the Huh7.5 and aLMF co-cultures, there were no significant gene changes 
and a large number of genes which remained unchanged suggesting the viral 
infection did not initiate any of the anti-viral pathways included on the array.  
However there were also a large number of genes which were undetermined 
due to a high Ct value (>30), and these genes could have possibly been 
altered significantly altered and so a few additional repeats would help make 
the data more robust (Fig. 4-4B).  Nevertheless, the ISG56 reporter, 
demonstrated to detect a range of IFNs, confirmed these various IFN 
pathways do not contribute to the stromal cell anti-viral mechanism.  
Interestingly, there was a low level of ISG56 activation in the cell density 
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control co-cultures containing CHO cells (Fig. 4-3C).  This could be possibly 
be due to CHO cells being recognised as a non-human cell type therefore 
potentially stimulating an anti-viral response in the Huh7.5 cells and so could 
possibly explain why the CHO cells can also inhibit HCV infection in 
neighbouring hepatoma cells, although to a lesser extent than the stromal 
cells (Fig 3-4B and Table 3-2).  Another factor to bear in mind with using 
CHO cells or any other cell type as a control for such experiments is that no 
cell is an inert cell and there will inevitably be a certain degree of cross-talk 
between two different cell types when they are co-cultured together.     
 
Our research group have previously characterised the phenotype of PHH in 
culture and investigated HCV infection of PHH using the various HCV 
infection systems present (unpublished data).  PHH infection was compared 
to several hepatoma cell lines, the optimal day post seeding for HCV infection 
established and the expression of the four key HCV receptors required for 
entry monitored over time in culture.  HCVpp infection of PHH indicated there 
was no donor variability at the entry step of HCV infection, however there was 
donor variability in HCV infection when the PHH were infected with HCVcc.  
This indicated that donor variability impacted the replication steps of HCV 
infection which has been previously reported by Marukian et al (2008).  
Marukian and colleagues went on to demonstrate the variation in replication 
was due to the variation in the interferon response and ISGs after HCVcc 
infection of PHH.  The overall level of HCV infection in PHH is lower when 
compared to various hepatoma cells due to factors such as the more intact 
anti-viral response and the PHH being more differentiated (Marukian et al 
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2008; Bhogal 2011; Yang 2011; Podevin 2010; Ploss 2010).  One of the key 
challenges with PHH culture in addition to the limited availability is that they 
de-differentiate over time in culture.  The role of stromal cells in the liver is to 
support hepatocyte function and so a number of studies have used stromal 
cells including non-human fibroblast cell lines, in co-culture systems to assist 
in maintaining hepatocyte function (Ploss 2010; Goulet 1988; Khetani and 
Bhatia 2008; Hui and Bhatia 2007).  So we investigated the role of aLMF in 
maintaining hepatoma cell function, focusing on differentiation status and 
polarity, two key characteristics of hepatocytes which are vital for their 
function contributing to the lower permissivity in PHH when compared to 
hepatoma cell lines.  Huh7.5 cells are not known as a differentiated cell line 
and unlike HepG2 cells, they can not polarize in culture.  The differentiation 
status of Huh7.5 cells remained unchanged in our co-culture system 
suggesting this does not account for the reduction in HCV infectivity.  aLMF 
did however appear to alter HepG2 polarity observed by microscopy however 
given that the majority of the data in this study used Huh7.5 cells, this was not 
investigated further.  Nevertheless, investigating the impact of stromal cells on 
hepatocyte polarity and how this impacts HCV infectivity would be interesting 
for further work and increase our understanding of the role stromal cells play 
on HCV disease progression in the liver. 
 
This chapter demonstrates the physiological relevance of our co-culture 
system, validating our data using this system and highlighting the importance 
of understanding the mechanism for future therapeutic avenues.  Interestingly, 
we were able to rule a number of potential pathways that would have 
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indicated a typical anti-viral response such as the innate immune response, 
IFNs and ISGs, cytokines and other soluble factors.  We were also able 
demonstrate that some mechanisms which could alter hepatocyte function 
and thus HCV infection such as albumin production and differentiation status, 
do not contribute to the ability of aLMF to reduce HCV infection.  Yet, HepG2 
polarity when in co-culture was altered with the preliminary data showing 
altered lumens in co-culture with aLMF compared to mono-cultures of HepG2 
cells (Fig.4-9) and occasionally observed what appeared to be membrane 
ruffling on the HepG2 cells in contact with the aLMF however this was 
preliminary data (data not shown).  Overall, these data lead us back to the 
inhibition being a cell contact based; possibly impacting the membrane 
dynamics or structure and so we wanted to investigate the cell-cell contacts 
occurring between these two cell types in more detail to elucidate a potential 
mechanism. 
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Chapter 5 aLMF inhibit HCV infection via two independent 
mechanisms: limiting CD81 lateral diffusion and VAP-1 
expression  
5.0 Introduction 
Having investigated and ruled out antiviral immune defence mechanisms 
playing a role in aLMF limitation of HCV infection in co-culture, we decided to 
focus on potential non-immune related mechanisms particularly cell mobility 
and membrane dynamics.  In Chapter 4, we established that the mechanism 
by which aLMF limit HCV infection is cell contact dependent.  When in contact 
with HepG2 cells, aLMF also appeared to alter the polarity of the hepatocytes.  
Based on these observations, we decided to focus on potential cell-cell 
contact mechanisms.   
 
The number of heterotypic cell-cell contacts occurring in our conventional 2D 
co-culture system could be influenced by the arrangement of the cells 
compared to the 3D arrangement found in the liver.  Therefore, we decided to 
model the co-culture system in 3D in order to mimic the spatial arrangement 
of these cell types in vivo.  We would then use this 3D model to establish if 
the cellular arrangement has an impact on the ability of aLMF to inhibit HCV 
infection in hepatoma cells. 
 
aLMFs are mobile cells (Brandao et al 2006; Iredale 2007; Friedman 2008) 
which led us to hypothesize that in co-culture they may be in contact with 
multiple hepatoma cells at different points in time as they migrate through the 
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culture responding to cell signals.  As the aLMF are migrating there is also the 
potential that they are laying down extracellular matrix (ECM) that may or may 
not be degraded.  This ECM could potentially act as a trap binding virus 
inoculum.  Therefore, we wanted to study virus binding to the aLMF cell 
membrane and ECM in order to establish a mechanism by which aLMF 
deplete virus and consequently reduce HCV infection.   
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5.1 aLMF in 3D co-culture have the ability to limit HCVpp entry 
The co-culture system established in Chapter 3 used conventional 2D co-
cultures that may not accurately mimic the complex multi-cellular environment 
found in the liver. Thus, we wanted to develop a 3D organoid culture that 
would contain multiple liver cell types in order to create a more realistic model 
of the liver microenvironment.  
 
With the guidance of Professor van Ijzendoorn at UMCG, we adapted the 
established 3D liver organoid Matrigel sandwich culture system to grow 
Huh7.5 cells (Fig.5-1A) and HepG2-CD81 cells (Fig.5-1B) (Elamin et al 2012; 
Molina et al 2012).  Unlike Huh7.5 cells, HepG2 cells do not express CD81 
and so they are non-permissive to HCV infection.  However, by endogenously 
expressing CD81 in HepG2 cells, they can be rendered permissive to HCV 
infection.  These cells were seeded in co-culture with aLMF, LX-2, or CHO 
cells at a 4:1 ratio of hepatoma:stromal cells.  This ratio was selected after 
optimisation steps with different ratios were tested which indicated that the 
larger size of the aLMF in relation to the HepG2-CD81 cells often disrupted 
the organoid cultures from forming over time.  The 4:1 ratio of 
hepatoma:stromal cells allowed the successful formation of organoid cultures 
in a 3D arrangement containing both cell types within the standard time frame 
of this system.  The 3D organoid cultures look like round 3D spheres made up 
of multiple cells, often with an empty space in the centre of the sphere shape 
which can be visualised by immunofluorescence imaging and taking z-stack 
image through the sphere like 3D organoid cultures.  As a control, cultures 
were also seeded in 2D without the Matrigel as established in Chapter 3 but at 
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a matching 4:1 ratio of hepatoma:stromal cells.  Cultures were infected 72 
hours post seeding with either HCVpp (Fig.5-1A-B) or HCVcc (Fig.5-1C).  
The cultures infected with HCVpp were lysed 48 hours post infection and the 
level of HCVpp infection determined by measuring luciferase activity.  Based 
on the comparable infection levels for the Huh7.5 mono-cultures in 2D without 
Matrigel and Huh7.5 mono-culture in 3D with Matrigel, we confirmed that the 
Matrigel sandwich culture system did not interfere with the luciferase readings 
(Fig.5-1A-B).  In the 2D cultures, the aLMF appeared to not inhibit HCV 
infection in co-culture which is inconsistent with the previous co-culture data, 
yet in 3D with Matrigel, the aLMF are showing an inhibition of infection as 
expected.  This could potentially be explained by the low number of aLMFs 
present in the 4:1 Huh7.5:aLMF co-culture ratio here, leading to fewer aLMF 
adhering, increased aLMF cell death and a even fewer aLMF cells present, as 
described in section 3.4.1.  The aLMF cells may have settled better at the 4:1 
ratio in the 3D Matrigel conditions as the Matrigel itself may have provided a 
scaffold for the cells to adhere to and is routinely used to enhance cell growth 
of primary cells or cells which are difficult to culture using normal tissue 
culture plates.   Overall, the results indicate that aLMF have the ability to 
reduce HCV entry in 3D cultures to levels comparable to the 2D cultures as 
indicated by the raw RLU values.  This suggests that even when the cells are 
cultured 2D co-cultures, the level of cell-cell contact achieved in 2D could 
potentially be mimicking the level of cell-cell contacts in 3D as found in the 
liver (Fig.5-1A-B).  We had hypothesised that a 3D arrangement of cells could 
potentially allow one aLMF cell to contact multiple Huh7.5 cells and form more 
cell-cell contacts with Huh7.5 cells than in the conventional 2D cultures which 
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we hypothesised would then lead to an enhanced reduction in HCV infection 
of Huh7.5 cells.   
 
Representative immunofluorescence images were taken of HCVcc infected 
Huh7.5 cells or HepG2-CD81 cells alone in 2D and 3D Matrigel cultures 
(Fig.5-1C).  The images show how the cells grow in 3D organoids making it 
difficult to focus on HCV positive cells and thus making it difficult to count the 
level of infection.  We concluded that HCVcc infections in 3D are difficult to 
enumerate at this time and so this system would be best suited for 
pseudoparticle infections.  Given the limited availability of mouse models to 
study HCV, after further optimization the 3D ‘liver’ cultures could provide a 
significant advance in studying the interaction(s) between liver cells and their 
role in the HCV lifecycle.   
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Figure 5-1 aLMF cultured in 3D limit HCVpp entry 
Ibidi chamber slides (8 well slides) were either uncoated or coated with 
Matrigel 30 minutes prior to seeding.  Huh7.5 cells (A) and HepG2-CD81 cells 
(B) were seeded in mono- or co- culture with aLMF, LX-2, and CHO cells at a 
4:1 ratio of hepatoma:stromal cells.  Cultures were infected 72 hours post 
seeding with either HCVpp (A-B) or HCVcc (C) for 48 hours.  (A-B) Cells 
were lysed and luciferase activity measured.  Data is expressed as relative 
light units (RLU) of HCVpp.  Data representative of n=2 independent repeats 
(n=2 aLMF donors).  Statistical comparison was made using the one way 
ANOVA and Bonferroni’s corrections were applied. All error bars show SD.  
(C) Cells were fixed and stained with anti-NS5A antibody detected by a 
secondary antibody conjugated with the Alexa488 (green) and DAPI to show 
nuclei (blue) (magnification x10). Data representative of n=2 independent 
repeats (n=2 aLMF donors).   
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5.2 aLMF are more mobile than hepatoma cells 
When HSCs become activated to aLMF in response to injury such as viral 
infection, the aLMF proliferate, synthesise various ECM including collagen, 
and become more mobile (Iredale 2007; Friedman 2008; Brandao et al 2006).  
As the mechanism of stromal cell anti-viral activity is dependent on cell 
contact, we wanted to explore the mobility of aLMF in co-culture.  We 
hypothesized that there would be a difference in aLMF mobility compared to 
hepatoma cells given the contractile nature of aLMF cells and that this 
difference could possibly have implications on HCV infection in co-culture.   
 
For this approach, we decided to use the Cell IQ for live cell imaging and cell 
tracking over time.  The Cell IQ maintains normal tissue culture conditions for 
the duration of imaging and the Cell-IQ SLF (single-label fluorescence) allows 
detection and quantification of green fluorescence.  Huh7.5 cells were co-
cultured at a 1:1 ratio with aLMF labelled with CMFDA green cell tracker dye.  
The cultures were allowed to settle overnight under normal cell culture 
incubation conditions before the tissue culture plates were inserted into the 
Cell IQ for live cell imaging.  The machine was programmed to obtain images 
at multiple positions in each well, every 30 minutes on both the phase and 
green fluorescence channel, which would allow us to distinguish between the 
unlabelled Huh7.5 cells and the CMFDA (green) labelled aLMF. 
 
The visual analysis of the Cell IQ tracking data and the representative images 
collected at 1, 4, 7.5, and 11 hours clearly indicate the aLMF (green) are more 
mobile than the hepatoma cells (unlabelled, grey) when in co-culture, with the 
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Huh7.5 cells showing minimal mobility in both mono- and co- culture 
conditions (Fig.5-2A).  We decided to also track the movement of synovial, 
bone marrow, and dermal fibroblasts in co-culture with Huh7.5 cells because 
we wanted to compare the mobility of aLMF to different types of fibroblasts in 
order to determine if liver derived fibroblasts are more mobile than other types 
of fibroblasts.  As above, Huh7.5 cells (unlabelled, grey) were co-cultured at a 
1:1 ratio with the different types of fibroblasts (green) and allowed to settle 
overnight before the cultures were imaged every 30 minutes on the Cell IQ.  
When comparing the mobility of these different fibroblasts in the 
representative images collected at 1, 4, 7, and 10.5 hours, we observed 
subtle differences (Fig.5-2B).  Compared to the other fibroblasts, the aLMFs 
appeared to be more mobile, more flexible and more contractile, changing 
shape and size more than the other fibroblasts and covering more surface 
area faster when moving around too.  The synovial fibroblasts and bone 
marrow fibroblasts behaved in a similar manner, with both fibroblast types 
appearing morphologically smaller and less elongated or spindle like.  Both 
fibroblast types also moved slower than the aLMFs, not contracting as much 
with the movements appearing to be more localised.  The dermal fibroblasts 
morphologically are more similar to the aLMF displaying a similar thin, 
stretched and elongated shape and size.  The dermal fibroblasts covered 
more surface area than the aLMF but appeared to move slightly slower than 
the aLMF.  Also the dermal fibroblasts appeared to have occupied majority of 
the space in co-culture with Huh7.5 cells, more space than any of the other 
fibroblast types had covered in co-culture.   
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When we tried to calculate the change in cell migration for the different 
fibroblasts, a number of key issues were identified.  The CMFDA green cell 
tracker dye used to label the aLMF was visible for 24-36 hours post imaging in 
the Cell IQ but beyond 36 hours, the green fluorescent signal bleached rapidly 
over time.  This rapid bleaching restricted the time available for imaging and 
made it increasing difficult to distinguish between the two cell types.  The 
CMFDA bleaching is illustrated over 72 hours and shows a single aLMF 
moving across the field of view within 153 frames (Fig.5-2C). However, the 
visual analysis of the images provided by the Cell IQ indicate that fibroblasts 
are more mobile that hepatoma cells. 
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Figure 5-2 aLMF are more mobile than hepatoma cells 
(A-C) Fibroblasts (green) were labelled with CMFDA green cell tracker dye 
then unlabelled Huh7.5 cells (grey) were seeded in mono-culture and in co-
culture at a 1:1 ratio with the different types of fibroblasts: aLMF (A), synovial, 
bone marrow, or dermal fibroblasts (B).  Cultures were allowed to settle for 24 
hours before being placed in the Cell IQ, which was set to image multiple 
points in each well every 30 minutes over night.  Representative images from 
the live cell time-lapse movies are shown at the indicated time points post 
incubating in the Cell IQ.  (C) Using the live cell time-lapse movie on the Cell 
IQ, a single CMFDA labelled aLMF was tracked over 72 hours using ImageJ 
software frame by frame, the red line represents the continuous movement of 
the aLMF tracked frame by frame over 72 hours (tracking analysis performed 
by Dave Mason). 
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5.3 Binding of HCVcc by aLMF cells or ECM is minimal 
Previous research indicates that aLMF play a role in response to liver injury 
such as viral infection using mechanisms such as synthesis of various ECM 
including collagen (Kisseleva 2008; Wang 2012; Schulze-Krebs et al 2005; 
Gomez et al 2009).  Therefore, we wanted to investigate whether there is a 
role for ECM produced by aLMF in the stromal cell mediated anti-viral activity, 
using mechanisms such as binding HCV particles and consequently depletion 
of available virus for infection (Jiang et al 2012; Barth 2003; Harmaia 2001; 
Jiang 2013). 
 
aLMF, LX-2, and the non-permissive control CHO cells were seeded in mono-
culture.  As a control for the stromal cells, three different hepatoma cell lines, 
Huh7.5, Huh7, and HepG2, were tested in parallel for their virus binding 
capacity.  Duplicate wells were seeded for testing virus binding to the cells 
(Fig.5-3, left panel) compared to the ECM (Fig.5-3, right panel).  Naïve 
Huh7.5 mono-cultures were seeded in order to test the infectivity of virus 
inoculum collected from the cells or ECM.  Select wells were treated with a 
lysis buffer consisting of PBS containing 0.5% Triton X (v/v) and 20mM 
ammonium hydroxide (NH4OH), 24 hours post seeding.  The lysis buffer was 
removed once the cells detached, which was observed by phase microscopy, 
in order to remove the cells and leave the ECM on the tissue culture plate 
(Butler 2005).  The remaining ECM was washed carefully with PBS three 
times.  HCVcc was then added to the wells containing either the cells or ECM 
alone for one hour, after which the total virus inoculum was removed, spin 
clarified, and undiluted to the naïve Huh7.5 mono-culture wells.  As a control 
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for virus binding to the tissue culture plate, HCVcc was incubated in an empty 
well and transferred to the naïve Huh7.5 mono-culture cells.  The naïve 
Huh7.5 mono-cultures with transferred virus inoculum were fixed 48 hours 
post infection and stained for NS5A in order to enumerate the number of HCV 
foci.  The foci count from the transferred virus inoculum is expressed relative 
to the empty well control.   
 
The results indicate that the hepatoma (Huh7 and HepG2) and stromal cells 
(aLMF, LX-2, and CHO cells) bind approximately 10% of the total virus 
inoculum (Fig.5-3, left panel).  Similarly, the ECM of the Huh7 and HepG2 
bind approximately 10% of the virus inoculum (Fig.5-3, right panel).  However, 
the ECM from the aLMF depleted approximately 21%±12.4 and the ECM from 
the LX-2 depleted approximately 35.6%±18.7 of the virus inoculum,  ECM 
from the non-permissive control CHO cells bound approximately 21.9%±10.0 
of the virus inoculum and Huh7.5 cells and ECM bound minimal virus 
inoculum.   
 
All together, these results suggest that the cells bind small amounts viral 
particles (approximately 10%) whereas the ECM from the stromal cells can 
bind slightly more viral particles, depending on the cell type (ranging from 
approximately 10-30%).  However, the level of virus inoculum bound is not 
equal to the level of viral inhibition seen in contact co-cultures in Chapter 3.  
Therefore, this suggests the role for stromal cell or ECM binding virus and 
consequently reducing HCV infectivity is minimal.    
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Figure 5-3 aLMF do not bind virus whereas aLMF ECM depletes virus 
minimally  
Huh7.5, Huh7, HepG2, aLMF, LX-2 and CHO cells were seeded in mono-
culture.  Duplicate wells were seeded for testing virus binding to the cells and 
ECM.  The wells for ECM testing were treated with a lysis buffer consisting of 
PBS containing 0.5% Triton X (v/v) and 20mM ammonium hydroxide (NH4OH), 
24 hours post seeding.  The lysis buffer was removed once the cells detached, 
which was observed by phase microscopy, in order to remove the cells and 
leave the ECM on the tissue culture plate (Butler 2005).  High titre HCVcc was 
added to the wells of cells or ECM and an empty well as a control.  The virus 
inoculum was removed after 1 hour, spin clarified, and the total inoculum 
added to naïve Huh7.5 ‘target’ cells for 48 hours before the cells were fixed, 
stained for NS5A, and the number of foci per well counted.  Date is graphed 
relative to the empty well control.  Data representative of n=1, aLMF=1.  
Statistical comparison to the relative empty well control was made using the 
Kruskal-Wallis test and Dunn’s corrections were applied.  All error bars show 
SD.   
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5.4 aLMF in co-culture limit the lateral diffusion speed of CD81 but not 
EGFR on membrane of hepatoma cells  
Previous work in our group showed that polarised HepG2 cells limited lipid, 
CD81, and HCVpp mobility compared to non-polarised hepatoma cells which 
in turn is thought to limit HCVpp entry (Harris 2013; Farquhar 2012; Helen 
2008).  In our co-culture model, we have seen aLMF limit HCVpp entry in 
various hepatoma cells described in this thesis including non-polarised 
HepG2 cells (data not shown).  We have also seen aLMF alter the polarity of 
HepG2 cells when in co-culture (section 4.9).  With this information and given 
that aLMF reduce HCV infectivity in neighbouring cells using a cell contact 
dependant mechanism, we wanted to investigate HCV receptor dynamics on 
hepatoma cells in co-culture with aLMF using live cell imaging.  For these 
studies, we decided to focus on CD81 and EGFR, which is a recently 
identified entry factor for HCV (Pileri et al 1998;Lindenbach 2005; Wakita 
2005; Zhong 2005; Lupberger et al 2011; Diao 2012). 
 
For this approach, we used real-time fluorescence recovery after 
photobleaching (FRAP) to investigate the effects aLMF have on membrane 
dynamics when in contact with Huh7.5 cells.  We were able to calculate the 
speed at which the protein can diffuse (diffusion coefficient) and the level of 
protein present and mobile at the cell surface (mobile fraction) using Huh7.5 
cells transduced with either green fluorescent protein (GFP)-tagged CD81 or 
GFP-tagged EGFR (Harris 2013; Mee 2009; Carter and Sorkin,1998).  Huh7.5 
transduced cells were seeded in mono- and co- culture with aLMF at a 1:1 
ratio on glass bottomed tissue culture dishes.  24 hours post seeding, cells 
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were imaged on a Ziess Confocal microscope.  Huh7.5 cells (green) in direct 
contact with aLMF (unlabelled) were selected for the FRAP studies and 
compared to Huh7.5 cells alone in mono-culture (Fig.5-4A).  The GFP-tagged 
CD81 or EGFR proteins were photobleached and FRAP measurements taken 
prior to and after photobleaching.  The FRAP data was normalised for 
background fluctuations and from these measurements we could determine 
mobile fraction and diffusion coefficient.   
 
We found that there was no significant difference in the mobile fraction (data 
not shown for mobile fraction) or in the diffusion coefficient of EGFR (Fig.5-
4B), indicating that there was no difference in the levels of receptor on the 
surface or in the speed of the receptor diffusion.  There was also no difference 
in the mobile fraction of CD81; however, there was a significant decrease in 
the diffusion speed of CD81 when we compared the Huh7.5 mono-culture to 
the co-culture (Fig.5-4C). 
 
This reduction in the CD81 diffusion coefficient on Huh7.5 cells when in co-
culture offers a potential mechanism by which the aLMF may be limiting HCV 
entry in neighboring hepatoma cells.  HCV requires Claudin-1 to associate 
with CD81 in order to enter the cell (Meredith et al., 2012b, Farquhar et al., 
2011, Farquhar and McKeating, 2008).  The complex interactions occurring 
between the aLMF and hepatoma cells cause a decrease in the speed of 
CD81 diffusion.  This decrease in diffusion speed could in turn result in fewer 
CD81-Claudin-1 transient associations and therefore fewer viral particles 
entering the cells, which would result in a decrease in HCV entry.   
  
199 
 
This mechanism could also explain why we observed a decrease in HCV 
spreading in co-culture in Chapter 3.  Any de novo virus, either cell free or 
from cell-cell transmission, would be limited by the decrease in the speed of 
CD81 thus limiting overall spread.  
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Figure 5-4 aLMF limit CD81 lateral diffusion on the hepatoma cell 
membrane but have no effect on EGFR 
(A) Representative immunofluorescence image of Huh7.5 cells expressing 
GFP-EGFR (green) in co-culture with aLMF (unlabelled) 24 hours post 
seeding.  Taken using the Ziess Confocal microscope (100x Plan Apochromat 
1.4NA oil immersion objective).  (B-C) Huh7.5 cells expressing GFP-EGFR 
(B) or GFP-CD81 (C) were seeded in mono- or co-culture with aLMF at a 1:1 
ratio. 24 hours post seeding, cultures were imaged on a Ziess Confocal 
microscope.  Huh7.5 cells in direct contact with aLMF were selected for FRAP 
analysis and compared to Huh7.5 cells in mono-culture.  The Huh7.5 cells 
were photobleached and FRAP measurements taken prior to and after 
photobleaching at 0.08 s per frame.  The FRAP data was normalised for 
background fluctuations.  Data representative of n=2, aLMF=2.  Statistical 
comparison was made using non-parametric Mann-Whitney t-tests * P<0.05. 
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5.5 Exploring the role of VAP-1 in HCV infection 
After identifying the reduction in cell surface CD81 diffusion speed on 
hepatoma cells as a potential contributing mechanism for aLMF anti-viral 
activity in co-culture, we wanted to investigate other cell surface proteins that 
may potentially play a role.  Emerging research in the Centre of Liver 
Research (CLR) identified VAP-1 as a potential target protein, therefore we 
collaborated with CLR researchers in order to investigate the role of fibroblast 
expressed VAP-1 on HCV infection in our co-culture system.  VAP-1 is a 
primary amine oxidase found in both bound and soluble form.  It has been 
implicated in the recruitment of leukocyte subtype to the liver where it is highly 
expressed by aLMF and liver sinusoidal endothelial cells (LSEC).  It can also 
be expressed on endothelium in inflamed skin and normal endothelial cells in 
the gut, lymphatic endothelium, and follicular dendritic cells (Weston, C.J. and 
Adams, D.H. 2011; Weston C.J 2014; Lalor 2002). 
 
5.5.1 VAP-1 expression on various liver cell types 
First, we wanted to demonstrate the level of VAP-1 expression on cells used 
in this thesis and in other liver cell populations.  RNA was extracted from 
biliary epithelial cells (BEC), mesenchymal stem cells (MSC), hepatocytes, 
hepatic sinusoidal endothelial cells (HSEC), a cell line overexpressing human 
VAP-1 (AxVAP-1), HEK293 cells expressing wild type VAP-1 (HEK293-wt-
VAP-1), HEK293 cells expressing enzyme dead VAP-1 (HEK293-Y471F-
VAP-1), aLMF from 2 donors (numbered 1 and 2), and hepatic stellate cells 
(HSC).  Some cells were also treated with TNF-α, IFN-γ, or LPS as indicated 
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in Fig.5-5A .  Data collected using semi-quantitative PCR and kindly provided 
by Dr. Chris Weston in the CLR indicate the level of VAP-1 expression in the 
various different cells types (Fig.5-5A).  As a positive control, AxVAP-1, 
HEK293-wt-VAP-1, and HEK293-Y471F-VAP-1 all show high VAP-1 
expression.  In comparison to these over expressed bands, there are faint 
bands indicating low level expression of VAP-1 detected in the aLMF donor 1 
and HSC both untreated and treated with TNF-α and IFN-γ for 24 hours 
(Weston C.J 2014).   
 
Specific cells of interest including HSEC, aLMF, HSC, and LX-2 were further 
analysed for VAP-1 copies using an absolute-quantitative qPCR (Fig.5-5B).  
Data kindly provided by Dr. Chris Weston, show that VAP-1 can be detected 
at the levels of 1000 or more copies of VAP-1 in HSEC, aLMF, primary HSC, 
and the LX-2 stellate cell line compared to a negative control cell line (dotted 
line) (Weston C.J 2014).  Taken together, this data reaffirms VAP-1 is 
expressed on primary aLMF and LX-2 cells, of which both have been shown 
in this thesis to limit HCV infection in hepatoma cells.  
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Figure 5-5 VAP-1 expression on various liver cell types 
Semi-quantitative PCR (A) and absolute-quantitative qPCR (B) was used to 
detect the level of VAP-1 expression in various liver derived primary cells and 
cells lines.  (A) VAP-1 is expressed at 552 bp and the control GAPDH at 258 
bp.  (B) Data is expressed as VAP-1 copies as determined by comparing 
results to a calibration curve of diluted VAP-1 expressing plasmid.  The dotted 
line indicates the level of VAP-1 detected in a negative control cell line.  Data 
kindly provided by Dr. Chris Weston in the CLR.  BEC, biliary epithelial cells; 
MSC, mesenchymal stem cells; HSEC, hepatic sinusoidal endothelial cells; 
HSC, hepatic stellate cells. 
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5.5.2 Inhibiting VAP-1 restores HCV infection in co-culture 
After establishing that the aLMF express VAP-1, we next wanted to 
investigate the role of aLMF expressed VAP-1 in the reduction of 
hepatocellular HCV infection when in co-culture.  For this approach, we used 
the mono-clonal antibody BTT1023 to inhibit VAP-1 activity.  Huh7.5 cells 
were seeded in mono-culture or co-culture with aLMF or LX-2.  Then 24 hours 
after seeding, cultures were either left untreated or treated with 20µg/mL 
BTT1023.  Cultures were infected 1 hour after BTT1023 treatment with 
HCVcc in the absence or presence of the antibody.  Cells were fixed and 
stained for NS5A 48 hours after infection and the level of infection 
enumerated by counting NS5A positive cells (Fig. 5-6).   
 
Dramatically, the co-cultures treated with the antibody BTT1023 showed 
levels of infection similar to that of the Huh7.5 mono-culture.  This restoration 
in the level of HCV infection suggests that VAP-1 expression on stromal cells 
plays a key role in anti-viral activity. 
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Figure 5-6 Inhibiting VAP-1 restores HCV infection in co-culture 
Huh7.5 cells were seeded in mono-culture or co-culture with aLMF or LX-2 
cells at a 1:1 ratio.  24 hours post seeding, cultures were treated with 
20µg/mL BTT1023 mono-clonal antibody targeting VAP-1 for 1 hour prior to 
infection with HCVcc.  After 48 hours in the absence or presence of BTT1023, 
cells were fixed, stained for NS5A, and the level of infection counted as the 
total number of infected cells per well.  Data expressed relative to the Huh7.5 
mono-culture condition.  Data representative of n=3 independent repeats (n=4 
aLMF donors).  Statistical comparison was made using the Kruskal-Wallis test 
(non-parametric) and Dunn’s corrections were applied.  All error bars show 
SD.   
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5.5.3 Anti-viral activity of rVAP-1 is dose dependant 
Having identified VAP-1 as a key player in stromal cell anti-viral activity, we 
next wanted to establish the level at which VAP-1 needs to be expressed in 
order to have an anti-viral effect.  For this approach, we used a recombinant 
form of VAP-1 (rVAP-1) and Huh7.5 cells, which we confirmed, did not 
express VAP-1 (Fig 5-5A).  Huh7.5 cells were seeded in mono-culture and 24 
hours post seeding treated with rVAP-1 at 100, 300, and 1000 ng/mL or left 
untreated as a control.  Cultures were infected with HCVcc 1 hour after being 
treated with rVAP-1 and the infection proceeded in the presence of rVAP-1. 
 
Analysis of the data indicates that rVAP-1 inhibits HCVcc infection in a dose 
dependant manner with HCV infection decreasing as the doses of rVAP-1 are 
increased (Fig 5-7).  Preliminary data demonstrated rVAP-1 inhibits HCVpp 
entry, VSVpp entry and inhibits HCV replication in Huh7A2HCV Replicon co-
cultures in a similar manner (data not shown as it was preliminary data which 
required more biological repeats especially as there had been some 
experiments in which the VAP-1 batches varied slightly in activity).   
 
This data combined with the data in section 5.5.2 indicates that both the 
surface expressed and soluble forms of VAP-1 have the ability to reduce HCV 
infection of hepatoma cells.  The mechanism by which VAP-1 decreases HCV 
infection needs to be further explored.  One hypothesis is that enzymatic 
activity is responsible for the reduction of HCV infection in vitro. In vivo high 
expression of VAP-1 in the diseased liver could also be interacting with 
various immune cells that would play a role in controlling HCV infection and 
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could provide an additional mechanism by which VAP-1 may exert anti-viral 
activity in vivo but it could also be interacting with stromal cells as shown here 
(Bonder 2005; Lalor 2002 recruitment; Lalor 2002 VAP; Lalor 2007; Lee 2013). 
  
208 
 
 
 
Figure 5-7 Anti-viral activity of rVAP-1 is dose dependant 
Huh7.5 cells in mono-culture were treated 24 hours after seeding with 100, 
300 and 1000 ng/mL rVAP-1 or left untreated as a control.  Then 1 hour after 
treatment, cultures were infected with HCVcc and the infection proceeded in 
the absence or presence of rVAP-1. After 48 hours, the cells were fixed, 
stained for NS5A, and the level of infection enumerated as the total number of 
infected cells per well.  Data is expressed relative to the untreated Huh7.5 
mono-culture condition.  Data representative of n=5 independent repeats.  
Statistical comparison was made using the Kruskal-Wallis test (non-
parametric) and Dunn’s corrections were applied.  All error bars show SD.  
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5.5.4 rVAP-1 does not affect the speed CD81 diffuses  
In section 5.4, we found that aLMF in co-culture limits the speed CD81 
diffuses on the hepatoma cell membrane, which could explain their ability to 
reduce HCV infection in neighbouring hepatoma cells.  We next wanted to 
determine if the decrease in CD81 diffusion speed is linked to aLMF 
expressed VAP-1. 
 
For this approach, mono-cultures of Huh7.5 cells transduced with GFP-tagged 
CD81 were treated with either 1000ng/mL rVAP-1, control buffer, or left 
untreated one hour prior to imaging on a Ziess Confocal microscope. The 
GFP-tagged CD81 proteins were photobleached and FRAP measurements 
taken prior to and after photobleaching.  The FRAP data was normalised for 
background fluctuations and from these measurements we could determine 
the mobile fraction and diffusion coefficient of CD81.   
 
The data shows that after treating the Huh7.5 cells with a high dose of rVAP-1, 
there was no significant difference in the level of CD81 present and mobile at 
the cell surface (Fig.5-8A) and no change in the diffusion coefficient of CD81 
(Fig.5-8B) when compared to the controls.  With this data, we can conclude 
that the anti-viral action of VAP-1 is independent to the ability of aLMF to limit 
CD81 dynamics.  Thus, the stromal cell anti-viral activity is mediated by two 
independent mechanisms. 
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Figure 5-8 rVAP-1 does not affect CD81 mobile fraction or diffusion 
coefficient 
Huh7.5 cells expressing GFP-CD81 were treated with 1000 ng/mL rVAP-1, 
control buffer, or left untreated as a control 24 hours post seeding in mono-
culture.  One hour post treatment, the cells were imaged on a Ziess Confocal 
microscope and the GFP-tagged CD81 proteins were photobleached and 
FRAP measurements taken prior to and after photobleaching.  The FRAP 
data was normalised for background fluctuations.  Data representative of n=2 
independent repeats.  Statistical comparison was made using non-parametric 
Mann-Whitney t-tests.   
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5.6 The ability of aLMF to reduce HCV infection is not specific to liver 
myofibroblasts  
To determine if the mechanism by which aLMF can reduce HCV infectivity in 
neighbouring cells was specific to liver derived fibroblasts or a global affect, 
we decided to use fibroblasts isolated from different sites of the body in co-
culture with infected hepatoma cells.  Dermal, synovial, and bone marrow 
fibroblasts were isolated and supplied by the Centre for Translational 
Inflammation Research.  The main function of fibroblasts in general is to 
assist in maintaining the structure of connective tissue by secreting various 
ECM which vary depending on their location.  Phenotypically there are subtle 
differences between the fibroblasts from different sites.  Bone marrow and 
synovial fibroblasts display a smaller size and shape compared to dermal 
fibroblasts which have a more elongated shape similar to aLMF (Fig.5-9A).  
These fibroblasts from different sites are also non-permissive to HCV infection 
(data not shown) as we established with aLMF (section 3.2). 
 
Dermal fibroblasts (DM), synovial fibroblasts (SY), bone marrow fibroblasts 
(BM), LX-2, and control CHO cells were co-cultured with Huh7.5 cells at a 1:1 
ratio, either in contact or separated by transwell inserts as detailed in section 
4.1.  Cultures were infected with HCVcc to investigate the complete virus 
lifecycle (Fig.5-9B) or infected with pseudoparticles HCVpp, VSVpp, and 
NEpp to investigate the entry step of viral infection (Fig.5-9C-D).  All 
infections were allowed to proceed for 48 hours before the cultures infected 
with HCVcc were fixed and stained for NS5A and cultures infected with 
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pseudoparticle viruses were lysed to allow the detection of the luciferase 
reporter gene activity. 
 
The results from co-culturing the various fibroblasts with hepatoma cells 
mimic the data obtained using aLMF.  All the fibroblasts tested in co-culture 
have the ability to reduce HCVcc infection in a cell contact dependent manner 
by approximately 70-80% (Fig.5-9B) and HCVpp entry by approximately 50-
75% (Fig.5-9C) compared to hepatoma mono-cultures.  There was no 
significant difference in the level of HCVcc infection when comparing across 
the fibroblasts in contact or in transwell. This preliminary data also suggests 
that fibroblasts reduce HCVpp entry more significantly then VSVpp entry, 
which may indicate that these fibroblasts are targeting an entry step specific 
to HCV entry (Fig.5-9C).  
  
Taken together, these data indicate the reduction in HCV infection in co-
culture is not specific to liver fibroblasts as primary fibroblasts from other sites 
are capable of reducing HCV infection in a similar manner to aLMF.  This data 
could lead to future studies identifying a mechanism of action such as a 
membrane expressed protein or function common to all fibroblasts, which may 
be contributing to the anti-viral responses.    
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Figure 5-9 The ability of aLMF to reduce HCV infection is not specific to 
liver myofibroblasts  
(A) Representative phase contrast images of aLMF (magnification x10).  (B-
D) Dermal (DM), synovial (SY), and bone marrow (BM) primary fibroblasts 
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along with LX-2 and the control non-permissive CHO cell were seeded in co-
culture with Huh7.5 cells at a 1:1 ratio either in contact or separated using 
transwell inserts.  The transwell inserts were added to the wells containing 
Huh7.5 cells 3 hours after seeding.  24 hours post adding the transwell inserts 
to the wells, the co-culture conditions were infected with either HCVcc (B) or 
the pseudoparticles HCVpp (C), VSVpp (D) and NEpp.  48 hours after 
infection, (B) HCVcc infected cultures were fixed, stained for NS5A, and the 
number of cells per foci were enumerated.  Statistical comparison was made 
using the Kruskal-Wallis test and Dunn’s corrections were applied.  48 hours 
after infection, (C-D) pseudoparticle infected cultures were lysed and the 
luciferase activity measured.  Data is expressed as relative light units (RLU) of 
HCVpp (C) or VSVpp (D) normalised to the NEpp control (Luc:No env).  Data 
representative of n=1 independent repeat (n=2 DM, n=2 SY and n=2 BM 
donors).  Statistical comparison was made using one way ANOVA tests to 
compare groups of data and Bonferroni’s corrections (parametric) were 
applied for pair wise comparisons of all data.  * P<0.05, **P<0.01 and *** 
P<0.001. All error bars show SD.   
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5.7 Discussion 
The data in Chapter 3 demonstrates that stromal cells, both HSC and aLMF, 
can significantly limit HCV the level of HCV entry, replication and spread of 
infection in neighbouring hepatoma cells via a cell contact dependent 
mechanism.  In the process of elucidating the mechanism of action, we were 
able to rule out a number of potential pathways that would have indicated a 
typical anti-viral response such as the innate immune response.  We also 
demonstrated in Chapter 4 that some potential mechanisms which could alter 
hepatocyte function and thus HCV infection, such as albumin production and 
differentiation status, does not contribute to the ability of aLMF to reduce HCV 
infection.  We then decided to focus how stromal cells could be acting on 
hepatoma cells in a cell contact dependant manner leading to inhibit HCV 
infection and factors which may influence the cell-cell contacts formed 
between these two cell types.  
 
Stromal cells are located in the Space of Disse, where they are in direct 
contact with hepatocytes allowing these non-parenchymal cells to support and 
maintain hepatocyte function via multiple complex interactions.  Also, as the 
HCV particle enters the liver it must pass through the sinusoids, across the 
sinusoidal endothelial into the Space of Disse in order to infect the 
hepatocytes, during which the viral particles could possibly, come into direct 
contact with HSCs ((Perrault 2009; Pohlmann, Zhang et al. 2003; Lozach, 
Amara et al. 2004; Lai, Sun et al. 2006; Lavon and Benvenisty 2005).  Studies 
have indicated that direct contact of HCV particles or proteins with HSC can 
lead to their activation which then induces fibrosis (Mazzocca et al 2002; 
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Mazzocca 2005; Bataller et al 2004; Wang et al 2013).  HSCs are the main 
source of aLMF, the key cells involved in fibrosis responsible for depositing 
ECM, described as elongated cells with highly proliferate, contractile and 
mobile qualities (Mederacke et al 2013; Taub 2004; Schulze-Krebs et al 2005; 
Gomez et al 2009; Friedman 2008; Brandao et al 2006) 
 
The preliminary data investigating aLMF mobility using the Cell IQ machine 
highlighted some issues which would require optimisation in the future, but we 
were able to observe from this data the general differences in cell mobility.  
aLMFs are more mobile in co-culture compared to Huh7.5 cells, and in 
general, the fibroblasts from different sites were also more mobile than the 
Huh7.5 cells.  The initial attempt at tracking the aLMF mobility raised an 
interesting point on which part of the cell should be tracked in our 
investigation, the cell nucleus or whole cell.  A nuclear stain could be used to 
track aLMF mobility.  However given the shape and size of the aLMF 
compared to the Huh7.5 cells and seeing as cell-cell interactions appear to be 
the key to aLMF limiting HCV infectivity, a more informative way of tracking 
the aLMF would be to track the whole cell.  A possible technique would be to 
use a fluorescently tagged protein expressed on the aLMF membrane that 
doesn’t bleach as fast over time.  Providing we could optimise the tracking 
and quantification, we could measure the rate of mobility in order to determine 
if the different rates correlated to differing degrees of HCV inhibition when in 
co-culture.  If so, we could then use various techniques such as agarose 
overlays, altering the temperature of live cell cultures to halt membrane 
dynamics or chemical inhibitors of cell migration or proliferation, to alter 
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fibroblast mobility and cell-cell contacts and then monitor how this also 
impacts HCV inhibition in co-culture.  
 
Understanding the impact of aLMF mobility on neighbouring hepatoma cells 
and HCV infection could elucidate potential mechanisms to target during 
fibrosis stages of HCV infection to either promote the inhibition of HCV 
infection or minimize the damage of fibrosis.  During fibrosis, aLMF lay down 
ECM, which under normal circumstances is degraded once the liver has 
repaired returning to a normal healthy state.  However, when the ECM is not 
degraded and aLMFs continue to proliferate, the liver becomes fibrotic which 
can become chronic, leading to hepatocellular carcinoma as in many HCV 
infected patients (Wynn 2008; Kisseleva et al 2011; Kisseleva et al 2008; 
Selden, Khalil et al. 1999; (Blight, McKeating et al. 2003; Lindenbach, Evans 
et al. 2005; Farquhar and McKeating 2008;).  Given the role of fibroblasts is to 
support the hepatocytes and one key mechanism by which this is achieved is 
the production of ECM, it was interesting to observe that neither the aLMF 
cells nor the ECM they produced can bind or deplete cell free HCV particles.  
Thus ruling out the role of aLMF and the ECM they produce in trapping 
hepatitis C viral particles.  In this experimental design, when the cells were 
incubated with the virus inoculum, there is a high probability of various ECM 
components also present in combination with the cells.  Interestingly, this 
potential combination of cells and ECM still bound less virus inoculum than 
the ECM itself, but one possibility could be the methodology used to remove 
the cells.  There are a number of different methods in the literature which can 
be used to remove cells from tissue culture plastic leaving the ECM behind 
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but whether these methods destroy components of the ECM or leave 
membrane debris behind will need to be determined as they could impact the 
outcome of the assay.  It could also be beneficial to measure the differences 
in amount of ECM produced and level of different ECM components produced 
when stromal cells are in mono- and co- culture, for example by using an 
ELISA.  The data here used ECM produced by stromal cell mono-cultures 
which does not take into account that the reduction was seen in co-culture 
conditions where the mechanism is a cell contact dependent mechanism, and 
there are many complex cell-cell interactions and paracrine signalling 
pathways between both cells types which may impact ECM production (Crapo 
2011). 
 
Investigating the effect of aLMF contact on Huh7.5 membrane dynamics 
revealed two independent mechanisms which are contributing to aLMF 
limiting HCV infection.  aLMF can limit CD81 lateral diffusion on Huh7.5 cells 
which in turn could lead to reduced HCV entry dynamics and an overall 
reduction in the level of HCV infection.  aLMF also express VAP-1 on the 
surface and as a soluble secreted form.  We have demonstrated both forms of 
VAP-1 appear to have anti-viral properties however as rVAP-1 failed to alter 
CD81 lateral diffusion it indicates the mechanism by which VAP-1 is anti-viral, 
is independent to CD81 dynamics.  The mechanism by which VAP-1 has anti-
viral properties is yet to be determined and there is still a lot to be understood 
about VAP-1.  Some known functions of VAP-1 which could be of importance 
in determining its anti-viral mechanism include its primary amine oxidase 
enzymatic activity responsible for generating aldehydes, ammonia and H2O2, 
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which leads to the secretion of chemokine via NFκB dependent mechanism 
(Bonder 2005; Lalor 2002 recruitment; Lalor 2002 VAP; Lalor 2007; Lee 2013).  
Recently, the amine oxidase activity HSC and aLMF expressed VAP-1 has 
been shown to modulate leukocyte migration.  Given that we know 
lymphocyte assisted HCV particles have enhanced hepatocyte infectivity, it 
would be interesting to expand this co-culture model and investigate if HSC or 
aLMF can differentially modulate leukocyte migration in the favour of HCV 
infection and if the anti-viral contact based mechanisms can counter the 
potential increased infection from infiltrating lymphocytes (Weston 2014; 
Stamataki 2009).   
 
Testing fibroblasts from different sites revealed that these cells can also inhibit 
HCV infection which signifies that the mechanism is not specific to liver 
myofibroblasts.  Different pseudoparticle viruses were also tested including 
measles, lassa and murine leukaemia virus (MLV) in our co-culture system 
(data not shown).  These data showed fibroblasts can also inhibit the entry of 
other viruses and so this model could possibly be expanded to investigate the 
role of stromal cells on other hepatotrophic viruses such as HBV. 
 
To determine the specificity of the mechanisms identified, future work would 
be needed to investigate whether the fibroblasts from different sites could also 
limit CD81 lateral diffusion and if they to express VAP-1.  However, in the 
context of understanding the role of stromal cells on hepatocellular HCV 
infection, the data suggests aLMF and LX-2 cells may be inhibiting HCV 
infection of hepatoma cells with VAP-1 expressed at the membrane or the 
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soluble released form.  This mechanism is independent to the ability of aLMF 
to reduce CD81 lateral diffusion speed thus leading to a reduction in HCV 
infection.  These observations uncover a new role for VAP-1 to regulate HCV 
replication and provide new therapeutic avenues for treating both the 
underlying inflammatory response and viral replication in chronic hepatitis.      
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Chapter 6 General Discussion 
The HCV replicon system and successful development of infectious HCV 
particles in cell culture (HCVcc), were the first in vitro systems that studied 
HCV infection and since then, significant progress has been made in 
understanding the HCV lifecycle and developing in vitro models to study HCV 
(Wakita et al 2005; Zhong et al 2005; Lindenbach et al 2005).  Recent 
advances in the field include the approval of a number of DAAs including the 
two protease inhibitors Simeprevir and Faldaprevir, and the NS5A polymerase 
inhibitor Sofosbuvir.  These DAAs have shown higher cure rates than the 
previously developed DAAs, Boceprevir and Telaprevir.  Despite the very 
promising cure rates, shorter treatment times, and fewer side effects with the 
latest DAAs, a patient’s response to such DAA treatments is genotype specific, 
predominantly benefiting patients with either genotype 1, 2 or 3, and 
unfortunately the therapies are also very costly (Welch and Jensen 2014, 
Manns et al 2014, Zeuzem 2014; Lawitz 2013; Jacobson 2013).   
 
In patients with chronic HCV, successfully treating the underlying viral 
infection has been shown to reverse fibrosis; however many patients often 
suffer severe cirrhosis, HCC or liver failure (Su et al 2014; Wynn et al 2008; 
Friedman et al 2008; Friedman et al 2007).  Although liver transplantation in 
HCV infected patients is a successful treatment option, the new liver becomes 
reinfected with circulating viruses leading to recurrent disease and poorer 
prognosis (Mutimer et al 2006; Rowe et al 2008).  Thus, HCV infection is still 
a major burden on liver transplantation.  With no vaccines available there 
remains a need to develop a HCV vaccine and novel HCV therapies to treat 
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current HCV infected patients, which are more cost effective and beneficial to 
patients suffering from more advanced liver diseases and a wider range of 
HCV genotypes. 
 
During chronic viral hepatitis, infected hepatocytes release various 
profibrogenic factors which activate HSCs into aLMF cells as part of the 
antiviral mechanisms designed to clear the infection.  HSCs are the primary 
source of aLMF and it is these aLMF cells which are the key player in liver 
fibrosis.  Liver fibrosis is defined as an excessive healing response with 
scarring and excessive ECM deposition, particularly collagen, in response to 
continuous liver injury (Kisseleva et al 2008; Su et al 2014; Mederacke et al 
2013; Wynn 2008; Kisseleva et al 2011).  Despite these cell types playing 
such a key role in fibrosis progression and HCV infection being a leading 
cause of liver fibrosis, there is little research into the understanding of the role 
of liver fibroblasts in hepatocellular HCV infection.   
 
Some studies have shown that HCV proteins E2, core, and NS3-NS5 can 
mediate liver fibrosis via a few mechanisms such as inducing profibrogenic 
responses and pro-inflammatory cytokines in HSCs (Zhan et al 2006; Jiang et 
al 2008; Deng et al 2008; Wang et al 2013; Mazzocca et al 2002; Bataller et al 
2004).  However many of these finding are based on physiologically irrelevant 
systems which do not co-culture HSCs with hepatocytes to mimic the liver 
microenvironment but instead stimulate the HSCs in isolation using 
recombinant HCV proteins or artificial chemical stimulation such as poly I:C 
and transfer the conditioned media to hepatoma cells in isolation to examine 
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the effects on HCV infection.  This technique allows the cytokines and soluble 
factors to be studied but ignores the role of cell-contact dependent mediators 
which may alter the profibrogenic mechanisms reported.  Other studies have 
used fibroblasts such as 3T3 mouse fibroblasts or stroma in co-culture 
systems to maintain human hepatocyte function, which is another key function 
of stromal cells within the liver and physiologically, these studies are trying to 
model the liver microenvironment more accurately but unfortunately utilise 
irrelevant stroma or stromal cells instead of human derived primary stromal 
cells (Ploss 2010; Khetani and Bhatia 2008; Hui and Bhatia 2007; Bhatia 
1999). 
 
More research into the role of non-parenchymal cells in HCV infection is 
needed in order to identify host pathways involved in HCV disease 
progression which can be targeted for novel therapies.  Studying the complex 
interplay between two cell types is not without its difficulties. However, such 
studies can identify novel findings such as the recent study investigating the 
role of LSEC on HCV infection.  It was previously thought that LSEC would 
bind HCV particles in the sinusoids and transfer the virus to hepatocytes, but 
work by Rowe et al (2014) revealed that LSEC actually acted to limit HCV 
infection via cell contact-dependent mechanisms and soluble factors.  The 
soluble factor VEGF-A secreted by hepatocytes suppresses LSEC expression 
of BMP4, a proviral factor which normally promotes HCV replication, thus 
highlighting a potential new therapeutic target (Protzer et al 2012; Goulet et al 
1988; Rowe et al 2014). 
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This study investigated the role of stromal cells in HCV infection, focusing on 
the HSC and the activated form of HSCs, the activated liver myofibroblast 
(aLMF).  The LX-2 stellate cell line was used to represent the HSC found in 
the liver alongside primary aLMFs in our study, neither of which supports HCV 
infection as they lack expression of all four key HCV receptors required for 
successful viral infection.  Using co-culture systems, we were able to show 
that the non-permissive stromal cells could limit HCV infection of neighbouring 
hepatocytes at the entry step, replication stage, and limit spread of HCV 
infection in a cell contact dependent manner. Though hepatocytes are the 
major site of HCV replication and the virus appears to be efficient at 
replication with 1012 viral particles produced per day, the level of infected 
hepatocytes in the liver is low, at an estimated 10-25%.  There are a number 
of known factors which contribute toward this, including the high mutation rate 
and genetic diversity which assist the virus in escaping immune recognition 
but may also result in defective HCV particles  ((Murray et al., 2008, Fishman 
et al., 2008, Weissenborn et al., 2009, Weissenborn et al., 2004); Vogel 
2009;(Gomez et al., 1999); Powers et al 2006; Liang et al 2009).  Given the 
close proximity of stromal cells to hepatocytes in the liver, and the data 
presented here indicating that stromal cells can significantly inhibit the levels 
of hepatocellular HCV infection, we can suggest that stromal cells also 
contribute towards the low levels of HCV infected hepatocytes detected in the 
liver. 
 
Given that the role of fibroblasts in the liver is to respond to chronic 
inflammation through various stimuli such as viral infection, as part of the host 
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immune response, one could argue that these observations would have been 
expected (Wynn 2008; Kisseleva et al 2011).  Fibroblasts can detect viral 
infection via a number of mechanisms; for example, they express toll-like 
receptors (TLRs) which can detect viral genomic material and they respond to 
various profibrogenic cytokine stimuli released by infected hepatocytes (Novo 
et al 2014; Holt et al 2008; Zhan et al 2006; Jiang et al 2008; Deng et al 2008; 
Wang et al 2013).  However, our investigations into the mechanism by which 
fibroblasts can reduce HCV infection, led us to quickly establish that the 
mechanism was a cell contact dependent mechanism, ruling out soluble 
factors such as cytokines.  We also used inhibitors to rule out the involvement 
of both the VEGF and NO pathways, however, this data is preliminary and 
future assays should also include additional positive controls.  Despite the 
anti-VEGF antibody having already been extensively used by our research 
group, the addition of exogenous BMP4 to increase HCV infection and BMP4 
combined with the anti-VEGF antibody used in this study will provide positive 
controls to indicate the anti-VEGF antibody can inhibit HCV infection levels 
caused by BMP4 increasing hepatocyte permissivity to support HCV infection 
(Rowe et al., 2014).   The Griess assay was used to assess supernatants for 
the presence of nitric oxide (NO) in untreated co-cultures compared to co-
cultures treated with a NO inhibitor.  Even though all the supernatants tested 
were negative for NO production, additional positive controls such as poly I:C 
stimulation of culture leading to the production of NO, could have been 
included on the Griess assay to prove the NO pathway can be stimulated in 
the cells tested.  A human anti-viral PCR array containing 84 key genes 
involved in the innate immune response was one of the techniques used to 
  
226 
rule out the role of the innate immune response in the ability of aLMFs to limit 
hepatocellular HCV infection.  The PCR array allowed us to compared 4 
samples but the data could be expanded with additional anti-viral PCR array 
kits.  The additional kits would allow us to run extra samples, in particular 
mono-cultures of fibroblasts uninfected and fibroblasts infected with HCV in 
order to help better interpret the array data is this study and better understand 
which signalling pathways are regulated as a result of the fibroblasts being 
stimulated from contact with HCV particles compared to signals from a 
neighbouring infected hepatocytes.   
 
Stromal cells create the microenvironment in the liver which supports the 
hepatocytes to function via cell contacts and secreting various cytokines.  In 
addition to releasing various cytokines, stromal cells can also produce various 
ECM components, particularly different types of collagen, which tends to 
accumulate during fibrosis; the liver’s natural wound healing response.  As 
fibrosis is triggered in HCV infected livers, we continued our investigation into 
the mechanism being related to the wound healing function of fibroblasts and 
their function as supportive cells to hepatocytes.  We were able to 
demonstrate minimal virus binding to the fibroblast cells or the ECM produced 
by the fibroblasts in this study thus eliminating the binding and depletion of 
circulating virus in the liver by fibroblasts or their ECM as a potential 
mechanism.  A number of previous studies have used stromal cells as 
supportive cells to maintain hepatocyte function in cell culture and so this lead 
us to investigate the differentiation status of hepatocytes in co-culture.  We 
hypothesized the stromal cells could be differentiating the hepatoma cell line 
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used in this study, pushing it more towards a hepatocyte like differentiation 
status which could lead to a decrease in infection, similar to the low levels of 
infection observed with highly differentiated PHHs.  However the 
differentiation status of the hepatoma cell line used in our co-culture system 
remained unchanged over time when in co-culture with stromal cells thus 
ruling out this mechanism also.  The differentiation status of the hepatoma cell 
line used may have remained unchanged because this particular cell line is 
incapable of becoming differentiated and not because the stromal cells can 
not differentiate hepatocytes or maintain primary hepatocyte differentiation 
status in cell culture. 
 
Two cell contact dependent mechanisms by which the fibroblasts can inhibit 
HCV infection in hepatocytes were identified in this study.  The first 
mechanism is that aLMF can limit CD81 lateral diffusion on hepatocytes which 
would explain the ability for aLMF to limit HCV entry.  Previous studies have 
shown that a decrease in CD81 lateral diffusion leads to fewer CD81-Claudin-
1 complexes on the hepatocyte cell membrane, which in turn limits HCV entry 
leading to decreased HCV infection.  The interaction between HCV particles 
and the receptors expressed by hepatocytes is key to facilitating the 
successful entry and infection of HCV.  This mechanism could also potentially 
explain why we observed a decrease in the spread of HCV infection in co-
culture.  Any de novo cell free or cell-cell transmitted virus would have 
difficulty in overcoming the decreased CD81 diffusion coefficient thus also 
limiting the overall spread of infection (Harris 2013; Harris 2010; Meredith 
2012).   
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The second mechanism identified in this study involved the fibroblast 
expressed VAP-1 molecule, which is expressed at the membrane surface but 
can also be secreted in a soluble form.  VAP-1 in an amine oxidase that has 
previously been shown to recruit leukocyte subtypes to the liver and elevated 
levels of the soluble secreted form of VAP-1 have been detected in patients 
with chronic liver disease, correlating with the level of fibrosis (Weston 2014; 
Weston 2011).  We were able to demonstrate that stromal cell expressed 
VAP-1 has the ability to inhibit HCV infection which can be restored following 
inhibition of VAP-1 using a mono-clonal antibody targeting VAP-1.  
Preliminary data indicates that stromal expressed VAP-1 can inhibit HCV 
infection at the entry step and replication stage.  Recombinant VAP-1 (rVAP-
1) was used to show that the anti-viral activity of rVAP-1 is dose dependent 
but does not contribute to the ability of aLMF to limit CD81 lateral diffusion, 
thus indicating the two mechanisms are independent.   
 
Some studies have investigated inhibiting VAP-1 as a potential therapy for 
preventing liver disease progression; however in the context of the data in this 
study, patients with HCV may not benefit from this therapy as inhibiting VAP-1 
increased the level of HCV infection in our study (Weston 2014; Lalor et al 
2002).  Therefore, further work investigating the role of stromal VAP-1 in HCV 
infection would provide valuable for HCV infected patients undergoing therapy, 
especially patients who may also have other underlying liver diseases which 
could impact the VAP-1 therapy.  To determine whether or not the mechanism 
of VAP-1 anti-viral action is catalysed by its semicarbazide-sensitive amine 
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oxidase (SSAO) enzymatic activity, the GFP-(Y471)VAP-1 construct can be 
compared to the wild type GFP-wtVAP-1 construct in HCV infection co-
cultures.  In the GFP-(Y471)VAP-1 construct, the tyrosine at position 471 has 
been replaced with a phenylalanine rendering the enzyme incapable of 
catalysis, and so expressing both the enzyme dead and wild type VAP-1 
constructs in cells which are negative for VAP-1 expression or over 
expressing the constructs in stromal cells and co-culturing with hepatoma 
cells could help determine the role of VAP-1 enzyme activity on HCV infection.  
As the constructs also express GFP, the cellular distribution of VAP-1 in 
stromal cells could also be investigated, to see if there are differences in 
localisation as a result of co-culturing or HCV infection (Jalkanen et al., 2007, 
Weston et al., 2014).  Nevertheless, the ability for fibroblasts to limit CD81 
dynamics and anti-viral properties of fibroblast expressed VAP-1 highlight the 
role stromal cells play in HCV infection of the liver and present two novel 
mechanisms by which the fibroblasts limit HCV infection.   
 
By nature, aLMF cells are very contractile, long cells and highly mobile, as we 
observed when tracking the cell mobility in co-culture using the Cell IQ.  Their 
large size allows them to be in contact with multiple hepatocytes in the liver 
which means even a low number of aLMFs could impact the level of HCV 
infection via these cell-contact based mechanisms.  It would be interesting to 
investigate the mobility of stromal cells in co-culture with infected hepatoma 
cells using the Cell IQ to see if the stromal cells can detect neighbouring 
infected hepatoma cells and if the presence of these infected hepatoma cells 
can alter the migration speed or direction of stromal cells, and whether or not 
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the stromal cells migrate towards infected hepatoma cells to mediate their cell 
contact dependant anti-viral activity.  While the immune response to HCV has 
been well studied, the role of non-parenchymal cell types and their effect on 
HCV infection has been studied to a lesser extent (Wynn 2008; Kisseleva et al 
2011; Mazzocca et al 2002; Mazzocca 2005; Bataller et al 2004; Wang et al 
2013).  We intend to apply this knowledge to improve our understanding of 
the liver microenvironment and the role it plays in antiviral responses in 
working towards novel therapies.  Despite the recent advances in DAA 
treatments for HCV infected patients, there are still issues surrounding high 
toxicity and costs associated with the therapies, some of which are also given 
in combination with the current standard of HCV treatment or ribavirin and 
pegylated interferon-α (Welch and Jensen 2014, Manns et al 2014, Zeuzem 
2014).  Another concern is that the patient’s response to these new 
treatments is genotype specific with only 3 of the 7 genotypes appearing to 
show the most success in treatments (Lawitz 2013; Jacobson 2013).  With 
approximately 170 million HCV infected people worldwide, about 70% of 
those acutely infected individuals go on to develop persistent and chronic 
infection, thus HCV infection is still a major burden on liver transplantation and 
a major cause of global mortality.  There is also still no vaccine for HCV and 
so the need for novel HCV therapies still remains (Pawlotsky 2011; Meredith, 
Wilson et al. 2012 Mutimer et al 2006; Rowe et al 2008;).   
 
We believed that novel therapies must be developed with a greater 
understanding of the liver microenvironment and host-virus interactions, 
potentially leading to possible pathways which can be targets for novel 
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therapies.  We also believed that given the role of stromal cells in maintaining 
the liver microenvironment, their role in liver disease progression and limited 
understanding on the role of these cells in HCV infection, that we should 
develop a physiologically relevant system to study the role of stromal cells on 
hepatocellular HCV infection.  This study established a co-culture system 
which allowed us to investigate the impact of stromal cells on HCV infection at 
various stages in the HCV lifecycle (entry, replication and spread), establish if 
the mechanism required cell contacts or was mediated via soluble factors, 
study the impact of stromal cells on hepatoma differentiation status and 
polarity, investigate HCV receptor membrane dynamics and also 
demonstrated a 3D co-culture technique which can move the conventional co-
cultures into a more physiologically relevant organoid co-culture model.  To 
develop the model further and to mimic the liver microenvironment even more 
closely, the 3D co-cultures could be set up using PHHs or polarised hepatoma 
cells which are growth arrested to mimic PHHs given the limited availability of 
PHHs for research.  The 3D organoid system could also be cultured at 
physiologically relevant oxygen levels and other non-parenchymal cell types 
could be added to the co-cultures however this may complicate the ability to 
decipher mechanisms even further.  The model could then be used to 
investigate further stromal cell mobility in 3D co-cultures and the impact of 
stromal cells on hepatoma membrane dynamics, polarity, tight junction 
formation and integrity, and how these factors impact HCV infection.   The 
model could also be used to investigate and screen potentially novel therapies 
in a more physiologically relevant system, which could be used to also model 
a fibrotic patient liver by altering the ratio of hepatoma to fibroblast cells. 
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This study investigated the role of stromal cells in HCV infection of the liver.  
The study first established that these cells are not permissive to HCV infection 
and then investigated the impact of stromal cells on the various steps of the 
HCV lifecycle in hepatocytes, identifying that stromal cells can inhibit HCV 
entry, replication and spread in neighbouring hepatocytes in a cell contact 
dependent manner.  Data in this thesis supports a cell contact mediated anti-
viral mechanism where by fibroblasts can affect hepatocyte membrane 
receptor dynamics, reducing the mobility of the HCV receptor CD81, impairing 
both viral entry and replication.  The data also indicates that VAP-1, which is 
expressed on the surface of fibroblasts, also significantly reduces virus 
infection independently of CD81 receptor modulation. These findings have 
greatly improved our understanding of how the interactions between hepatic 
cells affect HCV, and highlight the importance of non-parenchymal cells in 
mediating infection in the liver microenvironment.  
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